<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006257" GROUP_ID="RENAL" ID="767902082813233288" MERGED_FROM="" MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="077" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis">
<TITLE>Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease</TITLE>
<CONTACT MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16154" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><MIDDLE_INITIALS>FM</MIDDLE_INITIALS><LAST_NAME>Strippoli</LAST_NAME><POSITION>Editor and Regional Coordinator, Cochrane Renal Group</POSITION><EMAIL_1>Giovanni.Strippoli@diaverum.com</EMAIL_1><EMAIL_2>strippoli@negrisud.it</EMAIL_2><ADDRESS><DEPARTMENT>a) School of Public Health, University of Sydney, b) Cochrane Renal Group</DEPARTMENT><ORGANISATION>c) Diaverum Medical Scientific office, d) Mario Negri Sud Consortium, Italy</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+39 080 5580776</PHONE_1><PHONE_2>+39 349 5705884</PHONE_2><FAX_1>+39 080 5580776</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16154" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><MIDDLE_INITIALS>FM</MIDDLE_INITIALS><LAST_NAME>Strippoli</LAST_NAME><POSITION>Editor and Regional Coordinator, Cochrane Renal Group</POSITION><EMAIL_1>Giovanni.Strippoli@diaverum.com</EMAIL_1><EMAIL_2>strippoli@negrisud.it</EMAIL_2><ADDRESS><DEPARTMENT>a) School of Public Health, University of Sydney, b) Cochrane Renal Group</DEPARTMENT><ORGANISATION>c) Diaverum Medical Scientific office, d) Mario Negri Sud Consortium, Italy</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+39 080 5580776</PHONE_1><PHONE_2>+39 349 5705884</PHONE_2><FAX_1>+39 080 5580776</FAX_1></ADDRESS></PERSON><PERSON ID="D176488382E26AA2003ED3F5AA6BF491" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carmen</FIRST_NAME><LAST_NAME>Bonifati</LAST_NAME><EMAIL_1>cbonifati@katamail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency and Organ Transplanation</DEPARTMENT><ORGANISATION>University of Bari</ORGANISATION><CITY>Bari</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="14666" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Craig</LAST_NAME><POSITION>Senior Lecturer in Paediatrics</POSITION><EMAIL_1>m.craig@unsw.edu.au</EMAIL_1><EMAIL_2>mariac@chw.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Divison of Women's and Children's Health</DEPARTMENT><ORGANISATION>University of New South Wales</ORGANISATION><ADDRESS_1>St George Hospital</ADDRESS_1><ADDRESS_2>Gray Street</ADDRESS_2><CITY>Kogarah</CITY><ZIP>2025</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 93503637</PHONE_1><PHONE_2>+61 2 98451111</PHONE_2><FAX_1>+61 2 93503810</FAX_1></ADDRESS></PERSON><PERSON ID="16132" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sankar</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Navaneethan</LAST_NAME><EMAIL_1>navanes@ccf.org</EMAIL_1><EMAIL_2>sankardass@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Nephrology and Hypertension</DEPARTMENT><ORGANISATION>Glickman Urological and Kidney institute, Cleveland Clinic</ORGANISATION><CITY>Cleveland</CITY><ZIP>44195</ZIP><REGION>OH</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 216 6369230</PHONE_1><FAX_1>+1 216 4449378</FAX_1></ADDRESS></PERSON><PERSON ID="4552" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Craig</LAST_NAME><POSITION>Head of Clinical Research</POSITION><EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1><EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>(a) Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead</DEPARTMENT><ORGANISATION>(b) School of Public Health, The University of Sydney</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-26 15:35:21 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="16" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="8" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis"><DATE DAY="18" MONTH="3" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-18 04:06:34 +0100" MODIFIED_BY="Narelle Willis"><DATE DAY="13" MONTH="5" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 09:45:34 +0200" MODIFIED_BY="Narelle Willis">
<DATE DAY="26" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Sydney School of Public Health, non-established PhD scholarship</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>2002-03 Young Investigator Scholarship, Italian Society of Nephrology</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-27 14:59:06 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2008-08-26 15:35:59 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-26 15:35:59 +1000" MODIFIED_BY="[Empty name]">Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease</TITLE>
<SUMMARY_BODY>
<P>Kidney disease develops in 25% to 40% of diabetic patients, usually 20 to 25 years after the onset of diabetes. Approximately one third of those with diabetic kidney disease (DKD) will progress to end-stage kidney disease (ESKD) and will require long-term dialysis or possibly receive a kidney transplant. Many patients however may die from associated coronary artery disease or other cardiovascular causes before the onset of ESKD. Antihypertensive drugs have been shown to not only be of benefit to the heart but to also provide kidney protection by slowing the progression of DKD to ESKD. Two drugs in particular have been considered equally effective for patients with DKD - these are angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA). However studies have focused on kidney protection rather than over mortality. The aim of this review was to assess the benefits and harms or ACEI and AIIRA therapy in patients with DKD. Fifty studies (13,215 patients) were identified comparing ACEi to placebo, AIIRA to placebo and ACEi to AIIRA. The risk of death from any cause was not significantly reduced with the use of ACEi versus placebo, AIIRA versus placebo or ACEi versus AIIRA. However when we looked at the studies which used the maximum dose tolerated of ACEi rather than the lower, so-called renal doses, there was a significant reduction in the risk of death due to any cause. We were unable to determine which drug provides better protection due to the lack of head-to-head trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-27 14:58:27 +1000" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND>
<P>Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally effective for patients with diabetic kidney disease (DKD), but renal and not mortality outcomes have usually been considered. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the benefits and harms ACEi and AIIRA in patients with DKD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched MEDLINE (1966 to December 2005), EMBASE (1980 to December 2005), the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> issue 4 2005) and contacted known investigators.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Studies comparing ACEi or AIIRA with placebo or each other in patients with DKD were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-27 14:58:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>Two authors independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as risk ratio (RR) with 95% confidence intervals (CI). Heterogeneity among studies was explored using the Cochran Q statistic and the I² test, subgroup analyses and random effects meta-regression.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-27 14:58:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Forty nine studies (12,067 patients) were identified. Thirty eight compared ACEi with placebo, four compared AIIRA with placebo and seven compared ACEi and AIIRA directly. There was no significant difference in the risk of all-cause mortality for ACEi versus placebo (RR 0.91, 95% CI 0.71 to 1.17) and AIIRA versus placebo (RR 0.99, 95% CI 0.85 to 1.17). A subgroup analysis of studies using full-dose ACEi versus studies using half or less than half the maximum tolerable dose of ACEi showed a significant reduction in the risk of all-cause mortality with the use of full-dose ACEi (RR 0.78, 95% CI 0.61 to 0.98). Baseline mortality rates were similar in the ACEi and AIIRA studies. The effects of ACEi and AIIRA on renal outcomes (ESKD, doubling of creatinine, prevention of progression of micro- to macroalbuminuria, remission of micro- to normoalbuminuria) were similarly beneficial. Reliable estimates of effect of ACEi versus AIIRA could not be obtained from the three studies in which they were compared directly because of their small sample size.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Although the survival benefits of ACEi are known for patients with DKD, the relative effects on survival of ACEi with AIIRA are unknown due to the lack of adequate direct comparison studies. In placebo controlled studies, only ACEi (at the maximum tolerable dose, but not lower so-called renal doses) were found to significantly reduce the risk of all-cause mortality. Renal and toxicity profiles of these two classes of agents were not significantly different.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-27 14:59:06 +1000" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2008-08-27 14:52:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Diabetic kidney disease (DKD), defined as the presence of micro- or macroalbuminuria in patients with diabetes, occurs in 25% to 40% of type 1 and 2 diabetic patients within 20 to 25 years of the onset of diabetes (<LINK REF="REF-Ritz-1999" TYPE="REFERENCE">Ritz 1999</LINK>). Both types of patients probably share the same pathogenetic and clinical stages of renal damage, including renal hypertrophy, incipient (microalbuminuria: urine albumin excretion 30-300 mg/d) nephropathy, overt (macroalbuminuria: &gt; 300 mg/d) nephropathy and, finally, the presence of impairment of glomerular filtration rate (GFR) up to end-stage kidney disease (ESKD) (<LINK REF="REF-Mogensen-1995" TYPE="REFERENCE">Mogensen 1995</LINK>; <LINK REF="REF-Mogensen-1999" TYPE="REFERENCE">Mogensen 1999</LINK>) About one third of patients with DKD progress to ESKD (<LINK REF="REF-Ritz-1999" TYPE="REFERENCE">Ritz 1999</LINK>).</P>
<P>Agents used to delay the progression of DKD include beta-blockers, calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors (ACEi), and angiotensin II receptor antagonists (AIIRA). Since large scale randomised controlled trials (RCTs) have shown that ACEi and AIIRA slow the deterioration of renal function and reduce proteinuria, these have become the most broadly used agents in diabetic patients with nephropathy and major international guidelines (<LINK REF="REF-Arauz_x002d_Pacheo-2003" TYPE="REFERENCE">Arauz-Pacheo 2003</LINK>; <LINK REF="REF-JNC-7-2003" TYPE="REFERENCE">JNC 7 2003</LINK>) advocate for their equivalent use as first line agents in these populations (<LINK REF="STD-CAPTOPRIL-1993" TYPE="STUDY">CAPTOPRIL 1993</LINK>; <LINK REF="STD-HOPE-2000" TYPE="STUDY">HOPE 2000</LINK>; <LINK REF="STD-IDNT-2001" TYPE="STUDY">IDNT 2001</LINK>; <LINK REF="REF-Kasiske-1993" TYPE="REFERENCE">Kasiske 1993</LINK>; <LINK REF="STD-RENAAL-2001" TYPE="STUDY">RENAAL 2001</LINK>).<BR/>
<BR/>If a patient has diabetes and nephropathy, mortality is reported to be 10% to 40% within 10 years of diagnosis, depending on cardiovascular comorbidities, with the primary cause of early death being fatal cardiovascular events. The presence of micro- or macroalbuminuria has been shown to be an independent risk factor for early death due to cardiovascular events in diabetic patients over and above the increased risk conferred by the diabetic status (<LINK REF="REF-Dinneen-1997" TYPE="REFERENCE">Dinneen 1997</LINK>). Microalbuminuria is associated with a two- to fourfold increase in the risk of death whereas macroalbuminuria/overt proteinuria and hypertension are associated with an even higher risk when present together.</P>
<P>In view of current guidelines recommendations on equivalent use of ACEi and AIIRA in these populations, we performed a systematic review of RCTs of ACEi and AIIRA used in patients with DKD to evaluate the evidence basis supporting these statements, with particular focus on their effects on renal and cardiovascular outcomes.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the benefits and harms of ACEi and AIIRA in patients with DKD, with major focus on renal and cardiovascular outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-27 14:59:06 +1000" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2008-08-26 15:36:27 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>RCTs of at least six months duration in which ACEi or AIIRA were compared with placebo or no treatment or in which the relative effects of the agents were compared directly, head-to-head, in patients with DKD, were included in this systematic review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>RCTs of patients with DKD were included, independent of stage of nephropathy, either microalbuminuria (albumin excretion 30-300 mg/d) or macroalbuminuria (albumin excretion &gt;300 mg/d).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-08-26 15:36:13 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>ACEi versus placebo or no treatment</LI>
<LI>AIIRA versus placebo or no treatment</LI>
<LI>Head-to-head comparative RCTs of ACEi versus AIIRA</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-26 15:36:27 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>All-cause mortality</LI>
<LI>ESKD</LI>
<LI>Doubling of serum creatinine concentration</LI>
<LI>Progression from micro- to macroalbuminuria</LI>
<LI>Regression from micro- to normoalbuminuria</LI>
<LI>Drug related toxicity, including cough, headache, hyperkalaemia, impotence and pedal oedema</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-26 15:36:45 +1000" MODIFIED_BY="[Empty name]">
<P>Search strategies were independently designed and performed by two separate investigators (GFMS, MC) in collaboration with the Cochrane Renal Group's Trial Search Coordinators at various stages from 2003 with a final update in December 2005.</P>
<P>The following electronic biomedical databases were searched</P>
<OL>
<LI>Cochrane Renal Groups studies register and the Cochrane Central Register of Controlled Trials (CENTRAL, in <I>The Cochrane Library</I> issue 4 2005)</LI>
<LI>MEDLINE(1966 - December 2005)</LI>
<LI>EMBASE (1988 - December 2005)</LI>
</OL>
<P>We performed a combined search to identify studies for this review and the review <I>Antihypertensive agents for preventing diabetic kidney disease</I> (<LINK REF="REF-Strippoli-2005" TYPE="REFERENCE">Strippoli 2005</LINK>) and screened as described below.</P>
<P>CENTRAL and the Renal Group's specialised register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective (<U>http://www.cochrane.us/masterlist.asp</U>). Therefore we did not specifically search conference proceedings. Please refer to The Cochrane Renal Review Group's Module in <I>The Cochrane Library</I> for the most up-to-date list of conference proceedings.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-27 14:59:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>This review was undertaken by six authors (GFMS, MC, JD, CB, SDN, JCC). The search strategies described were used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened independently by (GS, MC, SDN and CB), who discarded studies that were not applicable based on the inclusion criteria for this review, however studies and reviews that might include relevant data or information on studies were retained initially and their full-text version was analysed. Authors GS, MC, SDN and CB independently assessed abstracts of all citations retrieved by the searches and, if necessary, the full text of these studies to determine study eligibility. Data extraction was carried out independently by the same reviewers using standard data extraction forms. Where more than one publication of one trial existed, only the publication with the most complete data was used. Any further information or clarification required from the authors was requested by written or electronic correspondence and relevant information obtained in this manner was included in the review. Disagreements in data extraction were resolved by discussion among authors.</P>
<SUBSECTION>
<HEADING LEVEL="3">Study quality</HEADING>
<P>The methodological quality of included studies was assessed independently by GFMS, MC, SDN and CB without blinding to authorship or journal using the checklist developed by the Cochrane Renal Group. Discrepancies were resolved by discussion among authors. The quality items assessed were allocation concealment, blinding of investigators, participants outcome assessors, data assessors, intention-to-treat analysis, and the completeness to follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality checklist</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Adequate (A): Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study</LI>
<LI>Unclear (B): Randomisation stated but no information on method used is available</LI>
<LI>Inadequate (C): Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<UL>
<LI>Blinding of investigators: Yes/no/not stated</LI>
<LI>Blinding of participants: Yes/no/not stated</LI>
<LI>Blinding of outcome assessor: Yes/no/not stated</LI>
<LI>Blinding of data analysis: Yes/no/not stated</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intention-to-treat analysis</HEADING>
<UL>
<LI>Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>Yes: Not specifically stated but confirmed upon study assessment</LI>
<LI>No: Not reported and lack of intention-to-treat analysis confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation).</LI>
<LI>No: Stated, but not confirmed upon study assessment</LI>
<LI>Not stated</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Completeness to follow-up</HEADING>
<P>Per cent of participants excluded or lost to follow-up.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical assessment</HEADING>
<P>The effect of ACEi or AIIRA in individual studies were summarised using risk ratio (RR) with 95% confidence intervals (CI). Data of all studies comparing the same interventions (ACEi versus placebo, AIIRA versus placebo, ACEi versus AIIRA) were pooled in meta-analyses using the random effects model. Heterogeneity of treatment effects between studies was examined using the Cochran Q and I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Subgroup analysis and random effects meta-regression were performed as applicable to explore the influence of the following sources of heterogeneity on treatment effect: duration of follow up, type of diabetes (type 1, type 2 or studies including mixed populations of type 1 and type 2 diabetic patients), type of drug (different agents of the same class), presence or absence of hypertension at baseline, stage of DKD (studies enrolling patients with microalbuminuria, macroalbuminuria or mixed populations of patients with micro- and macroalbuminuria), and specific quality items (allocation concealment, blinding, use of intention -to-treat analysis). meta-regression analyses were undertaken in STATA version 8.0.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-27 14:53:10 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2008-08-27 14:53:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>The combined search identified a total of 5701 citations, of which 5376 were excluded after title and abstract review. The major reasons for exclusion were a non-randomised design, non-antihypertensive interventions, study populations with non-DKD, and duplicate publications. Full text analysis of 325 articles lead to the final inclusion of 49 studies (73 publications) which met the inclusion criteria (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>- <I>Flow chart of study identification</I>) (<LINK REF="STD-ABCD-1996" TYPE="STUDY">ABCD 1996</LINK>; <LINK REF="STD-Ahmad-1997" TYPE="STUDY">Ahmad 1997</LINK>; <LINK REF="STD-Ahmad-2003" TYPE="STUDY">Ahmad 2003</LINK>; <LINK REF="STD-AIPRI-1996" TYPE="STUDY">AIPRI 1996</LINK>; <LINK REF="STD-ATLANTIS-SG-2000" TYPE="STUDY">ATLANTIS SG 2000</LINK>; <LINK REF="STD-Bakris-1994" TYPE="STUDY">Bakris 1994</LINK>; <LINK REF="STD-Bauer-1992" TYPE="STUDY">Bauer 1992</LINK>; <LINK REF="STD-Bojestig-2001" TYPE="STUDY">Bojestig 2001</LINK>; <LINK REF="STD-Capek-1994" TYPE="STUDY">Capek 1994</LINK>; <LINK REF="STD-CAPTOPRIL-1993" TYPE="STUDY">CAPTOPRIL 1993</LINK>; <LINK REF="STD-Carella-1999" TYPE="STUDY">Carella 1999</LINK>; <LINK REF="STD-Chase-1993" TYPE="STUDY">Chase 1993</LINK>; <LINK REF="STD-Cordonnier-1999" TYPE="STUDY">Cordonnier 1999</LINK>; <LINK REF="STD-Crepaldi-1998" TYPE="STUDY">Crepaldi 1998</LINK>; <LINK REF="STD-DETAIL-2004" TYPE="STUDY">DETAIL 2004</LINK>; <LINK REF="STD-DIABHYCAR-2004" TYPE="STUDY">DIABHYCAR 2004</LINK>; <LINK REF="STD-ESPRIT-2001" TYPE="STUDY">ESPRIT 2001</LINK>; <LINK REF="STD-EUCLID-1997" TYPE="STUDY">EUCLID 1997</LINK>; <LINK REF="STD-Garg-1998" TYPE="STUDY">Garg 1998</LINK>; <LINK REF="STD-Hansen-1994" TYPE="STUDY">Hansen 1994</LINK>; <LINK REF="STD-HOPE-2000" TYPE="STUDY">HOPE 2000</LINK>; <LINK REF="STD-IDNT-2001" TYPE="STUDY">IDNT 2001</LINK>; <LINK REF="STD-IRMA_x002d_2-2001" TYPE="STUDY">IRMA-2 2001</LINK>; <LINK REF="STD-JAPAN_x002d_IDDM-2002" TYPE="STUDY">JAPAN-IDDM 2002</LINK>; <LINK REF="STD-Jerums-2001" TYPE="STUDY">Jerums 2001</LINK>; <LINK REF="STD-Jerums-2004" TYPE="STUDY">Jerums 2004</LINK>; <LINK REF="STD-Ko-2005" TYPE="STUDY">Ko 2005</LINK>; <LINK REF="STD-Lacourciere-2000" TYPE="STUDY">Lacourciere 2000</LINK>; <LINK REF="STD-Laffel-1995" TYPE="STUDY">Laffel 1995</LINK>; <LINK REF="STD-Lebovitz-1994" TYPE="STUDY">Lebovitz 1994</LINK>; <LINK REF="STD-Marre-1987" TYPE="STUDY">Marre 1987</LINK>; <LINK REF="STD-Mathiesen-1999" TYPE="STUDY">Mathiesen 1999</LINK>; <LINK REF="STD-Muirhead-1999" TYPE="STUDY">Muirhead 1999</LINK>; <LINK REF="STD-Nankervis-1998" TYPE="STUDY">Nankervis 1998</LINK>; <LINK REF="STD-O_x0027_Donnell-1993" TYPE="STUDY">O'Donnell 1993</LINK>; <LINK REF="STD-Parving-1989" TYPE="STUDY">Parving 1989</LINK>; <LINK REF="STD-Parving-2001a" TYPE="STUDY">Parving 2001a</LINK>; <LINK REF="STD-Phillips-1993" TYPE="STUDY">Phillips 1993</LINK>; <LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK>; <LINK REF="STD-Ravid-1993" TYPE="STUDY">Ravid 1993</LINK>; <LINK REF="STD-RENAAL-2001" TYPE="STUDY">RENAAL 2001</LINK>; <LINK REF="STD-Rizzoni-2005" TYPE="STUDY">Rizzoni 2005</LINK>; <LINK REF="STD-Romero-1993" TYPE="STUDY">Romero 1993</LINK>; <LINK REF="STD-Sano-1994" TYPE="STUDY">Sano 1994</LINK>; <LINK REF="STD-Sato-2003" TYPE="STUDY">Sato 2003</LINK>; <LINK REF="STD-Stornello-1992" TYPE="STUDY">Stornello 1992</LINK>; <LINK REF="STD-Tan-2002" TYPE="STUDY">Tan 2002</LINK>; <LINK REF="STD-Trevisan-1995" TYPE="STUDY">Trevisan 1995</LINK>; <LINK REF="STD-Tutuncu-2001" TYPE="STUDY">Tutuncu 2001</LINK>). Data on characteristics of the populations, interventions and outcomes were extracted from all studies and supplemental data on design features and outcomes were obtained from the authors of ten studies or from duplicate publications relating to the primary trial.</P>
<P>Of the 49 studies, 38 (8970 patients) compared ACEi with placebo (<LINK REF="STD-ABCD-1996" TYPE="STUDY">ABCD 1996</LINK>; <LINK REF="STD-Ahmad-1997" TYPE="STUDY">Ahmad 1997</LINK>; <LINK REF="STD-Ahmad-2003" TYPE="STUDY">Ahmad 2003</LINK>; <LINK REF="STD-AIPRI-1996" TYPE="STUDY">AIPRI 1996</LINK>; <LINK REF="STD-ATLANTIS-SG-2000" TYPE="STUDY">ATLANTIS SG 2000</LINK>; <LINK REF="STD-Bakris-1994" TYPE="STUDY">Bakris 1994</LINK>; <LINK REF="STD-Bauer-1992" TYPE="STUDY">Bauer 1992</LINK>; <LINK REF="STD-Bojestig-2001" TYPE="STUDY">Bojestig 2001</LINK>; <LINK REF="STD-Capek-1994" TYPE="STUDY">Capek 1994</LINK>; <LINK REF="STD-CAPTOPRIL-1993" TYPE="STUDY">CAPTOPRIL 1993</LINK>; <LINK REF="STD-Carella-1999" TYPE="STUDY">Carella 1999</LINK>; <LINK REF="STD-Chase-1993" TYPE="STUDY">Chase 1993</LINK>; <LINK REF="STD-Cordonnier-1999" TYPE="STUDY">Cordonnier 1999</LINK>; <LINK REF="STD-Crepaldi-1998" TYPE="STUDY">Crepaldi 1998</LINK>; <LINK REF="STD-DIABHYCAR-2004" TYPE="STUDY">DIABHYCAR 2004</LINK>; <LINK REF="STD-ESPRIT-2001" TYPE="STUDY">ESPRIT 2001</LINK>; <LINK REF="STD-EUCLID-1997" TYPE="STUDY">EUCLID 1997</LINK>; <LINK REF="STD-Garg-1998" TYPE="STUDY">Garg 1998</LINK>; <LINK REF="STD-Hansen-1994" TYPE="STUDY">Hansen 1994</LINK>; <LINK REF="STD-HOPE-2000" TYPE="STUDY">HOPE 2000</LINK>; <LINK REF="STD-JAPAN_x002d_IDDM-2002" TYPE="STUDY">JAPAN-IDDM 2002</LINK>; <LINK REF="STD-Jerums-2001" TYPE="STUDY">Jerums 2001</LINK>; <LINK REF="STD-Jerums-2004" TYPE="STUDY">Jerums 2004</LINK>; <LINK REF="STD-Laffel-1995" TYPE="STUDY">Laffel 1995</LINK>; <LINK REF="STD-Lebovitz-1994" TYPE="STUDY">Lebovitz 1994</LINK>; <LINK REF="STD-Marre-1987" TYPE="STUDY">Marre 1987</LINK>; <LINK REF="STD-Mathiesen-1999" TYPE="STUDY">Mathiesen 1999</LINK>; <LINK REF="STD-Nankervis-1998" TYPE="STUDY">Nankervis 1998</LINK>; <LINK REF="STD-O_x0027_Donnell-1993" TYPE="STUDY">O'Donnell 1993</LINK>; <LINK REF="STD-Parving-1989" TYPE="STUDY">Parving 1989</LINK>; <LINK REF="STD-Parving-2001a" TYPE="STUDY">Parving 2001a</LINK>; <LINK REF="STD-Phillips-1993" TYPE="STUDY">Phillips 1993</LINK>; <LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK>; <LINK REF="STD-Ravid-1993" TYPE="STUDY">Ravid 1993</LINK>; <LINK REF="STD-Romero-1993" TYPE="STUDY">Romero 1993</LINK>; <LINK REF="STD-Sano-1994" TYPE="STUDY">Sano 1994</LINK>; <LINK REF="STD-Stornello-1992" TYPE="STUDY">Stornello 1992</LINK>; <LINK REF="STD-Trevisan-1995" TYPE="STUDY">Trevisan 1995</LINK>), four (2540 patients) compared AIIRA with placebo (<LINK REF="STD-Lacourciere-2000" TYPE="STUDY">Lacourciere 2000</LINK>; <LINK REF="STD-Muirhead-1999" TYPE="STUDY">Muirhead 1999</LINK>; <LINK REF="STD-RENAAL-2001" TYPE="STUDY">RENAAL 2001</LINK>; <LINK REF="STD-Tutuncu-2001" TYPE="STUDY">Tutuncu 2001</LINK>), and seven (557 patients) compared ACEi with AIIRA (<LINK REF="STD-DETAIL-2004" TYPE="STUDY">DETAIL 2004</LINK>; <LINK REF="STD-IDNT-2001" TYPE="STUDY">IDNT 2001</LINK>; <LINK REF="STD-IRMA_x002d_2-2001" TYPE="STUDY">IRMA-2 2001</LINK>; <LINK REF="STD-Ko-2005" TYPE="STUDY">Ko 2005</LINK>; <LINK REF="STD-Rizzoni-2005" TYPE="STUDY">Rizzoni 2005</LINK>; <LINK REF="STD-Sato-2003" TYPE="STUDY">Sato 2003</LINK>; <LINK REF="STD-Tan-2002" TYPE="STUDY">Tan 2002</LINK>).</P>
<P>Of studies comparing ACEi with placebo, 20 enrolled patients with type 1 diabetes, 13 enrolled patients with type 2 diabetes, and five enrolled mixed populations of type 1 and type 2 diabetic patients. Seventeen studies enrolled patients with hypertension at baseline, the remaining enrolled normotensive patients. In 20 studies, other antihypertensive agents were administered beyond the randomised interventions (ACEi or AIIRA) in a non-randomised fashion to equalise blood pressure in both groups, minimise the confounding effect of blood pressure. Twenty five studies enrolled patients with microalbuminuria, eight enrolled patients with macroalbuminuria, and five enrolled mixed populations of micro- and macroalbuminuric patients. Three studies also enrolled minimal proportions of patients with normoalbuminuria and were therefore included.</P>
<P>The four studies that compared AIIRA with placebo all enrolled hypertensive patients with type 2 diabetes. Antihypertensive co-interventions were given in all four studies. Two studies enrolled patients with microalbuminuria and the other two studies enrolled patients with macroalbuminuria.<B>
<BR/>
</B>
<BR/>Of the seven studies comparing ACEi with AIIRA directly, six enrolled microalbuminuric patients and one enrolled mixed populations of micro- and macroalbuminuric patients. Six studies enrolled patients with type 2 diabetes and one study enrolled patients with both type 1 and type 2 diabetes. Six studies enrolled hypertensive patients and one trial enrolled normotensive participants. Antihypertensive co-interventions were given in two studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-26 15:38:24 +1000" MODIFIED_BY="[Empty name]">
<P>By current standards, trial methodological quality was suboptimal.</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Allocation concealment was unclear in 40/49 (82%) studies, inadequate in 1/49 (2%) trial, and adequate in 8/49 (16%) studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Blinding occurred in the participants in 36/49 (73%) studies, investigators in 32/49 (65%) studies, and outcome assessors in 4/49 (8%) studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reported intention-to-treat analysis</HEADING>
<P>An intention-to-treat analysis was used in 15/49 (31%) studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of follow-up</HEADING>
<P>Between 0% and 20% of patients were lost to follow-up in 45/49 (92%) studies and between 21% and 41% were lost to follow-up in 4/49 (8%) studies.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-26 15:50:52 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">All-cause mortality</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus placebo/no treatment</HEADING>
<P>There was no significant reduction in the risk of all-cause mortality with ACEi compared with placebo/no treatment (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (21 studies, 7295 patients): RR 0.91, 95% CI 0.71 to 1.17). This analysis was dominated by two studies, which contributed 49.68% and 37.78% of the weight to the summary estimate (<LINK REF="STD-DIABHYCAR-2004" TYPE="STUDY">DIABHYCAR 2004</LINK>; <LINK REF="STD-HOPE-2000" TYPE="STUDY">HOPE 2000</LINK>) but there was no significant heterogeneity between the studies (heterogeneity &#967;² = 11.04, I² = 27.6 %). A subgroup analysis of studies which used ACEi at the maximum tolerable dose compared with placebo/no treatment, there was a significant reduction in the risk of all-cause mortality (Analysis <I>1.02</I> (5 studies, 2034 patients): RR 0.78, 95% CI 0.61 to 0.98) while this was not found in studies using half or less than half the maximum tolerable dose of these agents (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>
<U>.1</U> (4 studies, 5261 patients): RR 1.18, 95% CI 0.41 to 3.44). There was no significant heterogeneity in any of these analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">AIIRA versus placebo/no treatment</HEADING>
<P>No statistically significant reduction in the risk of all-cause mortality was found in the five studies (3409 patients) of AIIRA versus placebo/no treatment (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>: RR 0.99, 95% CI 0.85 to 1.17). This analysis was dominated by two studies, which contributed 64.6% and 34.9% of the weight to the summary estimate (<LINK REF="STD-IDNT-2001" TYPE="STUDY">IDNT 2001</LINK>; <LINK REF="STD-RENAAL-2001" TYPE="STUDY">RENAAL 2001</LINK>). There was no significant heterogeneity between the studies (&#967;² = 0.63 , I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus AIIRA</HEADING>
<P>No statistically significant reduction in the risk of all-cause mortality was found in the only three studies (307 patients) that compared ACEi with AIIRA (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>: RR 0.92, 95% CI 0.31 to 2.78).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ESKD and doubling of serum creatinine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus placebo/no treatment</HEADING>
<P>There was a significant reduction in the risk of ESRD with ACEi compared to placebo/no treatment (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (10 studies, 6819 patients): RR 0.60, 95% CI 0.39 to 0.93) with no significant heterogeneity between the studies (&#967;² = 1.71, I² = 0%).</P>
<P>There was some evidence of reduction of the risk of doubling of serum creatinine concentration with ACEi compared to placebo/no treatment (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (9 studies, 6780 patients): RR 0.68, 95% CI 0.47 to 1.00). There was no significant heterogeneity between the studies (&#967;² = 9.52, I² = 37.0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">AIIRA versus placebo/no treatment</HEADING>
<P>There was a significant reduction in the risk of ESKD with AIIRA compared to placebo/no treatment (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (3 studies, 3251 patients): RR 0.78, 95% CI 0.67 to 0.91) with no significant heterogeneity between the studies (&#967;² = 0.05, I² = 0%).</P>
<P>There was also a significant reduction in the risk of doubling of serum creatinine concentration with AIIRA compared to placebo/no treatment (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (3 studies, 3251 patients), RR 0.79, 95% CI 0.67 to 0.93), with no significant heterogeneity between the studies (&#967;² = 1.22, I² = 18.2%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus AIIRA</HEADING>
<P>The seven studies that compared ACEi with AIIRA did not report the outcome of ESKD or doubling of serum creatinine, and we were unable to obtain these data from the authors.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Progression from micro- to macroalbuminuria</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus placebo/no treatment</HEADING>
<P>ACEi significantly reduced the risk of progression from micro- to macroalbuminuria (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (17 studies, 2036 patients): RR 0.45, 95% CI 0.29 to 0.69).There was no significant heterogeneity between the studies (&#967;² = 26.48, I² = 47.1%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">AIIRA versus placebo/no treatment</HEADING>
<P>The use of AIIRA versus placebo/no treatment was also associated with a significant reduction in the risk of progression from micro- to macroalbuminuria (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK> (3 studies, 761 patients): RR 0.49, 95% CI 0.32 to 0.75), with no significant heterogeneity between the studies (&#967;² = 1.10, I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus AIIRA</HEADING>
<P>Progression from micro to macroalbuminuria was reported in one trial (41 patients) only, which showed no significant difference in risk (<LINK REF="STD-Ko-2005" TYPE="STUDY">Ko 2005</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Regression for micro- to normoalbuminuria</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus placebo/no treatment</HEADING>
<P>There was a significant increase in regression from micro- to normoalbuminuria with ACEi versus placebo/no treatment <I>(</I>
<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (16 studies, 1910 patients): RR 3.06, 95% CI 1.76 to 5.35), with no significant heterogeneity between the studies (&#967;² = 23.91, I² = 45.6%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">AIIRA versus placebo/no treatment</HEADING>
<P>There was a significant increase in regression from micro- to normoalbuminuria with AIIRA versus placebo/no treatment (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> (2 studies, 670 patients): RR 1.42, 95% CI 1.05 to 1.93) with no significant heterogeneity between the studies (&#967;² = 0.51, I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus AIIRA</HEADING>
<P>Regression from micro- to normoalbuminuria was reported in only one head-to-head study and showed a non-significant difference in the risk (<LINK REF="STD-Tutuncu-2001" TYPE="STUDY">Tutuncu 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Toxicity</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">ACEi versus placebo/no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Cough</HEADING>
<P>The use of ACEi was associated with a significant increase in the risk of cough (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (10 studies, 7087 patients): RR 3.17, 95% CI 2.29 to 4.38), with no significant heterogeneity between the studies (&#967;² = 4.30, I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hyperkalaemia</HEADING>
<P>The use of ACEi was not found to be associated with a significant increase in the risk of hyperkalaemia (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (2 studies, 1219 patients): RR 0.85, 95% CI 0.32 to 2.21), with no significant heterogeneity between the studies (&#967;² = 0.05, I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Headache</HEADING>
<P>Four studies (6186 patients) reported headaches and there was no significant increase in the risk of headache with ACEi compared to placebo/no treatment (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>: RR 0.92, 95% CI 0.33 to 2.53). Also in this analysis, there was no significant heterogeneity between the studies (&#967;² = 3.20, I² = 6.2%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Impotence</HEADING>
<P>Five studies (1528 patients) reported on impotence, and there was no evidence of a significant difference in the risk with ACEi compared to placebo/no treatment (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>: RR 1.02, 95% CI 0.26 to 3.91), and there was no significant heterogeneity between the studies (&#967;² = 0.61, I² = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">AIIRA versus placebo/no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Cough</HEADING>
<P>AIIRA were not found to be associated with an increased risk of cough compared to placebo/no treatment (Analysis <I>2.07</I> (2 studies, 194 patients): RR 4.93, 95% CI 1.00 to 24.35). There was no significant heterogeneity between the studies (&#967;² = 1.43, I² = 30.0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hyperkalaemia</HEADING>
<P>There was a significant increase in the risk of hyperkalaemia with AIIRA compared to placebo/no treatment (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK> (1study, 1148 patients): RR 5.41, 95% CI 1.20 to 24.28).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Headache</HEADING>
<P>One trial (91 patients) of AIIRA versus placebo/no treatment reported the outcome of headache and found no significant increase in risk with AIIRA (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>: RR 0.70, 95% CI 0.03 to 16.68).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Impotence</HEADING>
<P>There were no studies of AIIRA versus placebo/no treatment reporting the outcome of impotence.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Investigation of sources of heterogeneity</HEADING>
<P>Metaregression and subgroup analyses for sources of heterogeneity were only possible in studies of ACEi versus placebo/no treatment given the small number of studies evaluating AIIRA versus placebo/no treatment or ACEi versus AIIRA directly. There was no evidence that the effect of ACEi on all-cause mortality (interaction P value = 0.84), doubling of serum creatinine (interaction P value = 0.56), ESKD (interaction P value = 0.05) and progression from micro- to macroalbuminuria (interaction P value = 0.12) varied according to type of diabetes. On the contrary, the rate of regression from micro- to normoalbuminuria was significantly higher in patients with type 2 diabetes (interaction P value &lt; 0.001).</P>
<P>The presence (versus absence) of hypertension in the enrolled populations did not significantly impact on the effect of ACEi compared to placebo/no treatment on all-cause mortality (interaction P value = 0.45), doubling of serum creatinine (interaction P value = 0.22), ESKD (interaction P value = 0.34), but normotensive patients had a significantly higher rate of progression from micro- to macroalbuminuria (interaction P value = 0.001) and significantly higher rate of regression from micro- to normoalbuminuria (interaction P value = 0.01).</P>
<P>The stage of nephropathy in enrolled populations (microalbuminuria versus macroalbuminuria or mixed populations with micro- or macroalbuminuria) did not significantly affect any of these outcomes in patients treated with ACEi compared to placebo/no treatment (all-cause mortality, interaction P value = 0.92; doubling of serum creatinine, interaction P value = 0.88, ESKD, interaction P value = 0.55, progression from micro- to macroalbuminuria, interaction P value = 0.86, regression from micro- to normoalbuminuria, interaction P value = 0.80). There were also no significant variations in the effect of ACEi versus placebo/no treatment on any of these outcomes by any trial quality indicators (allocation concealment, blinding, use of intention-to-treat analysis and proportions of patients lost to follow-up). The few significant differences observed in these analyses were all explained by the results of the large <LINK REF="STD-HOPE-2000" TYPE="STUDY">HOPE 2000</LINK> study. When we excluded this study from our analyses, results were homogeneous for all outcomes.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-26 15:46:59 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Key findings</HEADING>
<P>Placebo controlled studies have shown a survival advantage for ACEi when used at the maximum tolerable dose but not at "renal doses" (half or less than half the maximum tolerable dose) in patients with DKD. On the other hand, there has been no data showing a survival advantage with AIIRA versus placebo/no treatment, in patients with DKD. The relative survival advantage of one class of antihypertensives over the other in this population is, however, still unknown because only indirect comparisons based on small studies are available. ACEi, used at the maximum tolerable dose, significantly reduced the risk of all-cause mortality (mainly cardiovascular) by about 20% and progression from micro- to macroalbuminuria by about 55%. They also increased the rate of regression from micro- to normoalbuminuria by about threefold. We found no evidence that these effects are related to baseline hypertension, type of diabetes, stage of DKD, and duration of treatment. In comparison, current studies of AIIRA in patients with DKD have not shown a reduction in all-cause mortality, with a RR of 0.99 and narrow 95% CI (0.85 to 1.17), which is unlikely to be explained by chance alone. There is strong evidence that AIIRA are beneficial for renal outcomes, with a reduction in risk of ESKD and doubling of serum creatinine of about 22%, a reduction in progression rates from micro- to macroalbuminuria by around 51%, and an increase in the regression from micro- to normoalbuminuria of about 42%. Three potential explanations for these apparent different effects between the two classes of antihypertensives are chance, confounding, and true differences. The usual 5% level for statistical significance was reached for all renal outcomes for AIIRA versus ACEi,and this threshold was reached for ESKD, the prevention of progression from micro- to macroalbuminuria, and regression of micro- to normoalbuminuria, but not doubling of serum creatinine. The point estimates of effect for all renal outcomes favoured ACEi versus AIIRA, but there was some imprecision surrounding these summary point estimates for ACEi due to lower event rates and because of the heterogeneity in study results due to one large study (<LINK REF="STD-HOPE-2000" TYPE="STUDY">HOPE 2000</LINK>). For all cause mortality, the absence of benefit shown by AIIRA is unlikely to be due to chance alone because the summary point estimate is close to unity (0.99) and the 95% CIs are relatively narrow. We did not formally test differences in ACEi and AIIRA through indirect comparison since there are clear differences in the design and conduct of the ACEi and AIIRA studies, which may explain apparent differences in results if such non randomised comparison was performed. In particular, micro-HOPE primarily included high cardiac risk patients with relatively low renal risk, and although end of treatment blood pressure was not different between the two groups (possibly due to survival bias), equalisation of blood pressure was not targeted and so may have confounded the observed benefit of ramipril. True differences in the relative effects of ACEi and AIIRA can only be established by adequately powered studies that directly compare the two agents, which unfortunately are currently not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Comparison with existing knowledge</HEADING>
<P>In studies that enrolled patients with diabetes without nephropathy (which have not been included in this review), it has been shown that intensive control of blood pressure with any agent reduced cardiovascular morbidity and mortality, independent of type of agent used (<LINK REF="REF-Grossman-2001" TYPE="REFERENCE">Grossman 2001</LINK>). In addition, in one study in which losartan was compared to atenolol in hypertensive patients with diabetes, losartan significantly reduced the risk of all-cause mortality (<LINK REF="REF-Wachtell-2003" TYPE="REFERENCE">Wachtell 2003</LINK>). Following myocardial infarction, ACEi have been shown to reduce all-cause mortality (<LINK REF="REF-Zunetti-1996" TYPE="REFERENCE">Zunetti 1996</LINK>), whereas no relevant information with AIIRA are available. Our findings are consistent with other large meta-analyses in patients with congestive heart failure, which showed a significant reduction in the risk of all cause mortality with ACEi versus placebo/no treatment but not for AIIRA (<LINK REF="REF-Cohn-2001" TYPE="REFERENCE">Cohn 2001</LINK>; <LINK REF="REF-Garg-1995" TYPE="REFERENCE">Garg 1995</LINK>). Previous studies have already analysed the role of various antihypertensive agents, including ACEi and AIIRA, in patients affected by DKD. Particular focus was on the effect of ACEi in specific categories of patients (e.g. only type 1 diabetics). A recent meta-analysis of individual patient data from the ACEi in DKD Triallist Group concluded that in normotensive patients with type 1 diabetes and microalbuminuria, ACEi significantly reduced progression to macroalbuminuria and increased the chances of regression to normoalbuminuria (<LINK REF="REF-ACEIDN-2001" TYPE="REFERENCE">ACEIDN 2001</LINK>). An earlier metaregression analysis indicated that ACEi reduced proteinuria and preserved GFR in patients with diabetes, independent of changes in systemic blood pressure (<LINK REF="REF-Kasiske-1993" TYPE="REFERENCE">Kasiske 1993</LINK>). The main difference with our study is that we included both ACEi and AIIRA studies, obtained additional data from the authors when possible, and evaluated all outcomes of interest, including all-cause mortality, and not simply the traditional renal outcomes. Another meta-analysis on the effects of inhibitors of the renin-angiotensin system and other antihypertensive agents on renal outcomes has been recently published (<LINK REF="REF-Casas-2005" TYPE="REFERENCE">Casas 2005</LINK>). This analysis, which included small studies conducted in high-risk patients with diabetic and non-diabetic chronic nephropathies, concluded that there are no superior effects of renin-angiotensin-system blockers over other antihypertensive agents in chronic nephropathies. Comparison between these data and ours is difficult because of different inclusion criteria and research questions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Strengths and limitations</HEADING>
<P>The strength of this investigation is that it represents a comprehensive systematic review with rigid inclusion criteria for RCTs only; and a comprehensive search strategy. Data extraction, data analysis, and methodological quality assessments were performed by two or more independent investigators, and consistency was checked with all six authors. The major limitation of our study is the lack of direct comparative data of ACEi and AIIRA. Studies directly comparing the two agents were only few and small and did not report outcomes relevant to patients, therefore they were largely uninformative. Other limitations include the small number and suboptimal quality of included studies and the potential for publication bias. These issues are unlikely to be influential as the review is dominated by a few larger studies.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-26 15:46:43 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-08-26 15:46:43 +1000" MODIFIED_BY="[Empty name]">
<P>The role of ACEi in the management of patients with DKD is well established. Recently, equivalence of the newer and more expensive class of antihypertensive agents, AIIRA, has been widely advocated and is accepted in current practice. For example, the Joint National Committee on Prevention, Diagnosis and Management of Hypertension (<LINK REF="REF-JNC-7-2003" TYPE="REFERENCE">JNC 7 2003</LINK>) and the guidelines of the American Diabetes Association (ADA, <LINK REF="REF-Arauz_x002d_Pacheo-2003" TYPE="REFERENCE">Arauz-Pacheo 2003</LINK>), suggest that ACEi and AIIRA can be used interchangeably. Our study shows that there is randomised trial evidence that ACEi versus placebo/no treatment used at their maximum tolerable dose prevent death in patients with DKD, but not that AIIRA versus placebo/no treatment do. Both agents prevent progression of nephropathy and promote regression to a more favourable clinical pattern of normoalbuminuria. The relative effects of ACEi and AIIRA are uncertain. These data suggest that outside of a comparative RCT, ACEi, the cheaper class of agent with proven survival benefit, should be used as first line treatment.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The findings of this study mandate an adequately powered comparative trial of ACEi versus AIIRA with renal and all-cause mortality as measured outcomes. In general studies of the newer pharmacological agents (AIIRA) have been designed as placebo-controlled rather than direct comparisons with existing agents (ACEi). This clearly makes it easier to prove that there is a benefit with the new agent, but harder to prove differential advantage compared to existing ones, as this may be only done by indirect comparison. It should be therefore recommended that future studies compare these agents directly. Given the recent promising results of combination therapy, a factorial trial may be the preferred design. Meanwhile, undertaking an individual patient data meta-analysis may allow the effects of baseline cardiac and renal disease to be better understood and accounted for through subgroup analysis. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are indebted to Narelle Willis for editorial support and Sandra Puckeridge for administrative support. Ruth Mitchell, Linda Heslop and Gail Higgins provided search strategies for this review. We are also indebted to Janice Pogue and the HOPE triallists, Drs M Ravid, PJ Phillips, HH Parving, R Romero, S Katayama, EM Mathiesen, BR Brenner, and KC Tan who provided data of their studies upon request. This study was partly funded by a "2002 Young Investigator Scholarship" awarded to Giovanni FM Strippoli by the Italian Society of Nephrology, and by a University of Sydney School of Public Health non-established PhD scholarship.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None declared</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-26 15:44:26 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Strippoli GFM: Design, conduct, data-extraction, data-analysis, data interpretation, writing the review</LI>
<LI>Bonifati C: Data-extraction, data entry and interpretation, writing the review</LI>
<LI>Craig M: Data-extraction, writing the review</LI>
<LI>Navaneethan S: Data-extraction, data entry and interpretation, writing of review</LI>
<LI>Craig JC: Design, conduct, data-analysis, data interpretation, writing the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-27 14:54:30 +1000" MODIFIED_BY="Narelle S Willis">
<STUDIES MODIFIED="2008-08-27 14:54:30 +1000" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2008-08-27 14:54:30 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-ABCD-1996" MODIFIED="2008-08-26 15:52:47 +1000" MODIFIED_BY="[Empty name]" NAME="ABCD 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-26 15:52:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estacio RO, Jeffers B, Biggerstaff S, Schrier RW</AU>
<TI>Effects of a calcium channel antagonist versus an ace inhibitor on diabetic nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>114A</PG>
<IDENTIFIERS MODIFIED="2008-08-26 15:52:36 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-26 15:52:36 +1000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00445260"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estacio RO, Jeffers BW, Gifford N, Schrier RW</AU>
<TI>Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>23</YR>
<VL>Suppl 2</VL>
<PG>B54-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10860192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW</AU>
<TI>The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>10</NO>
<PG>645-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9486993"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-26 15:52:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estacio RO, Mehler P, Esler A, Schrier RW</AU>
<TI>Aggressive lowering of blood pressure in normotensive type 2 diabetic patients: beneficial effects on stroke, progression of retinopathy and nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>146A</PG>
<IDENTIFIERS MODIFIED="2008-08-26 15:52:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-26 15:52:47 +1000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00445261"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estacio RO, Savage S, Nagel NJ, Schrier RW</AU>
<TI>Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>3</NO>
<PG>242-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8877260"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Estacio RO. Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. [Clinical Trial. Journal Article. Randomized Controlled Trial] American Journal of Cardiology. 82(9B):9R-14R, 1998 Nov 12. UI: 9822137&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estacio RO, Schrier RW</AU>
<TI>Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial</TI>
<SO>American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>9B</NO>
<PG>9R-14R</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9822137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR</AU>
<TI>Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>5</NO>
<PG>753-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12578880"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Savage S, Estacio RO, Jeffers B, Schrier RW</AU>
<TI>Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM</TI>
<SO>Diabetes Care</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>11</NO>
<PG>1243-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8908388"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Schrier RW. Estacio RO. Esler A. Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. [Clinical Trial. Journal Article. Randomized Controlled Trial] Kidney International. 61(3):1086-97, 2002 Mar. UI: 11849464&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schrier RW, Estacio RO, Esler A, Mehler P</AU>
<TI>Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>2</NO>
<PG>1086-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11849464"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schrier RW, Estacio RO, Jeffers B</AU>
<TI>Appropriate Blood Pressure Control in NIDDM (ABCD) Trial</TI>
<SO>Diabetologia</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>12</NO>
<PG>1646-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8960857"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmad-1997" NAME="Ahmad 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ahmad J. Siddiqui MA. Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes Care. 20(10):1576-81, 1997 Oct. UI: 9314638&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad J, Siddiqui MA, Ahmad H</AU>
<TI>Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>10</NO>
<PG>1576-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9314638"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmad-2003" NAME="Ahmad 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Ahmad J. Shafique S. Abidi SM. Parwez I. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes Research &amp;amp; Clinical Practice. 60(2):131-8, 2003 May. UI: 12706322&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad J, Shafique S, Abidi SM, Parwez I</AU>
<TI>Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects</TI>
<SO>Diabetes Research &amp; Clinical Practice</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>2</NO>
<PG>131-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12706322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AIPRI-1996" NAME="AIPRI 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Maschio G. Alberti D. Janin G. Locatelli F. Mann JF. Motolese M. Ponticelli C. Ritz E. Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial] New England Journal of Medicine. 334(15):939-45, 1996 Apr 11. UI: 8596594&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M et al</AU>
<TI>Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>15</NO>
<PG>939-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8596594"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ATLANTIS-SG-2000" NAME="ATLANTIS SG 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;O'Hare P. Bilbous R. Mitchell T. O' Callaghan CJ. Viberti GC. Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Diabetes Care. 23(12):1823-9, 2000 Dec. UI: 11128360&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>O'Hare P, Bilbous R, Mitchell T, O'Callaghan CJ, Viberti GC. Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group</AU>
<TI>Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>12</NO>
<PG>1823-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11128360"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakris-1994" NAME="Bakris 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Bakris GL. Slataper R. Vicknair N. Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Diabetes &amp;amp; its Complications. 8(1):2-6, 1994 Jan-Mar. UI: 8167383&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bakris GL, Slataper R, Vicknair N, Sadler R</AU>
<TI>ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects</TI>
<SO>Journal of Diabetes &amp; its Complications</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>1</NO>
<PG>2-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8167383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-1992" NAME="Bauer 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Bakris GL. Barnhill BW. Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. [Clinical Trial. Journal Article. Randomized Controlled Trial] Kidney International. 41(4):912-9, 1992 Apr. UI: 1325010&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bakris GL, Barnhill BW, Sadler R</AU>
<TI>Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection</TI>
<SO>Kidney International</SO>
<YR>1992</YR>
<VL>41</VL>
<NO>4</NO>
<PG>912-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1325010"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bojestig-2001" NAME="Bojestig 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Bojestig M. Karlberg BE. Lindstrom T. Nystrom FH. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Diabetes Care. 24(5):919-24, 2001 May. UI: 11347755&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bojestig M, Karlberg BE, Lindstrom T, Nystrom FH</AU>
<TI>Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>5</NO>
<PG>919-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11347755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capek-1994" NAME="Capek 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Capek M. Schnack C. Ludvik B. Kautzky-Willer A. Banyai M. Prager R. Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Clinical Investigator. 72(12):961-6, 1994 Dec. UI: 7711427&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Capek M, Schnack C, Ludvik B, Kautzky-Willer A, Banyai M, Prager R</AU>
<TI>Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study</TI>
<SO>Clinical Investigator</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>12</NO>
<PG>961-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7711427"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAPTOPRIL-1993" NAME="CAPTOPRIL 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Lewis EJ. Hunsicker LG. Bain RP. Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.[see comment][erratum appears in N Engl J Med 1993 Jan 13;330(2):152]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] New England Journal of Medicine. 329(20):1456-62, 1993 Nov 11. &lt;br&gt;UI: 8413456&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lewis EJ, Hunsicker LG, Bain RP, Rohde RD</AU>
<TI>The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>20</NO>
<PG>1458-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8413456"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carella-1999" NAME="Carella 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Carella MJ. Gossain VV. Jones J. The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients. [Clinical Trial. Controlled Clinical Trial. Journal Article] Journal of Medicine. 30(5-6):305-20, 1999. UI: 10851564&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carella MJ, Gossain VV, Jones J</AU>
<TI>The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients</TI>
<SO>Journal of Medicine</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>5-6</NO>
<PG>305-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10851564"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chase-1993" NAME="Chase 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Chase HP. Garg SK. Harris S. Hoops S. Jackson WE. Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. [Clinical Trial. Journal Article. Randomized Controlled Trial] Annals of Ophthalmology. 25(8):284-9, 1993 Aug. UI: 8239321&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL</AU>
<TI>Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>8</NO>
<PG>284-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8239321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cordonnier-1999" NAME="Cordonnier 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Cordonnier DJ. Pinel N. Barro C. Maynard M. Zaoui P. Halimi S. Hurault de Ligny B. Reznic Y. Simon D. Bilous RW. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Journal of the American Society of Nephrology. 10(6):1253-63, 1999 Jun. &lt;br&gt;UI: 10361863&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cordonnier DJ, Pinel N, Barro C, Maynard M, Zaoui P, Halimi S et al</AU>
<TI>Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>6</NO>
<PG>1253-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10361863"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crepaldi-1998" NAME="Crepaldi 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Crepaldi G. Carta Q. Deferrari G. Mangili R. Navalesi R. Santeusanio F. Spalluto A. Vanasia A. Villa GM. Nosadini R. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Diabetes Care. 21(1):104-10, 1998 Jan. &lt;br&gt;UI: 9538979&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F et al</AU>
<TI>Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>1</NO>
<PG>104-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9538979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DETAIL-2004" NAME="DETAIL 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Barnett AH. Bain SC. Bouter P. Karlberg B. Madsbad S. Jervell J. Mustonen J. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.[see comment][erratum appears in N Engl J Med. 2005 Apr 21;352(16)1731]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] New England Journal of Medicine. 351(19):1952-61, 2004 Nov 4. UI: 15516696&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J et al</AU>
<TI>Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>19</NO>
<PG>1952-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15516696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DIABHYCAR-2004" NAME="DIABHYCAR 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Marre M. Lievre M. Chatellier G. Mann JF. Passa P. Menard J. DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).[see comment][erratum appears in BMJ. 2004 Mar 20;328(7441):686]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] BMJ. 328(7438):495, 2004 Feb 28. UI: 14960504&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marre M, Lievre M, Chatellier G, Mann J, Passa P, Menard J</AU>
<TI>Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7438</NO>
<PG>495-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14960504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ESPRIT-2001" NAME="ESPRIT 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Diabetes. 50(4):843-50, 2001 Apr. UI: 11289051&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baines LA</AU>
<TI>Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT)</TI>
<SO>Diabetes</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>4</NO>
<PG>843-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11289051"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EUCLID-1997" NAME="EUCLID 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Chaturvedi N. Stevenson J. Fuller JH. Rottiers R. Ferriss B. Karamanos B. Kofinis A. Petrou C. Ionescu-Tirgovisite C. Iosif C. Tamas G. Bibok G. Kervnyi Z. Kis-Gombos P. Toth J. Ferriss JB. Grealy G. Priem H. Koivisto V. Tuominen J. Kostamo E. Idzior-Walus B. Solnica B. Galicka-Latalie D. Michel G. Keipes M. Giuliani A. Herode A. Santeusanio F. Bueti A. Bistoni D. Cagini. Navalesi R. Penno G. Nannipieri M. Rizzo L. Miccoli R. Ghirlanda G. Cotroneo P. Manto A. Minella A. Saponara C. Ward J. Plater M. Ibrahim S. Ibbotson S. Mody C. Papazoglou N. Manes C. Soulis K. Voukias M. Muggeo M. Cacciatori V. Gemma ML. Dellera A. Castellarin A. Irsigler K. Abrahamian H. Gurdet C. Willinger C. Nelstrop A. Feben C. Walford S. McLelland V. Hughes S. Metelko Z. Roglic G. Rogulja Pepeonik Z&lt;br&gt;Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Lancet. 349(9068):1787-92, 1997 Jun 21. UI: 9269212&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chaturvedi N, Stevenson J, Fuller JH, Rottiers R, Ferriss B, Karamanos B et al</AU>
<TI>Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9068</NO>
<PG>1787-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9269212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Penno G. Chaturvedi N. Talmud PJ. Cotroneo P. Manto A. Nannipieri M. Luong LA. Fuller JH. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Diabetes. 47(9):1507-11, 1998 Sep. &lt;br&gt;UI: 9726242&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M et al</AU>
<TI>Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM</TI>
<SO>Diabetes</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>9</NO>
<PG>1507-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9726242"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garg-1998" MODIFIED="2008-08-27 14:54:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Garg 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-27 14:54:30 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Garg SK. Chase HP. Jackson WE. Harris S. Carmain JA. Hansen MH. Riche CR. Icaza G. Marshall G. Renal and retinal changes after treatment with Ramipril and pentoxifyline in subjects with IDDM. [Journal: Article] Annals of Ophthalmology-Glaucoma. Vol. 30(1)(pp 33-37), 1998. AN: 1998093196&lt;/p&gt;" NOTES_MODIFIED="2008-08-27 14:54:30 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garg SK, Chase HP, Jackson WE, Harris S, Carmain JA, Hansen MH et al</AU>
<TI>Renal and retinal changes after treatment with Ramipril and pentoxifylline in subjects with IDDM</TI>
<SO>Annals of Ophthalmology-Glaucoma</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>1</NO>
<PG>33-7</PG>
<IDENTIFIERS MODIFIED="2008-08-26 15:53:10 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-26 15:53:10 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1998093196"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1994" NAME="Hansen 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Hansen KW. Klein F. Christensen PD. Sorensen K. Andersen PH. Moller J. Pedersen EB. Christiansen JS. Mogensen CE. Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabete et Metabolisme. 20(5):485-93, 1994 Sep-Oct. UI: 7859897&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hansen KW, Klein F, Christensen PD, Sorensen K, Andersen PH, Moller J et al</AU>
<TI>Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients</TI>
<SO>Diabete et Metabolisme</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>5</NO>
<PG>485-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7859897"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Viberti G. Mogensen CE. Groop LC. Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] JAMA. 271(4):275-9, 1994 Jan 26. UI: 8295285&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viberti G, Mogensen CE, Groop LC, Pauls JF</AU>
<TI>Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<NO>4</NO>
<PG>275-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8295285"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HOPE-2000" NAME="HOPE 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.[see comment][erratum appears in Lancet 2000 Sep 2;356(9232):860]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Lancet. 355(9200):253-9, 2000 Jan 22. UI: 10675071&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gerstein HC, Yusuf S, Mann JF, Hoogwerf B, Zinman B, Held C et al</AU>
<TI>Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9200</NO>
<PG>253-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10675071"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mann JF. Gerstein HC. Pogue J. Bosch J. Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.[see comment]. [Clinical Trial. Controlled Clinical Trial. Journal Article. Multicenter Study] Annals of Internal Medicine. 134(8):629-36, 2001 Apr 17. UI: 11304102&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S</AU>
<TI>Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>8</NO>
<PG>629-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11304102"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IDNT-2001" NAME="IDNT 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Berl T. Hunsicker LG. Lewis JB. Pfeffer MA. Porush JG. Rouleau JL. Drury PL. Esmatjes E. Hricik D. Parikh CR. Raz I. Vanhille P. Wiegmann TB. Wolfe BM. Locatelli F. Goldhaber SZ. Lewis EJ. Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.[see comment][summary for patients in Ann Intern Med. 2003 Apr 1;138(7):I43; PMID: 12667050]. [Clinical Trial. Journal Article. Randomized Controlled Trial] Annals of Internal Medicine. 138(7):542-9, 2003 Apr 1. UI: 12667024&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al</AU>
<TI>Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>7</NO>
<PG>542-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12667024"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lewis EJ. Hunsicker LG. Clarke WR. Berl T. Pohl MA. Lewis JB. Ritz E. Atkins RC. Rohde R. Raz I. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] New England Journal of Medicine. 345(12):851-60, 2001 Sep 20. UI: 11565517 &lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al</AU>
<TI>Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>12</NO>
<PG>851-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11565517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRMA_x002d_2-2001" NAME="IRMA-2 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Parving HH. Lehnert H. Brochner-Mortensen J. Gomis R. Andersen S. Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] New England Journal of Medicine. 345(12):870-8, 2001 Sep 20. &lt;br&gt;UI: 11565519&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P et al</AU>
<TI>The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>12</NO>
<PG>870-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11565519"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JAPAN_x002d_IDDM-2002" NAME="JAPAN-IDDM 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Katayama S. Kikkawa R. Isogai S. Sasaki N. Matsuura N. Tajima N. Urakami T. Uchigata Y. Ohashi Y. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM).[erratum appears in Diabetes Res Clin Pract 2002 Jul;57(1):71]. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes Research &amp;amp; Clinical Practice. 55(2):113-21, 2002 Feb. UI: 11796177&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N et al</AU>
<TI>Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM)</TI>
<SO>Diabetes Research &amp; Clinical Practice</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>2</NO>
<PG>113-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11796177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jerums-2001" NAME="Jerums 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Jerums G. Allen TJ. Campbell DJ. Cooper ME. Gilbert RE. Hammond JJ. Raffaele J. Tsalamandris C. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] American Journal of Kidney Diseases. 37(5):890-9, 2001 May. UI: 11325669&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ et al</AU>
<TI>Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>5</NO>
<PG>890-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11325669"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jerums-2004" NAME="Jerums 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Jerums G. Allen TJ. Campbell DJ. Cooper ME. Gilbert RE. Hammond JJ. O'Brien RC. Raffaele J. Tsalamandris C. Melbourne Diabetic Nephropathy Study Group. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Diabetic Medicine. 21(11):1192-9, 2004 Nov. UI: 15498085&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ et al</AU>
<TI>Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria</TI>
<SO>Diabetic Medicine</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1192-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15498085"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ko-2005" NAME="Ko 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Ko GT. Tsang CC. Chan HC. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril. [Clinical Trial. Journal Article. Randomized Controlled Trial] Advances in Therapy. 22(2):155-62, 2005 Mar-Apr. UI: 16020405&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ko GT, Tsang CC, Chan HC</AU>
<TI>Stabilization and regression of albuminuria in chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril</TI>
<SO>Advances in Therapy</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>2</NO>
<PG>155-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16020405"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacourciere-2000" NAME="Lacourciere 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Lacourciere Y. Belanger A. Godin C. Halle JP. Ross S. Wright N. Marion J. Lacourciere Y. Belanger A. Godin C. Halle JP. Ross S. Wright N. Marion JLong-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. [Clinical Trial. Controlled Clinical Trial. Journal Article] Kidney International. 58(2):762-9, 2000 Aug. UI: 10916100&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N et al</AU>
<TI>Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy</TI>
<SO>Kidney International</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>2</NO>
<PG>762-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10916100"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laffel-1995" NAME="Laffel 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Laffel LM. McGill JB. Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] American Journal of Medicine. 99(5):497-504, 1995 Nov. UI: 7485207&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Laffel LM, McGill JB, Gans DJ</AU>
<TI>The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group</TI>
<SO>American Journal of Medicine</SO>
<YR>1995</YR>
<VL>99</VL>
<NO>5</NO>
<PG>497-504</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7485207"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lebovitz-1994" NAME="Lebovitz 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Lebovitz HE. Wiegmann TB. Cnaan A. Shahinfar S. Sica DA. Broadstone V. Schwartz SL. Mengel MC. Segal R. Versaggi JA. et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. [Clinical Trial. Journal Article. Randomized Controlled Trial] Kidney International - Supplement. 45:S150-5, 1994 Feb. UI: 8158885&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V et al</AU>
<TI>Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria</TI>
<SO>Kidney International - Supplement</SO>
<YR>1994</YR>
<VL>45</VL>
<PG>S150-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8158885"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marre-1987" NAME="Marre 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Marre M. Chatellier G. Leblanc H. Guyene TT. Menard J. Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. [Clinical Trial. Journal Article. Randomized Controlled Trial] BMJ. 297(6656):1092-5, 1988 Oct 29. UI: 2848604&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P</AU>
<TI>Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria</TI>
<SO>BMJ</SO>
<YR>1988</YR>
<VL>297</VL>
<NO>6656</NO>
<PG>1092-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2848604"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Marre M. Leblanc H. Suarez L. Guyenne TT. Menard J. Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. [Clinical Trial. Journal Article. Randomized Controlled Trial] British Medical Journal Clinical Research Ed.. 294(6585):1448-52, 1987 Jun 6. UI: 3038254&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marre M, Leblanc H, Suarez L, Guyenne TT, Menard J, Passa P</AU>
<TI>Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria</TI>
<SO>British Medical Journal Clinical Research Ed</SO>
<YR>1987</YR>
<VL>294</VL>
<NO>6585</NO>
<PG>1448-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3038254"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Marre M. Microalbuminuria and ACE inhibition in non-hypertensive diabetics. [Journal Article] Journal of Diabetic Complications. 4(2):84-5, 1990 Apr-Jun. UI: 2145309&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marre M</AU>
<TI>Microalbuminuria and ACE inhibition in non-hypertensive diabetics</TI>
<SO>Journal of Diabetic Complications</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>2</NO>
<PG>84-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2145309"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathiesen-1999" NAME="Mathiesen 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Hansen PM. Mathiesen ER. Kofoed-Enevoldsen A. Deckert T. Possible effect of angiotensin-converting enzyme inhibition on glomerular charge selectivity. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Diabetes &amp;amp; its Complications. 9(3):158-62, 1995 Jul-Sep. UI: 7548979&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen PM, Mathiesen ER, Kofoed-Enevoldsen A, Deckert T</AU>
<TI>Possible effect of angiotensin-converting enzyme inhibition on glomerular charge selectivity</TI>
<SO>Journal of Diabetes &amp; its Complications</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>3</NO>
<PG>158-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7548979"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mathiesen ER. Hommel E. Giese J. Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial] BMJ. 303(6794):81-7, 1991 Jul 13. UI: 1860008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathiesen ER, Hommel E, Giese J, Parving HH</AU>
<TI>Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>303</VL>
<NO>6794</NO>
<PG>81-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1860008"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mathiesen ER. Hommel E. Hansen HP. Smidt UM. Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. [Clinical Trial. Journal Article. Randomized Controlled Trial] BMJ. 319(7201):24-5, 1999 Jul 3. UI: 10390455&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH</AU>
<TI>Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<NO>7201</NO>
<PG>24-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10390455"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muirhead-1999" MODIFIED="2008-08-26 15:53:36 +1000" MODIFIED_BY="[Empty name]" NAME="Muirhead 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-26 15:53:36 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Muirhead N. Feagan BF. Mahon J. Lewanczuk RZ. Rodger NW. Botteri F. Oddou-Stock P. Pecher E. Cheung R. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial. [Journal: Article] Current Therapeutic Research, Clinical &amp;amp; Experimental. Vol. 60(12)(pp 650-660), 1999. AN: 2000024629&lt;/p&gt;" NOTES_MODIFIED="2008-08-26 15:53:36 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muirhead N, Feagan BF, Mahon J, Lewanczuk RZ, Rodger NW, Botteri F et al</AU>
<TI>The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>12</NO>
<PG>650-60</PG>
<IDENTIFIERS MODIFIED="2008-08-26 15:53:36 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-26 15:53:36 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2000024629"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nankervis-1998" NAME="Nankervis 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Nankervis A. Nicholls K. Kilmartin G. Allen P. Ratnaike S. Martin FI. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Metabolism: Clinical &amp;amp; Experimental. 47(12 Suppl 1):12-5, 1998 Dec UI: 9867064&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FI</AU>
<TI>Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study</TI>
<SO>Metabolism: Clinical &amp; Experimental</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>12 Suppl 1</NO>
<PG>12-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9867064"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Donnell-1993" NAME="O'Donnell 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;O'Donnell MJ. Rowe BR. Lawson N. Horton A. Gyde OH. Barnett AH. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Human Hypertension. 7(4):327-32, 1993 Aug. UI: 8410923&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH</AU>
<TI>Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>4</NO>
<PG>327-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8410923"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parving-1989" NAME="Parving 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Parving HH. Hommel E. Damkjaer Nielsen M. Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. [Clinical Trial. Journal Article. Randomized Controlled Trial] BMJ. 299(6698):533-6, 1989 Aug 26. UI: 2507061&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parving HH, Hommel E, Damkjaer Nielsen M, Giese J</AU>
<TI>Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>299</VL>
<NO>6698</NO>
<PG>533-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2507061"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parving-2001a" NAME="Parving 2001a" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Parving HH. Brenner BM. Cooper ME. de Zeeuw D. Keane WF. Mitch WE. Remuzzi G. Snapinn SM. Zhang Z. Shahinfar S. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. [Danish] [Clinical Trial. Journal Article. Randomized Controlled Trial] Ugeskrift for Laeger. 163(40):5514-9, 2001 Oct 1. UI: 11601117&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE et al</AU>
<TI>Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>40</NO>
<PG>5514-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11601117"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Parving HH. Hommel E. Jensen BR. Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. [Clinical Trial. Journal Article. Randomized Controlled Trial] Kidney International. 60(1):228-34, 2001 Jul. UI: 11422755&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parving HH, Hommel E, Jensen BR, Hansen HP</AU>
<TI>Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients</TI>
<SO>Kidney International</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>1</NO>
<PG>228-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11422755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-1993" NAME="Phillips 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Phillips PJ. Phillipou G. Bowen KM. Lowe J. Yue DK. Wischusen J. Pater G. Diabetic microalbuminuria and cilazapril. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] American Journal of Medicine. 94(4A):58S-60S, 1993 Apr 23. UI: 8488862&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Phillips PJ, Phillipou G, Bowen KM, Lowe J, Yue DK, Wischusen J et al</AU>
<TI>Diabetic microalbuminuria and cilazapril</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>94</VL>
<NO>4A</NO>
<PG>58S-60S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8488862"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poulsen-2001" NAME="Poulsen 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Poulsen PL. Ebbehoj E. Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Internal Medicine. 249(5):433-40, 2001 May. UI: 11350567&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poulsen PL, Ebbehoj E, Mogensen CE</AU>
<TI>Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2001</YR>
<VL>249</VL>
<NO>5</NO>
<PG>433-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11350567"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Poulsen PL. Ebbehoj E. Nosadini R. Fioretto P. Deferrari G. Crepaldi G. Mogensen CE. Early ACE-i intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24 h ambulatory blood pressure, and renal function. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes &amp;amp; Metabolism. 27(2 Pt 1):123-8, 2001 Apr. UI: 11353877&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poulsen PL, Ebbehoj E, Nosadini R, Fioretto P, Deferrari G, Crepaldi G et al</AU>
<TI>Early ACE-i intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24 h ambulatory blood pressure, and renal function</TI>
<SO>Diabetes &amp; Metabolism</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>2 Pt 1</NO>
<PG>123-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11353877"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravid-1993" MODIFIED="2008-08-26 15:53:55 +1000" MODIFIED_BY="[Empty name]" NAME="Ravid 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-08-26 15:53:55 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ravid M. Clutter WE. Long-term effect of enalapril on normotensive type II diabetes mellitus. [Journal: Note] Annals of Internal Medicine. Vol. 119(SUPPL. 1), 1993. AN: 1993289276&lt;/p&gt;" NOTES_MODIFIED="2008-08-26 15:53:55 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravid M, Clutter WE</AU>
<TI>Long-term effect of enalapril on normotensive type II diabetes mellitus</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>119</VL>
<NO>Suppl 1</NO>
<PG>6</PG>
<IDENTIFIERS MODIFIED="2008-08-26 15:53:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-26 15:53:55 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1993289276"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ravid M. Lang R. Rachmani R. Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial] Archives of Internal Medicine. 156(3):286-9, 1996 Feb 12. UI: 8572838&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravid M, Lang R, Rachmani R, Lishner M</AU>
<TI>Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>3</NO>
<PG>286-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8572838"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ravid M. Neumann L. Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. [Clinical Trial. Journal Article. Randomized Controlled Trial] Kidney International. 47(3):907-10, 1995 Mar. UI: 7752591&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravid M, Neumann L, Lishner M</AU>
<TI>Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors</TI>
<SO>Kidney International</SO>
<YR>1995</YR>
<VL>47</VL>
<NO>3</NO>
<PG>907-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7752591"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ravid M. Savin H. Jutrin I. Bental T. Katz B. Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Annals of Internal Medicine. 118(8):577-81, 1993 Apr 15. UI: 8452322&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M</AU>
<TI>Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>118</VL>
<NO>8</NO>
<PG>577-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8452322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RENAAL-2001" NAME="RENAAL 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Brenner BM. Cooper ME. de Zeeuw D. Keane WF. Mitch WE. Parving HH. Remuzzi G. Snapinn SM. Zhang Z. Shahinfar S. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] New England Journal of Medicine. 345(12):861-9, 2001 Sep 20. UI: 11565518&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al</AU>
<TI>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>12</NO>
<PG>861-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11565518"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizzoni-2005" NAME="Rizzoni 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Rizzoni D. Porteri E. De Ciuceis C. Sleiman I. Rodella L. Rezzani R. Paiardi S. Bianchi R. Ruggeri G. Boari GE. Muiesan ML. Salvetti M. Zani F. Miclini M. Rosei EA. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. [Clinical Trial. Journal Article. Randomized Controlled Trial] Hypertension. 45(4):659-65, 2005 Apr. &lt;br&gt;UI: 15723969&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rizzoni D, Portieri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R et al</AU>
<TI>Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus</TI>
<SO>Hypertension</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>4</NO>
<PG>659-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15723969"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romero-1993" NAME="Romero 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Romero R. Salinas I. Lucas A. Abad E. Reverter JL. Johnston S. Sanmarti A. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes Care. 16(4):597-600, 1993 Apr. UI: 8462386&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Romero R, Salinas I, Lucas A, Abad E, Reverter JL, Johnston S et al</AU>
<TI>Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors</TI>
<SO>Diabetes Care</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>4</NO>
<PG>597-600</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8462386"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sano-1994" NAME="Sano 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Sano T. Hotta N. Kawamura T. Matsumae H. Chaya S. Sasaki H. Nakayama M. Hara T. Matsuo S. Sakamoto N. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetic Medicine. 13(2):120-4, 1996 Feb. UI: 8641115&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H et al</AU>
<TI>Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study</TI>
<SO>Diabetic Medicine</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>2</NO>
<PG>120-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8641115"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Sano T. Kawamura T. Matsumae H. Sasaki H. Nakayama M. Hara T. Matsuo S. Hotta N. Sakamoto N. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes Care. 17(5):420-4, 1994 May. UI: 8062609&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T et al</AU>
<TI>Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients</TI>
<SO>Diabetes Care</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>5</NO>
<PG>420-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8062609"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2003" NAME="Sato 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Sato A. Tabata M. Hayashi K. Saruta T. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. [Clinical Trial. Journal Article] Clinical &amp;amp; Experimental Nephrology. 7(3):215-20, 2003 Sep. &lt;br&gt;UI: 14586718&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sato A, Tabata M, Hayashi K, Saruta T</AU>
<TI>Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy</TI>
<SO>Clinical &amp; Experimental Nephrology</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>3</NO>
<PG>215-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14586718"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stornello-1992" NAME="Stornello 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Stornello M. Valvo EV. Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. [Clinical Trial. Controlled Clinical Trial. Journal Article] Journal of Cardiovascular Pharmacology. 14(6):851-5, 1989 Dec. UI: 2481772&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stornello M, Valvo EV, Scapellato L</AU>
<TI>Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1989</YR>
<VL>14</VL>
<NO>6</NO>
<PG>851-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2481772"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Stornello M. Valvo EV. Scapellato L. Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial] Clinical Science. 82(1):19-23, 1992 Jan. &lt;br&gt;UI: 1310913&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stornello M, Valvo EV, Scapellato L</AU>
<TI>Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers</TI>
<SO>Clinical Science</SO>
<YR>1992</YR>
<VL>82</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1310913"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2002" NAME="Tan 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Tan KC. Chow WS. Ai VH. Lam KS. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes/Metabolism Research Reviews. 18(1):71-6, 2002 Jan-Feb. UI: 11921421&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tan KC, Chow WS, Ai VH, Lam KS</AU>
<TI>Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria</TI>
<SO>Diabetes/Metabolism Research Reviews</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>1</NO>
<PG>71-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11921421"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trevisan-1995" NAME="Trevisan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Trevisan R. Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] American Journal of Hypertension. 8(9):876-83, 1995 Sep. UI: 8541002&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Trevisan R, Tiengo A</AU>
<TI>Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group</TI>
<SO>American Journal of Hypertension</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>9</NO>
<PG>876-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8541002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tutuncu-2001" NAME="Tutuncu 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Tutuncu NB. Gurlek A. Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Acta Diabetologica. 38(4):157-61, 2001 Dec. UI: 11855793&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tutuncu NB, Gurlek A, Gedik O</AU>
<TI>Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study</TI>
<SO>Acta Diabetologica</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>4</NO>
<PG>157-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11855793"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-REIN-1998" NAME="REIN 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Ruggenenti P. Perna A. Gherardi G. Gaspari F. Benini R. Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial] Lancet. 352(9136):1252-6, 1998 Oct 17. UI: 9788454&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G</AU>
<TI>Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9136</NO>
<PG>1252-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9788454"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-26 15:57:45 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-26 15:56:21 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACEIDN-2001" MODIFIED="2008-08-26 15:54:10 +1000" MODIFIED_BY="[Empty name]" NAME="ACEIDN 2001" TYPE="JOURNAL_ARTICLE">
<AU>ACE Inhibitors in Diabetic Nephropathy Trialist Group</AU>
<TI>Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting-enzyme inhibitors? A meta-analysis of individual patient data</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>5</NO>
<PG>370-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11242497"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arauz_x002d_Pacheo-2003" MODIFIED="2008-08-26 15:54:15 +1000" MODIFIED_BY="[Empty name]" NAME="Arauz-Pacheo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Arauz-Pacheo C, Parrott MA, Raskin P, American Diabetes Association</AU>
<TI>Treatment of hypertension in adults with diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26 Suppl 1</VL>
<PG>S80-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12502624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Casas-2005" MODIFIED="2008-08-26 15:54:17 +1000" MODIFIED_BY="[Empty name]" NAME="Casas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD et al</AU>
<TI>Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9502</NO>
<PG>2026-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16338452"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cohn-2001" MODIFIED="2008-08-26 15:54:19 +1000" MODIFIED_BY="[Empty name]" NAME="Cohn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators</AU>
<TI>A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>23</NO>
<PG>1667-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11759645"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dinneen-1997" MODIFIED="2008-08-26 15:54:21 +1000" MODIFIED_BY="[Empty name]" NAME="Dinneen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dinneen SF, Gerstein HC</AU>
<TI>The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1997</YR>
<VL>157</VL>
<NO>13</NO>
<PG>1413-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9224218"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garg-1995" MODIFIED="2008-08-26 15:54:24 +1000" MODIFIED_BY="[Empty name]" NAME="Garg 1995" TYPE="JOURNAL_ARTICLE">
<AU>Garg R, Yusuf S</AU>
<TI>Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>18</NO>
<PG>1450-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7654275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grossman-2001" MODIFIED="2008-08-26 15:54:26 +1000" MODIFIED_BY="[Empty name]" NAME="Grossman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Grossman E, Messerli FH, Goldbourt U</AU>
<TI>Intensive blood pressure control and drugs reduce morbidity and mortality in hypertension and diabetes mellitus</TI>
<SO>Evidence Based Medicine</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>2</NO>
<PG>44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 2001419226"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-08-26 15:54:28 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-JNC-7-2003" MODIFIED="2008-08-26 15:54:33 +1000" MODIFIED_BY="[Empty name]" NAME="JNC 7 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al</AU>
<TI>Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC-7 report</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>19</NO>
<PG>2560-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12748199"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kasiske-1993" MODIFIED="2008-08-26 15:54:37 +1000" MODIFIED_BY="[Empty name]" NAME="Kasiske 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF</AU>
<TI>Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>118</VL>
<NO>2</NO>
<PG>129-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8416309"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mogensen-1995" MODIFIED="2008-08-26 15:54:39 +1000" MODIFIED_BY="[Empty name]" NAME="Mogensen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mogensen CE</AU>
<TI>Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients</TI>
<SO>Journal of Diabetes &amp; its Complications</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>4</NO>
<PG>337-49</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8573761"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mogensen-1999" MODIFIED="2008-08-26 15:54:41 +1000" MODIFIED_BY="[Empty name]" NAME="Mogensen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mogensen CE</AU>
<TI>Drug treatment for hypertensive patients in special situations: diabetes and hypertension</TI>
<SO>Clinical &amp; Experimental Hypertension (New York)</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>5-6</NO>
<PG>895-906</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10423111"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ritz-1999" MODIFIED="2008-08-26 15:54:43 +1000" MODIFIED_BY="[Empty name]" NAME="Ritz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ritz E, Ortho SR</AU>
<TI>Nephropathy in patients with type 2 diabetes mellitus</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>15</NO>
<PG>1127-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10511612"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2005" MODIFIED="2008-08-26 15:56:21 +1000" MODIFIED_BY="[Empty name]" NAME="Strippoli 2005" TYPE="COCHRANE_REVIEW">
<AU>Strippoli GFM, Craig M, Craig JC</AU>
<TI>Antihypertensive agents for preventing diabetic kidney disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-26 15:56:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-26 15:56:21 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004136.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wachtell-2003" MODIFIED="2008-08-26 15:54:52 +1000" MODIFIED_BY="[Empty name]" NAME="Wachtell 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE et al</AU>
<TI>Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>11</NO>
<PG>901-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14644892"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zunetti-1996" MODIFIED="2008-08-26 15:54:54 +1000" MODIFIED_BY="[Empty name]" NAME="Zunetti 1996" TYPE="JOURNAL_ARTICLE">
<AU>Zuanetti G</AU>
<TI>Prognosis of diabetic patients post-MI: the role of ACE inhibitor treatment. GISSI-3 Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico</TI>
<SO>Journal of Diabetes &amp; its Complications</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>3</NO>
<PG>139-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8807459"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-08-26 15:57:45 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Strippoli-2004" MODIFIED="2008-08-26 15:54:59 +1000" MODIFIED_BY="[Empty name]" NAME="Strippoli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC</AU>
<TI>Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>329</VL>
<NO>7470</NO>
<PG>828-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15459003"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-27 14:54:11 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-27 14:54:11 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-27 13:51:06 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-ABCD-1996">
<CHAR_METHODS>
<P>Country: USA<BR/>Setting/Design: Multicentre<BR/>Time frame: NS<BR/>Randomisation method: Permuted block randomisation within strata<BR/>Blinding<BR/>- Participants: No<BR/>- Investigators: No<BR/>- Outcome assessors: No<BR/>- Data analysis: No<BR/>Intention-to-treat: No<BR/>Follow-up period: 5-7 years<BR/>Loss to follow-up: NS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:51:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 40-74 years</LI>
<LI>DM: Type 2</LI>
<LI>Mean BP: 80-89 mm Hg</LI>
<LI>Patients are likely to complete 5-7 years of study; patients willing to participate after a complete discussion of the study and who have signed the consent from; patients unlikely to move from Denver area within the next 5 years</LI>
</UL>
<P>
<B>Enalapril group 1</B>
</P>
<UL>
<LI>Number: 52</LI>
<LI>Age: 49.8 (43-58)</LI>
<LI>Sex (M/F): 30/22</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 51</LI>
<LI>Age: 50.3 (45-55)</LI>
<LI>Sex (M/F): 30/21</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Pregnant or lactating females. Women of childbearing potential not using reliable contraception; potential pregnancy during the study</LI>
<LI>Allergies to dihydropyridines or ACEi</LI>
<LI>Recent or current substance abusers</LI>
<LI>State of mental or physical competence inadequate to comply the study</LI>
<LI>Second to third-degree uncorrected heart block</LI>
<LI>MI or CVA within the previous 6 months or CAB surgery within the previous 3 months</LI>
<LI>Unstable angina pectoris within the previous six months</LI>
<LI>Congestive heart failure (NYHA III or IV)</LI>
<LI>Treatment with ACEi or CCB</LI>
<LI>Accelerated/malignant hypertension (current the previous 5 years)</LI>
<LI>Current severe peripheral vascular disease manifested by gangrene or imminent amputation</LI>
<LI>Imminent or recent aortic dissection and/or previous mesenteric infarction</LI>
<LI>HD or peritoneal dialysis and/or SCr &gt; 3 mg/dL</LI>
<LI>Bilateral renal artery stenosis or renal artery stenosis in a solitary functioning kidney</LI>
<LI>Organ transplant recipients</LI>
<LI>Significant hyperkalaemia (3 or more measurements &gt; 6 mEq/L)</LI>
<LI>Progressive nephropathic diseases other than diabetic nephropathy</LI>
<LI>Severe liver disease</LI>
<LI>History of malignancies or active cancer</LI>
<LI>DBP &lt; 80 mm Hg off antihypertensive agents</LI>
<LI>Isolated systolic hypertension (SBP mean &gt; 160 mm Hg and DBP mean &lt; 90 mm Hg off all antihypertensive agents)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:23:30 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Enalapril group 1</B>
</P>
<UL>
<LI>Intensive treatment: DBP target 75 mm Hg</LI>
<LI>5 mg/d titrated to 10, 20 and then 40 mg/d as initial medication plus placebo</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Moderate BP control: DBP target 80-89 mm Hg</LI>
<LI>Placebo</LI>
</UL>
<P>
<B>Co-interventions</B>
<BR/>If study intervention alone did not achieve the target BP, then open-labeled antihypertensive medication were added in a step-wise manner. Additional antihypertensive agents added at the descretion of tne medical director but did not include a CCB or ACEi</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:23:21 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>GFR</LI>
<LI>UAE</LI>
<LI>Creatinine clearance</LI>
<LI>BP</LI>
<LI>Retinopathy</LI>
<LI>Neuropathy</LI>
<LI>CVE</LI>
<LI>Laboratory measurements</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 16:35:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmad-1997">
<CHAR_METHODS>
<P>Country: India<BR/>Setting/Design: University<BR/>Time frame: NS<BR/>Randomisation method: NS<BR/>Blinding<BR/>- Participants: Yes<BR/>- Investigators: No<BR/>- Outcome assessors: No<BR/>- Data analysis: No<BR/>Intention-to-treat: No<BR/>Follow-up period: 5 years<BR/>Loss to follow-up: 13</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 16:35:31 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 43-55 years</LI>
<LI>Known duration of diabetes &lt; 15 years</LI>
<LI>No history and clinical or laboratory evidence of non-diabetic renal, systemic, cardiac or hepatic diseases</LI>
<LI>BMI &lt; 27 kg/m²</LI>
<LI>Normal BP values on 2 consecutive examinations (SBP &lt;/= 140 mm Hg; DBP &lt;/= 90 mm Hg)</LI>
<LI>GFR &gt; 90 mL/min</LI>
<LI>AER of 20-200 µg/min on 2 consecutive visits without evidence of UTI</LI>
</UL>
<P>
<B>Enalapril group 1</B>
</P>
<UL>
<LI>Number: NS</LI>
<LI>Age: NS</LI>
<LI>Sex(M/F): NS</LI>
</UL>
<P>
<B>Enalapril group 2</B>
</P>
<UL>
<LI>Number: NS</LI>
<LI>Age: NS</LI>
<LI>Sex(M/F): NS</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:28:45 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Enalapril group 1</B>
<BR/>10 mg/d </P>
<P>
<B>Enalapril group 2</B>
<BR/>Moderate treatment </P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:29:00 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AER</LI>
<LI>GFR</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 16:35:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmad-2003">
<CHAR_METHODS>
<P>Country: India<BR/>Setting/Design: University<BR/>Time frame: NS<BR/>Randomisation method: NS<BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 5 years<BR/>Loss to follow-up: 13</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 16:35:46 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1</LI>
<LI>Age: &lt; 40 years</LI>
<LI>Duration of diabetes: 5-25 years</LI>
<LI>HbA1c: &lt; 9% for preceding 3 months</LI>
<LI>BP: Sitting &lt; 140/90 mm Hg on no antihypertensive treatment</LI>
<LI>GFR: &gt; 90mL/min</LI>
<LI>BMI: Stable</LI>
<LI>AER: 20-200 µg/min on 2 consecutive visits</LI>
<LI>Renal biopsy at entry and the end of the study</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 37</LI>
<LI>Age: 31.3 (3.2)</LI>
<LI>Sex (M/F): 19/18</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 36</LI>
<LI>Age: 31.7 (3.8)</LI>
<LI>Sex (M/F): 19/17</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Evidence of non-diabetic renal disease, systemic, cardiac and hepatic disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:29:57 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Enalapril group</B>
<BR/>10 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:30:12 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>UAE</LI>
<LI>BP</LI>
<LI>GFR</LI>
<LI>Histomorphometric features (mean glomerular volume, mesangial volume and glomerular basement membrane thickness)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:51:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-AIPRI-1996">
<CHAR_METHODS>
<P>Country: Italy <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes<BR/> - Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 36 months <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:51:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>SCr: 1.5-4.0 mg/dL</LI>
<LI>CrCl: 30-60 mL/min with variations of less than 30% in at least 3 measurements of CrCl during a 3-month screening period and less than 15% during a subsequent 2-week single blind placebo period</LI>
</UL>
<P>
<B>Benazepril group</B>
</P>
<UL>
<LI>Number: NS</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: NS</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Treatment with corticosteroid, NSAIDs or immunosuppressive drugs</LI>
<LI>AER &gt; 10 g/24 h and serum albumin &lt; 25g/L (each measured at least 3 times, and twice during the screening period)</LI>
<LI>Renovascular hypertension</LI>
<LI>Malignant hypertension or a MI or CVA in the 6 months preceding the study</LI>
<LI>CHF (NYHA III - IV)</LI>
<LI>DM type 1</LI>
<LI>Elevated serum aminotransferase concentration</LI>
<LI>Collagen disease</LI>
<LI>Obstructive uropathy</LI>
<LI>Cancer</LI>
<LI>Chronic cough</LI>
<LI>History of allergy to an ACEi</LI>
<LI>Drug or alcohol abuse</LI>
<LI>Pregnancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:33:01 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Benazepril group</B>
<BR/>0 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:33:11 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Doubling of the baseline SCr concentration or the need for dialysis</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:53:27 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-ATLANTIS-SG-2000">
<CHAR_METHODS>
<P>Country: UK <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 42</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:53:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1</LI>
<LI>Microalbuminuria: 20-200 µg/min in 2 of 3 collections</LI>
<LI>Untreated BP: &lt; 150/90 mm Hg for patients &lt; 50 years and &lt; 165/90 mm Hg for patients 50-65 years</LI>
</UL>
<P>
<B>Ramipril group 1</B>
</P>
<UL>
<LI>Number: 47</LI>
<LI>Age: 44 (11)</LI>
<LI>Sex (M/F): 44/3</LI>
</UL>
<P>
<B>Ramipril group 2</B>
</P>
<UL>
<LI>Number: 45</LI>
<LI>Age: 40 (13)</LI>
<LI>Sex (M/F): (44/1)</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 48</LI>
<LI>Age: 40 (12)</LI>
<LI>Sex (M/F): 46/2</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Pregnant or lactating</LI>
<LI>Women of child-bearing potential and not using adequate contraception</LI>
<LI>Concomitant therapy for hypertension</LI>
<LI>Treatment one or more NSAIDs</LI>
<LI>History of drug or alcohol abuse</LI>
<LI>Other known renal diseases or raised</LI>
<LI>Creatinine levels &gt; 120 &#956;mol/L)</LI>
<LI>Liver function twice that of normal on repeat testing</LI>
<LI>Iodine sensitivity</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:37:54 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Ramipril group 1</B>
<BR/>25 mg/d</P>
<P>
<B>Ramipril group 2</B>
<BR/>5 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:38:07 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AER</LI>
<LI>BP</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 16:39:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bakris-1994">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: Hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 18 months <BR/>Loss to follow-up: 7</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 16:39:16 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1</LI>
<LI>Positive family history for cardiovascular disease</LI>
<LI>Hypertension</LI>
</UL>
<P>
<B>Lisinopril group</B>
</P>
<UL>
<LI>Number: 8</LI>
<LI>Age: 28 (7)</LI>
<LI>Sex (M/F): 3/5</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 7</LI>
<LI>Age: 25 (6)</LI>
<LI>Sex (M/F): 4/3</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:39:28 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Lisinopril group</B>
<BR/>75 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:39:40 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Changes in renal size</LI>
<LI>Microalbuminuria</LI>
<LI>MAP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:51:46 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bauer-1992">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 18 months <BR/>Loss to follow-up: 9</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:51:46 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 or 2</LI>
<LI>Proteinuria: &gt; 500 mg/d before drug randomisation</LI>
<LI>No clinical or laboratory evidence of primary renal disease</LI>
<LI>Creatinine clearance: &gt; 20 mL/min/1.73 m²</LI>
<LI>Clinical evidence of additional diabetic target organ damage (diabetic retinopathy and/or peripheral neuropathy)</LI>
<LI>Persistent DBP &lt; 90 mm Hg on either no drug therapy or no conventional antihypertensive drugs excluding ACEi and CCB</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 18</LI>
<LI>Age: 44 (26-66)</LI>
<LI>Sex (M/F): 11/7</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 15</LI>
<LI>Age: 57 (47-70)</LI>
<LI>Sex (M/F): 13/2</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>HbA1c: Consistently greater than 12%</LI>
<LI>Non-compliance with drug therapy</LI>
<LI>History of hyperkalaemia or baseline serum potassium &gt; 5.2 mmol/L</LI>
<LI>Decompensated CHF</LI>
<LI>Unstable angina pectoris or history of a MI within 6 months of entering the protocol</LI>
<LI>CVD within 12 months of entering the protocol</LI>
<LI>Females with the potential to become pregnant</LI>
<LI>History of hypersensitivity reaction to ACEi peptide-like drugs</LI>
<LI>Evidence of clinically important bladder dysfunction</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:46:34 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Enalapril group</B>
<BR/>5-40 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Conventional antihypertensive drugs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:46:46 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>BP</LI>
<LI>Protein excretion/24 h</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 16:48:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bojestig-2001">
<CHAR_METHODS>
<P>Country: Sweden <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 16:47:53 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Normotensive patients (BP &lt; 90 mm Hg) with microalbuminuria (20-200 µg/min) in 2 of 3 urine collections</LI>
</UL>
<P>
<B>Ramipril group 1</B>
</P>
<UL>
<LI>Number:19</LI>
<LI>Age: 42 (10)</LI>
<LI>Sex (M/F):13/6</LI>
</UL>
<P>
<B>Ramipril group 2</B>
</P>
<UL>
<LI>Number: 18</LI>
<LI>Age: 39 (10)</LI>
<LI>Sex (M/F): 14/4</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 18</LI>
<LI>Age: 38(9)</LI>
<LI>Sex (M/F): 14/4</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Patients treated with any form of antihypertensive medication</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:48:08 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Ramipril group 1</B>
<BR/>1.25 mg/d</P>
<P>
<B>Ramipril group 2</B>
<BR/>5 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:48:23 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>ACE activity and PRA</LI>
<LI>BP</LI>
<LI>AER</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:51:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Capek-1994">
<CHAR_METHODS>
<P>Country: Austria <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 12 months <BR/>Loss to follow-up: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:51:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2 Microalbuminuria: 30-300 mg/24 h in 3 or more 24h urine collections</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 9</LI>
<LI>Age: 64 (8.2)</LI>
<LI>Sex (M/F): 5/4</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 6</LI>
<LI>Age: 63.8 (1.1)</LI>
<LI>Sex (M/F):2/4</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Heart disease</LI>
<LI>Pregnancy</LI>
<LI>Impaired renal function (SCr &lt; 1.4 mg/dL)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:50:18 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Captopril group</B>
<BR/>37.5 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:50:34 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>BP</LI>
<LI>AER</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:51:58 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-CAPTOPRIL-1993">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 36 months <BR/>Loss to follow-up: 108</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:51:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age:18-49 years</LI>
<LI>DM: Type 1 for at least 7 years, with an onset before the age of 30 years</LI>
<LI>Diabetic retinopathy</LI>
<LI>AER: &gt; 500 mg/24 h</LI>
<LI>SCr: &lt; 2.5 mg/dL</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 207</LI>
<LI>Age: 35 (7)</LI>
<LI>Sex (M/F): 107/100</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 202</LI>
<LI>Age: 34 (8)</LI>
<LI>Sex (M/F): 109/93</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Pregnancy</LI>
<LI>Dietary evaluation indicating marked departure from standard dietary recommendation</LI>
<LI>White cell count: &lt; 2500/mm³</LI>
<LI>CHF (NYHA III or worse)</LI>
<LI>Serum potassium: &gt; 6 mmol/L</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:51:35 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Captopril group</B>
<BR/>75 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:51:47 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Doubling of SCr</LI>
<LI>Death, dialysis and transplantation</LI>
<LI>Changes in renal function (SCr, CrCl, urinary protein excretion)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:52:03 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Carella-1999">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: University hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:52:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Diabetics with persistent albuminuria</LI>
<LI>Duration of diabetes: &lt; 5 years</LI>
<LI>Age: &lt; 50 years</LI>
<LI>Undetectable C-peptide levels in the face of hyperglycaemia or definite history of keto-acidosis</LI>
<LI>Weight: &lt; 30% IBW</LI>
<LI>BP: &lt; 140/90 mm Hg during 2 consecutive clinic visits</LI>
</UL>
<P>
<B>Fosinopril group</B>
</P>
<UL>
<LI>Number: 8</LI>
<LI>Age: 38 (6)</LI>
<LI>Sex (M/F): 3/5</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 8</LI>
<LI>Age: 38 (6)</LI>
<LI>Sex (M/F): 3/5</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Pregnant women</LI>
<LI>Athletes participating in regular vigorous activity</LI>
<LI>Smokers, alcohol or substance abusers</LI>
<LI>History of recurrent UTI (&gt; 3 in previous five years) or other causes of renal disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:53:35 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Fosinopril group</B>
<BR/>10 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:53:53 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AER</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 16:54:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chase-1993">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding<BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 16:54:25 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1</LI>
<LI>AER: 20-200 µg/min on at least 3 of 4 initial overnight urine collections</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 7</LI>
<LI>Age: 22 (8.4)</LI>
<LI>Sex (M/F): 7/0</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 9</LI>
<LI>Age: 19.9 (4.4)</LI>
<LI>Sex (M/F): 5/4</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 16:54:38 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Ramipril group</B>
<BR/>5.0 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:54:48 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AER</LI>
<LI>CrCl</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 18:29:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cordonnier-1999">
<CHAR_METHODS>
<P>Country: France <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 24 months<BR/>Loss to follow-up: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 18:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2</LI>
<LI>Age: 25-65 years (those under 40 were accepted only if they were diabetic for more than 2 years and did not require insulin)</LI>
<LI>BMI: &lt; 33 kg/m²</LI>
<LI>HbA1c: &gt; twice the maximal normal value</LI>
<LI>Proteinuria: &gt; 70 mg/24 h</LI>
<LI>CrCl: &gt; 60 mL/min</LI>
<LI>Normal sized kidneys with symmetrical function evaluated by scintigraphy or pyelography</LI>
</UL>
<P>
<B>Perindopril group</B>
</P>
<UL>
<LI>Number: 11</LI>
<LI>Age: 47 (7)</LI>
<LI>Sex (M/F): 11/0</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 11</LI>
<LI>Age: 47 (12)</LI>
<LI>Sex (M/F): 7/4</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Women that were not postmenopausal or didn't using medically accepted contraceptives</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 18:29:06 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Perindopril group</B>
<BR/>4 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Prazosin/diuretics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 16:57:13 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>BP</LI>
<LI>Proteinuria</LI>
<LI>CrCl</LI>
<LI>Histological characteristics</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:53:30 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Crepaldi-1998">
<CHAR_METHODS>
<P>Country: Italy <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 36 months <BR/>Loss to follow-up: 10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:53:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1</LI>
<LI>Age: 18-65 years</LI>
<LI>Onset of diabetes: Before 35 years and insulin treatment within 3 years of diagnosis</LI>
<LI>Clinical stability: HbA1c &lt; 11-30%</LI>
<LI>SBP: 115-140 mm Hg</LI>
<LI>DBP: 75-90 mm Hg</LI>
<LI>AER: 20-200 µg/min from 3 timed overnight urine collections at a routine control during the year before the trial</LI>
</UL>
<P>
<B>Lisinopril group</B>
</P>
<UL>
<LI>Number: 33</LI>
<LI>Age: 38 (11)</LI>
<LI>Sex (M/F): 21/11</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 44</LI>
<LI>Age: 37 (10)</LI>
<LI>Sex (M/F): 23/11</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Impaired renal function (SCr &gt; 10% above the upper limit of the normal laboratory range)</LI>
<LI>AER &gt; 200 µg/min</LI>
<LI>History of any non-diabetic renal disease</LI>
<LI>Haematuria</LI>
<LI>Evidence of clinically significant liver or haematological disease</LI>
<LI>Evidence of aortic or mitral valve obstruction, arrhythmias, unstable angina or a history of MI within the previous 3 months</LI>
<LI>Clinical evidence of autonomic neuropathy</LI>
<LI>Systemic malignancy</LI>
<LI>Hyperkalaemia</LI>
<LI>Serum triglycerides: &gt; 3.4 mmol/L or total cholesterol &gt; 6.5 mmol/L</LI>
<LI>Known familiar lipid disorders</LI>
<LI>Known risk of transmitting AIDS or viral hepatitis</LI>
<LI>Known hypersensitivity or contraindications to ACEi, or atenolol</LI>
<LI>Women of childbearing age not using medically acceptable methods of birth control (oral contraceptives were not allowed) or those planning a pregnancy during the treatment period</LI>
<LI>Treatment compliance over the 4-week placebo run-in of 85%</LI>
<LI>Patient on antihypertensive treatment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:00:07 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Lisinopril group</B>
<BR/>2.5-20 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Atenolol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:00:27 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Progression rate of micro- to persistent macroalbuminuria</LI>
<LI>Number of patients who had a 50% yearly increase in AER above baseline values</LI>
<LI>Number of patients who showed a regression rate from micro- to persistent normoalbuminuria</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:53:44 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-DETAIL-2004">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: Central location-based on permuted blocks <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No<BR/> - Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 5 years <BR/>Loss to follow-up: 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:53:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 35-80 years</LI>
<LI>DM: Type 2 treated by diet, diet plus oral hypoglycaemic drugs (for at least 1 year), or insulin preceded by treatment with oral agents (also for at least 1 year). Among those whose diabetes was treated with insulin, the onset of diabetes had to have occurred after the age of 40 and the BMI had to be more than 25 at the time of diagnosis</LI>
<LI>Hypertension: Mild to moderate with a resting BP &lt; 180/95 mm Hg after at least 3 months of ACEi therapy before entry into the study</LI>
<LI>Renal morphology: Normal</LI>
<LI>UAE: Mean of 3 consecutive overnight values between 11 and 999 µg/min with 2 values &gt; 10 &#956;g/min</LI>
<LI>HbA1c: &lt; 12</LI>
<LI>SCr: &lt; 1.6 mg/dL</LI>
<LI>GFR: &gt; 70 mL/min/1.73 m²</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 130</LI>
<LI>Age: 60.0 (9.1)</LI>
<LI>Sex (M/F): 95/35</LI>
</UL>
<P>
<B>Telmiosartan group</B>
</P>
<UL>
<LI>Number: 120</LI>
<LI>Age: 61.2 (8.5)</LI>
<LI>Sex (M/F): 87/33</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Any condition (other than cardiovascular disease) that could restrict long-term survival and known allergy to study drugs or iohexol</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:02:02 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Enalapril group</B>
<BR/>20 mg/d</P>
<P>
<B>Telmiosartan group</B>
<BR/>80 mg/d</P>
<P>
<B>Co-interventions</B>
<BR/>Others antihypertensive agents (except ACEi or AIRA) were allowed after 2 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:02:38 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Changes in GFR</LI>
<LI>UAE</LI>
<LI>SCr</LI>
<LI>BP</LI>
<LI>The rates of clinical events (ESKD, MI, stroke, CHF)</LI>
<LI>Rate of death from all causes</LI>
<LI>Rate of adverse events</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:52:20 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-DIABHYCAR-2004">
<CHAR_METHODS>
<P>Country: France <BR/>Setting/Design: <BR/>Multicentre <BR/>Time frame: 1995-2001 <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 3-6 months <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:52:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: &gt; 50 years</LI>
<LI>DM: Type 2</LI>
<LI>AER: &gt; 20 mg/L</LI>
</UL>
<P>
<B>Ramipril group</B>
</P>
<UL>
<LI>Number: 2443</LI>
<LI>Age: 65.2 (8.4)</LI>
<LI>Sex (M/F): 1701/742</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 2469</LI>
<LI>Age: 65.0 (8.3)</LI>
<LI>Sex (M/F): 1731/738</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>SCr &gt; 150 µmol/L</LI>
<LI>Treatment with insulin, ACEi or AIIRA</LI>
<LI>Documented CHF</LI>
<LI>MI during the past 3 months</LI>
<LI>UTI</LI>
<LI>Previous intolerance to an ACEi</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:04:26 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Ramipril group</B>
<BR/>1.25 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:04:55 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cardiovascular death</LI>
<LI>CVE</LI>
<LI>ESKD</LI>
<LI>Doubling of creatinine</LI>
<LI>Amputation beyond MTP joint</LI>
<LI>Regression of micro- to normoalbuminuria, macro- to micro/normoalbuminuria</LI>
<LI>Adverse events (cough, hypertension, vertigo, diarrhoea, headache)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:52:26 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-ESPRIT-2001">
<CHAR_METHODS>
<P>Country: UK <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 3 years <BR/>Loss to follow-up: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:52:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 before age of 40 years</LI>
<LI>Age: 18-65 years</LI>
<LI>AER: 30-1500 µg/min</LI>
<LI>GRF: &gt; 70 mL/min</LI>
<LI>SCr: &lt; 130 µmol/L</LI>
<LI>BP: Sitting &lt; 150/90 mm Hg on no antihypertensive treatment</LI>
<LI>Patients had to agree to a renal biopsy at entry and the end of the study</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 18</LI>
<LI>Age: 37 (24-64)</LI>
<LI>Sex (M/F): 11/7</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 18</LI>
<LI>Age: 38 (20-60)</LI>
<LI>Sex (M/F): 13/5</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Uncontrolled diabetes (HbA1c &gt; 6 SD above the local normal range)</LI>
<LI>Current antihypertensive NSAIDs</LI>
<LI>Hyperkalaemia</LI>
<LI>Other renal or urinary tract disease</LI>
<LI>Liver disease</LI>
<LI>Recent CVD or cardiac disease</LI>
<LI>Pregnancy</LI>
<LI>Any contraindication to renal biopsy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:06:20 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Enalapril group</B>
<BR/>10 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:06:42 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>GFR</LI>
<LI>AER</LI>
<LI>BP</LI>
<LI>Structural parameters (Vv mesangium, Vv matrix, GBM thickness)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:52:31 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-EUCLID-1997">
<CHAR_METHODS>
<P>Country: UK <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: Yes <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 82</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:52:31 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 20-59 years</LI>
<LI>Males and females</LI>
<LI>DM: Type 1 (diagnosis before age 36 and the need for continuous insulin therapy within a year of diagnosis)</LI>
<LI>Resting DBP: 75-90 mm Hg and SBP &lt;/= 155 mm Hg</LI>
</UL>
<P>
<B>Lisinopril group</B>
</P>
<UL>
<LI>Number: 265</LI>
<LI>Age: 33 (27-40)</LI>
<LI>Sex (M/F): 155/110</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 265</LI>
<LI>Age: 33 (28-41)</LI>
<LI>Sex (M/F): 167/98</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>History of renal-artery stenosis, cardiac-valve obstruction, or accelerated hypertension</LI>
<LI>Recent (within the previous 3 months) MI, coronary bypass surgery, stroke, or CHF</LI>
<LI>Abnormal renal function: SCr &gt; 1.8 mg/dL in the previous 6 months, persistent proteinuria (albustix positive or an AER &gt; 250 µg/min) or persistent haematuria on 3 occasions within the previous 12 months</LI>
<LI>Postural hypotension</LI>
<LI>Medication that affects BP</LI>
<LI>Previous idiosyncratic reaction to ACEi</LI>
<LI>Seropositive for hepatitis B or HIV</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:08:10 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Lisinopril group</B>
<BR/>10-20 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:08:16 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AER</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 17:09:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garg-1998">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: Yes <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 12 months <BR/>Loss to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 17:09:28 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1</LI>
<LI>AER: 20-300 g/min on at least 2 overnight urine collections</LI>
<LI>Early background diabetic retinopathy</LI>
</UL>
<P>
<B>Ramipril group</B>
</P>
<UL>
<LI>Number: 7</LI>
<LI>Age: 26.1 (2.17)</LI>
<LI>Sex (M/F): 1/6</LI>
</UL>
<P>
<B>Ramipril + pentoxifylline group</B>
</P>
<UL>
<LI>Number: 7</LI>
<LI>Age: 23.7 (1.1)</LI>
<LI>Sex (M/F): 3/4</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 4</LI>
<LI>Age: 24.1 (0.93)</LI>
<LI>Sex (M/F): 2/2</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:09:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Ramipril group</B>
<BR/>5 mg/d</P>
<P>
<B>Ramipril + pentoxifylline group</B>
<BR/>5 mg/d + 400 mg 3x/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:09:57 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>BP</LI>
<LI>AER</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 17:11:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansen-1994">
<CHAR_METHODS>
<P>Country: Denmark <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 17:10:33 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 (duration 4-28 years)</LI>
<LI>Onset of diabetes: Before 39 years</LI>
<LI>Age: 18-55 years</LI>
<LI>BP: &lt; 160/95 mm Hg for patients &gt;35 years and &lt; 145/90 mm Hg &lt; 35 years</LI>
<LI>UAE: 20-200 µg/min in more than 1 of 3 overnight urines collected during a screening procedure</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 10</LI>
<LI>Age: 32 (13)</LI>
<LI>Sex (M/F): 9/1</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 12</LI>
<LI>Age: 33 (8)</LI>
<LI>Sex (M/F): 9/3</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Treatment with antihypertensive or diuretic drugs</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:10:45 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Captopril group</B>
<BR/>100 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:11:09 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>BP</LI>
<LI>UAE</LI>
<LI>Renal clearance</LI>
<LI>Extracellular volume</LI>
<LI>Echocardiography</LI>
<LI>Glycaemic control</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 17:12:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HOPE-2000">
<CHAR_METHODS>
<P>Country: Canada <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: Yes<BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: mean 4.5 years <BR/>Loss to follow-up:13</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 17:12:10 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Patients with and without diabetes aged 55 years or older with a history of cardiovascular disease (coronary artery disease, stroke, or peripheral vascular disease) or diabetes plus at least one other cardiovascular risk factor (total cholesterol &gt; 5.2 mmol/L, HDL cholesterol &lt; 0.9 mmol/L, hypertension, known microalbuminuria, or current smoking)</LI>
</UL>
<P>
<B>Ramipril group</B>
</P>
<UL>
<LI>Number: 1808</LI>
<LI>Age: 65.3 (6.4)</LI>
<LI>Sex (M/F): 1112/636</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 1769</LI>
<LI>Age: 65.6 (6.6)</LI>
<LI>Sex (M/F): 1143/626</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Dipstick-positive proteinuria or established diabetic nephropathy</LI>
<LI>Other severe renal disease</LI>
<LI>Hyperkalaemia</LI>
<LI>CHF</LI>
<LI>Low ejection fraction (&lt; 0.4)</LI>
<LI>Uncontrolled hypertension</LI>
<LI>Recent MI or stroke (&lt; 4weeks)</LI>
<LI>Use of or hypersensitivity to vitamin E or ACEi</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:12:33 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Ramipril group</B>
<BR/>10 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:12:59 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Development of MI, stroke or cardiovascular death</LI>
<LI>Total mortality, admission to hospital for CHFor unstable angina, cardiovascular revascularisation or development of overt nephropathy</LI>
<LI>Any heart failure, worsening angina, and the development of diabetes in people with no history of the disorder</LI>
<LI>Progression of microalbuminuria or overt nephropathy in participants with diabetes</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 17:15:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IDNT-2001">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 30 months <BR/>Loss to follow-up: 11</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 17:14:37 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 30-70 years</LI>
<LI>DM: Type 2</LI>
<LI>Hypertension: BP &gt; 135/85 mm Hg or documented treatment with antihypertensive agents</LI>
<LI>Proteinuria at least 900 mg/24h</LI>
<LI>SCr: 1-3.0 mg/dL in women and 1.2-3.0 mg/dL in men</LI>
</UL>
<P>
<B>Irbesartan group</B>
</P>
<UL>
<LI>Number: 579</LI>
<LI>Age: 59.3 (7.1)</LI>
<LI>Sex (M/F): 378/201</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 569</LI>
<LI>Age: 58.3 (8.2)</LI>
<LI>Sex (M/F): 403/166</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 17:14:48 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Irbesartan group</B>
<BR/>75-300 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Antihypertensive agents other than ACEi, AIIRA and CCB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 17:15:15 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Doubling of SCr</LI>
<LI>Onset of ESKD (initiation of dialysis, renal transplantation or SCr &gt;/= 6 mg/dL)</LI>
<LI>Death from any cause</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 18:19:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRMA_x002d_2-2001">
<CHAR_METHODS>
<P>Country: Denmark <BR/>Setting/Design: Muticentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 2 years <BR/>Loss to follow-up: 77</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 18:18:34 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Hypertensive patients with type 2 DM</LI>
<LI>Age: 30-70 years</LI>
<LI>Persistent microalbuminuria (AER 20-200 µg/min in 2 of 3 consecutive, sterile, overnight urine samples)</LI>
<LI>SCr &#8804; 1.5 mg/dL for men and &#8804; 1.1 mg/dL for women</LI>
</UL>
<P>
<B>Irbesartan group 1</B>
</P>
<UL>
<LI>Number:195</LI>
<LI>Age: 58.4 (8)</LI>
<LI>Sex (M/F): 129/66</LI>
</UL>
<P>
<B>Irbesartan group 2</B>
</P>
<UL>
<LI>Number: 194</LI>
<LI>Age: 57.3 (7.9)</LI>
<LI>Sex (M/F): 137/57</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 201</LI>
<LI>Age: 58.3 (8.7)</LI>
<LI>Sex (M/F): 138/63</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Non-diabetic kidney disease</LI>
<LI>Cancer</LI>
<LI>Life-threatening disease with death expected to occur within 2 years</LI>
<LI>Indication for ACEi or AIRA</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 18:18:48 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Irbesartan group 1</B>
<BR/>150 mg/d</P>
<P>
<B>Irbesartan group 2</B>
<BR/>300 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Diuretics, beta-blockers, CCB (except dihydropyridines), and alpha blockers</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 18:19:05 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Incidence of progression to diabetic nephropathy</LI>
<LI>AER</LI>
<LI>CrCl</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 18:20:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-JAPAN_x002d_IDDM-2002">
<CHAR_METHODS>
<P>Country: Japan <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: mean 1.5years <BR/>Loss to follow-up: 22</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 18:20:16 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 before the age of 20 years</LI>
<LI>Age: 20-50 years</LI>
<LI>AER: &gt; 30 mg/d at the time of screening in 2 consecutive sterile urine samples collected overnight</LI>
<LI>Hypertensive cases: DBP &lt; 90mm Hg with antihypertensive agents other than ACEi, CCB and AIIRA</LI>
</UL>
<P>
<B>Imidapril group</B>
</P>
<UL>
<LI>Number: 26</LI>
<LI>Age: 36.2 (6.7)</LI>
<LI>Sex (M/F): 13/13</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 26</LI>
<LI>Age: 30.9 (8.5)</LI>
<LI>Sex (M/F): 6/20</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 27</LI>
<LI>Age: 33.4 (7.9)</LI>
<LI>Sex (M/F): 9/18</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Poor glycaemic control (HbA1c &gt; 10%)</LI>
<LI>SCr &gt; 2 mg/dL</LI>
<LI>Other renal, endocrine, cardiac, liver, gastrointestinal, or connective tissue diseases</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 18:20:36 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Imidapril group</B>
<BR/>5 mg/d</P>
<P>
<B>Captopril group</B>
<BR/>37.5 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Antihypertensive agents other than ACEi, CCB and AIIRA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 18:20:57 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AER</LI>
<LI>BP</LI>
<LI>Glycaemic control</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-26 18:29:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jerums-2001">
<CHAR_METHODS>
<P>Country: Australia <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 24-36 months <BR/>Loss to follow-up: 9</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-26 18:29:37 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 16-65 years</LI>
<LI>DM: Type 1 for at least 5 years with persistent ketonuria and weight loss on presentation</LI>
<LI>Microalbuminuria: 2 or 3 measurements of albumin excretion rate between 20-200 µg/min performed on overnight urine collections</LI>
<LI>BP: Supine 160/90 mm Hg or less if 40 years or older or 140/90 mm Hg or less if &gt; 40 years</LI>
</UL>
<P>
<B>Perindopril group</B>
</P>
<UL>
<LI>Number: 13</LI>
<LI>Age: 35 (5)</LI>
<LI>Sex (M/F): 4/9</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 10</LI>
<LI>Age: 28 (3)</LI>
<LI>Sex (M/F): 7/3</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Non-diabetic renal disease</LI>
<LI>Significant renal impairment (SCr &gt; 0.2 mmol/L)</LI>
<LI>Haematuria</LI>
<LI>Cardiac failure</LI>
<LI>Hypertension</LI>
<LI>Concurrent systemic disease</LI>
<LI>Poor diabetic control (HbA1c &gt; 10%)</LI>
<LI>Serum potassium &gt; 5 mmol/L</LI>
<LI>Recurrent UTI</LI>
<LI>Patients at high risk for pregnancy</LI>
<LI>Patients with another condition or therapy that might pose a risk to the patient or confound the results of the study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-26 18:29:40 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Perindopril group</B>
<BR/>2-8 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-26 18:22:49 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AER</LI>
<LI>BP</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:55:18 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jerums-2004">
<CHAR_METHODS>
<P>Country: Australia <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 66 months(median) <BR/>Loss to follow-up: 32</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:54:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 15-65 years</LI>
<LI>DM: Type 2 for at least 1 year</LI>
<LI>Microalbuminuria: 2 of 3 consecutive measurements of UAE between 20-200 µg/min performed on overnight urine collections</LI>
<LI>BP: Supine 140/90 mm Hg</LI>
</UL>
<P>
<B>Perindopril group</B>
</P>
<UL>
<LI>Number: 23</LI>
<LI>Age: 50 (2)</LI>
<LI>Sex (M/F): 14/9</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 27</LI>
<LI>Age: 53 (1)</LI>
<LI>Sex (M/F): 15/12</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Non-diabetic renal disease</LI>
<LI>SCr &gt; 200 µmol</LI>
<LI>Haematuria</LI>
<LI>Cardiac failure</LI>
<LI>Hypertension</LI>
<LI>Concurrent systemic disease</LI>
<LI>Poor diabetic control (HbA1c &gt; 10%)</LI>
<LI>Serum potassium &gt; 5mmol/L</LI>
<LI>Recurrent UTI</LI>
<LI>Patients at high risk for pregnancy</LI>
<LI>Patients with another condition or therapy that might pose a risk to the patient or confound the results of the study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 13:54:54 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Perindopril group</B>
<BR/>2-8 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Diuretics, CCB, beta-blockers if blood pressure remained uncontrolled.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 13:55:18 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>Development of macroproteinuria or reversal to the normoalbuminuric range</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 13:57:18 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ko-2005">
<CHAR_METHODS>
<P>Country: Hong Kong<BR/>Setting/Design: Teaching hospitals<BR/>Time frame: NS<BR/>Randomisation method: NS<BR/>Blinding<BR/>- Participants: No<BR/>- Investigators: No<BR/>- Outcome assessors: No<BR/>- Data analysis: No<BR/>Intention-to-treat: Yes<BR/>Follow-up period: 1 year<BR/>Loss to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 13:56:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2 Normal renal function or early stage nephropathy</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 20</LI>
<LI>Age: 59.7 (11.8)</LI>
<LI>Sex (M/F): 9/13</LI>
</UL>
<P>
<B>Valsartan group</B>
</P>
<UL>
<LI>Number: 22</LI>
<LI>Age: 62.1 (10.5)</LI>
<LI>Sex (M/F): 12/8</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Uncontrolled hypertension (sitting BP &gt; 200/115 mm Hg)</LI>
<LI>History of MI</LI>
<LI>CVA</LI>
<LI>Uncontrolled CHF within the previous 6 months</LI>
<LI>Significant renal impairment (SCr &gt; 150 µmol/L)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 13:57:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril group</B>
<BR/>5-10 mg/d</P>
<P>
<B>Valsartan group</B>
<BR/>80-160 mg/d</P>
<P>
<B>Co-interventions</B>
<BR/>Other antihypertensive agents</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 13:57:18 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>BP</LI>
<LI>AER</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:54:11 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lacourciere-2000">
<CHAR_METHODS>
<P>Country: Canada <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 12 months <BR/>Loss to follow-up: 11</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:54:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2 diagnosed &gt;/= 30 years of age</LI>
<LI>Hypertension: Mild to moderate essential (sitting DBP 90-115 mm Hg)</LI>
<LI>AER: 20-350 µg/min without evidence of UTI</LI>
</UL>
<P>
<B>Losartan group</B>
</P>
<UL>
<LI>Number: 52</LI>
<LI>Age: 59.2 (9.2)</LI>
<LI>Sex (M/F): 39/13</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 51</LI>
<LI>Age: 57.8 (10.5)</LI>
<LI>Sex (M/F): 44/7</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Evidence or suspicion of renovascular disease</LI>
<LI>History of malignant hypertension</LI>
<LI>SBP &gt; 210 mm Hg</LI>
<LI>CVA in the previous 12 months or current transient Ischaemic attacks</LI>
<LI>MI within the previous 12 months</LI>
<LI>Clinically significant arteriovenous conduction disturbances and/or arrhythmias</LI>
<LI>Unstable angina</LI>
<LI>History of heart failure</LI>
<LI>SCr &#8805; 200 mmol/L</LI>
<LI>Serum potassium &#8805; 5.5 mmol/L or &#8804; 3.5mmol/L</LI>
<LI>Treatment with oral corticosteroid</LI>
<LI>Concomitant use of agents that may affect BP except beta-blockers and nitrates used in the treatment of stable angina</LI>
<LI>Drug or alcohol abuse</LI>
<LI>Pregnancy</LI>
<LI>Breast feeding</LI>
<LI>Ineffective contraception</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:00:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Losartan group</B>
<BR/>50 mg/d</P>
<P>
<B>Enalapril group</B>
<BR/>5-10 mg/d</P>
<P>
<B>Co-interventions</B>
<BR/>Antihypertensive agents other than ACEi, AIIRA and CCB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:00:55 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>BP</LI>
<LI>AER</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:03:03 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Laffel-1995">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 43</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:02:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 14-57 years</LI>
<LI>IDDM: Diagnosed before 45 years</LI>
<LI>Overnight AER: 20-200 µg/min</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 70</LI>
<LI>Age: 32 (8.1)</LI>
<LI>Sex (M/F): 53/47</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 73</LI>
<LI>Age: 33.4 (9.0)</LI>
<LI>Sex (M/F): 48/52</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>HbA1c &#8805; 11.5%</LI>
<LI>SCr and potassium levels beyond the normal ranges</LI>
<LI>White blood cell count &lt; 3500/mm³</LI>
<LI>BP &#8805; 140/90 mm Hg</LI>
<LI>Antihypertensive therapy (CCB, beta blockers)</LI>
<LI>Pregnancy</LI>
<LI>Lactation</LI>
<LI>Failure to use adequate contraception for women of child-bearing ages</LI>
<LI>Histories of renal, cardiac, hepatic, gastrointestinal or autoimmune diseases</LI>
<LI>Use of NSAIDs (except for low-dose aspirin not to exceed 650 mg/d)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:02:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Captopril group</B>
<BR/>100 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Prazosin-clonidine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:03:03 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>CrCl</LI>
<LI>Progression to hypertension</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:04:15 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lebovitz-1994">
<CHAR_METHODS>
<P>Country: USA<BR/>Setting/Design: Multicentre<BR/>Time frame: NS<BR/>Randomisation method: NS<BR/>Blinding<BR/>- Participants: Yes<BR/>- Investigators: Yes<BR/>- Outcome assessors: No<BR/>- Data analysis: No<BR/>Intention-to-treat: No<BR/>Follow-up period: 36 months<BR/>Loss to follow-up: 44</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:03:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2</LI>
<LI>DBP: &gt; 90mm Hg or therapy for hypertension</LI>
<LI>GFR: 30-100 mL/min/1.73 m²</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 35</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 40</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Exclusion criteria:</B> NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:04:01 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril group</B>
<BR/>5-40 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Alpha and beta adrenergic antagonist, diuretics and CCB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:04:15 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>BP</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:05:37 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Marre-1987">
<CHAR_METHODS>
<P>Country: France <BR/>Setting/Design: Hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 6 months <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:05:01 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 20-60</LI>
<LI>DM: Type I or 2 known for at least five years</LI>
<LI>BMI: &lt;30 kg/ m²</LI>
<LI>AER: 30-300 mg/24 h in at least 2 of 3 monthly measurements</LI>
<LI>BP: Supine &lt; 160/95 mm Hg on 3 consecutive monthly visits to the outpatient clinic</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 10</LI>
<LI>Age: 39.3 (11.6)</LI>
<LI>Sex (M/F): 6/4</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 10</LI>
<LI>Age: 38.9 (10.9)</LI>
<LI>Sex (M/F): 6/4</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Heart, kidney, liver or systemic disease</LI>
<LI>No taking drugs except antidiabetic agent or contraceptives</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:05:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril group</B>
<BR/>20 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:05:37 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>BP</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:07:04 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mathiesen-1999">
<CHAR_METHODS>
<P>Country: Denmark <BR/>Setting/Design: Hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 4 years (8 years for GFR) <BR/>Loss to follow-up: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:06:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 microalbuminuria</LI>
<LI>Age: &lt; 50</LI>
<LI>Onset of diabetes: Before the age of 41</LI>
<LI>Duration of diabetes: 5-30 years</LI>
<LI>DBP: &lt; 95mm Hg</LI>
<LI>No other disease</LI>
</UL>
<P>
<B>Captopril + bendrofluazide group</B>
</P>
<UL>
<LI>Number: 21</LI>
<LI>Age: 31 (8)</LI>
<LI>Sex (M/F): 10/11</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 23</LI>
<LI>Age: 27(8)</LI>
<LI>Sex (M/F): 12/11</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:06:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Captopril + bendrofluazide group</B>
<BR/>Captopril (100 mg/d) + bendrofluazide (2.5 mg/d)</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:07:04 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>GFR</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:09:27 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Muirhead-1999">
<CHAR_METHODS>
<P>Country: Canada <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 13 months <BR/>Loss to follow-up: 19</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:08:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2</LI>
<LI>Age: &#8805; 18</LI>
<LI>AER: 20-300 µg/min with GFR &#8805; 60 mL/min/1.73 m²</LI>
<LI>Normotensive and treated hypertension &#8804; 160/95 mm Hg</LI>
</UL>
<P>
<B>Valsartan group 1</B>
</P>
<UL>
<LI>Number: 31</LI>
<LI>Age: 53.7 (9.5)</LI>
<LI>Sex (M/F): 22/9</LI>
</UL>
<P>
<B>Valsartan group 2</B>
</P>
<UL>
<LI>Number: 31</LI>
<LI>Age: 58.3 (9.5)</LI>
<LI>Sex (M/F): 18/13</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 29</LI>
<LI>Age: 56.7 (10)</LI>
<LI>Sex (M/F): 21/8</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 31</LI>
<LI>Age: 55.5 (11.3)</LI>
<LI>Sex (M/F): 28/3</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Women of child-bearing potential using estrogen/progesterone</LI>
<LI>Patients with brittle diabetes that is at increased risk of hypoglycaemia</LI>
<LI>History of non-compliance with medical regimens</LI>
<LI>Patients who experienced symptomatic hypotension who progressed to hypertension (SBP &gt; 95 mm Hg despite treatment with beta-blockers or diuretics)</LI>
<LI>Patients who experienced serious adverse experiences related to the study treatment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:09:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Valsartan group 1</B>
<BR/>80 mg/d</P>
<P>
<B>Valsartan group 2</B>
<BR/>160 mg/d</P>
<P>
<B>Captopril group</B>
<BR/>75 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:09:27 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>Progression to clinical proteinuria</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:10:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nankervis-1998">
<CHAR_METHODS>
<P>Country: Australia <BR/>Setting/Design: Hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 36 months <BR/>Loss to follow-up: 9</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:10:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 and 2</LI>
<LI>Age: 18-65 years</LI>
<LI>Microalbuminuria (AER 20-200 mg/L on 2 of 3 consecutive occasions)</LI>
<LI>SCr: &lt; 120µmol/L</LI>
<LI>Stable glycaemic control</LI>
</UL>
<P>
<B>Perindopril group</B>
</P>
<UL>
<LI>Number: 20</LI>
<LI>Age: 43 (3)</LI>
<LI>Sex (M/F): 16/4</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 20</LI>
<LI>Age: 49 (3)</LI>
<LI>Sex (M/F): 16/4</LI>
</UL>
<P>
<B>Exclusion criteria</B>
<BR/>Non-diabetic renal disease or other major disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:10:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Perindopril group</B>
<BR/>4 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>CCB, beta-blockers, alpha-blockers or diuretic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:10:28 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>GFR</LI>
<LI>AER</LI>
<LI>Histomorphometric features of renal biopsies</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:13:47 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-O_x0027_Donnell-1993">
<CHAR_METHODS>
<P>Country: UK <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 48 weeks <BR/>Loss to follow-up: 9</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:13:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 or 2</LI>
<LI>Age: 18-70 years Incipient diabetic nephropathy</LI>
<LI>DBP: Resting &#8804; 90 mm Hg</LI>
</UL>
<P>
<B>Lisinopril group</B>
</P>
<UL>
<LI>Number: 15</LI>
<LI>Age: 48.3 (13.0)</LI>
<LI>Sex (M/F): 11/4</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 17</LI>
<LI>Age: 49.1 (16.0)</LI>
<LI>Sex (M/F): 12/5</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Hypertension of any aetiology</LI>
<LI>Heart failure, aortic outflow obstruction, unstable angina or MI in the preceding 3 months</LI>
<LI>Renal disease other than diabetic nephropathy</LI>
<LI>SCr &gt; 140 µmol/L</LI>
<LI>Low protein diet</LI>
<LI>Systemic malignancy</LI>
<LI>Clinically significant abnormality of hepatic, haemopoietic or endocrine function</LI>
<LI>Women of childbearing potential not using a medically acceptable method of birth control</LI>
<LI>Continuous subcutaneous insulin infusion</LI>
<LI>Hypersensitivity to ACEi</LI>
<LI>Treatment with the following medications: aldose reductase inhibitors, myoinositol, steroids, gold, penicillamine, NSAIDs, monoamine oxidase inhibitors, appetite suppressants, lithium, vasopressor nasal decongestants or cimetidine</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:13:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Lisinopril group</B>
<BR/>10 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:13:47 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>Urinary excretion of prostaglandins</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:14:58 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Parving-1989">
<CHAR_METHODS>
<P>Country: Denmark <BR/>Setting/Design: Hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 12 months <BR/>Loss to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:14:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Normotensive insulin dependent diabetics</LI>
<LI>AER &gt; 300 mg/24 h</LI>
<LI>SCr &lt; 120µmol/L or GFR &gt; 60 mL/min/1.73 m²</LI>
<LI>BP: 3 or more consecutive readings &lt; 150/90 mm Hg</LI>
<LI>No oedema</LI>
<LI>No taking other drugs apart from oral contraceptives</LI>
<LI>Age &lt; 50 years</LI>
<LI>Onset of DM: &lt; 41 years</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 15</LI>
<LI>Age: 32 (8)</LI>
<LI>Sex (M/F): 10/5</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 17</LI>
<LI>Age: 30 (8)</LI>
<LI>Sex (M/F): 13/4</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:14:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Captopril group</B>
<BR/>25-100 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:14:58 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>BP</LI>
<LI>GRF</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:16:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Parving-2001a">
<CHAR_METHODS>
<P>Country: Denmark <BR/>Setting/Design: Hospital <BR/>Time frame: NS <BR/>Randomisation method: Yes <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 96 months <BR/>Loss to follow-up: 18</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:15:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1 (onset of diabetes before 41 years)</LI>
<LI>Age: &lt; 50 years</LI>
<LI>Persistent albuminuria: &lt; 300 mg/24 h</LI>
<LI>SCr: &lt; 120 µmol/L</LI>
<LI>GFR: &gt; 60 mL/min/1.73 m²</LI>
<LI>BP: Average of 3 or more consecutive readings &lt; 159/90 mm Hg</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 16</LI>
<LI>Age: 32 (8)</LI>
<LI>Sex (M/F): 10/5</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Number: 17</LI>
<LI>Age: 30 (8)</LI>
<LI>Sex (M/F): 13/5</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Oedema</LI>
<LI>Drugs (except oral contraceptives)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:16:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Captopril group</B>
<BR/>12.5-125 mg/d</P>
<P>
<B>Control group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Diuretics, dihydropyridine, CCB, beta-blocker</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:16:49 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>BP</LI>
<LI>Albuminuria</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:20:12 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Phillips-1993">
<CHAR_METHODS>
<P>Country: USA<BR/>Setting/Design: Hospital<BR/>Time frame: NS<BR/>Randomisation method: NS<BR/>Blinding<BR/>- Participants: Yes<BR/>- Investigators: Yes<BR/>- Outcome assessors: No<BR/>- Data analysis: No<BR/>Intention-to-treat: No<BR/>Follow-up period: 24 months<BR/>Loss to follow-up: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:19:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 18-65 years</LI>
<LI>AER: 30-300 mg/24 h on 2 of 3 occasions</LI>
<LI>HbA1c: &lt; 13.5%</LI>
<LI>DB: Mean sitting DBP &#8804; 95 mm Hg on 2 of 3 occasions</LI>
<LI>BMI: &#8804; 32 kg/m²</LI>
<LI>Compliance: 80%</LI>
</UL>
<P>
<B>Cilaxapril group</B>
</P>
<UL>
<LI>Number: 14</LI>
<LI>Age: 47.1 years (22-63)</LI>
<LI>Sex (M/F): 13/1</LI>
<LI>BMI: 27.1 (23-32)</LI>
<LI>Duration of diabetes: 14.7 years (2-34)</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Number: 11</LI>
<LI>Age: 44.6 (25-63)</LI>
<LI>Sex (M/F): 9/2</LI>
<LI>BMI: 28 (25-32)</LI>
<LI>Duration of diabetes: 13.2 years (6-22)</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Cardiovascular or other medical diseases</LI>
<LI>Reported adverse effects to cilazapril</LI>
<LI>Taking medication affecting BP or had a history of any contraindication to ACEi</LI>
<LI>Women of childbearing potential</LI>
<LI>Uncooperative</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:20:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Cilaxapril group</B>
<BR/>2.5 or 5 mg/d (DBP &#8805; 85 mm Hg) for 24 weeks</P>
<P>
<B>Control group</B>
<BR/>Matched placebo</P>
<P>
<B>Co-interventions</B>: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:20:12 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:21:08 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Poulsen-2001">
<CHAR_METHODS>
<P>Country: Denmark <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 24 months <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:20:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 1</LI>
<LI>Age:18-65 years</LI>
<LI>Duration of diabetes: 3-41 years</LI>
<LI>BP: &lt; 160/90 mm Hg</LI>
</UL>
<P>
<B>Lisinopril group</B>
</P>
<UL>
<LI>Number: 33</LI>
<LI>Age: 34.9 (11.8)</LI>
<LI>Sex (M/F): 18/7</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 25</LI>
<LI>Age: 38.5 (10.4)</LI>
<LI>Sex (M/F): 22/11</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<OL>
<LI>Other chronic illness</LI>
<LI>Medical treatment apart from insulin</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:20:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Lisinopril group</B>
<BR/>40 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:21:08 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>BP and AMBP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:22:19 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ravid-1993">
<CHAR_METHODS>
<P>Country: Israel <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes<BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 5 years <BR/>Loss to follow-up: 8</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:21:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: &lt; 50 years</LI>
<LI>DM: Type 2 with duration of less than 10 years</LI>
<LI>BMI: &lt; 27 kg/m²</LI>
<LI>BP: Normal on 2 consecutive examinations (BP &lt; 130/90 mm Hg; MAP &lt; 107 mm Hg)</LI>
<LI>SCr: &lt; 1.4 mg/dL</LI>
<LI>AER: 30-300 mg/24 h on 2 consecutive visits without evidence of UTI</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 49</LI>
<LI>Age: 43.5 (3)</LI>
<LI>Sex (M/F): 21/28</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 45</LI>
<LI>Age: 44.8 (3.5)</LI>
<LI>Sex (M/F): 21/24</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Evidence of systemic, renal, cardiac or hepatic diseases</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:22:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril group</B>
<BR/>10 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Long-acting nifedipine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:22:19 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>Renal function</LI>
<LI>Glycaemic control</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:24:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-RENAAL-2001">
<CHAR_METHODS>
<P>Country: USA <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding - Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: Yes <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: mean 3.4 years <BR/>Loss to follow-up: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:23:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2 Nephropathy (presence on 2 occasions of a ratio of urinary albumin to urinary creatinine from a first morning specimen of at least 300 and SCr between 1.3-3 mg/dL with a lower limit of 1.5 mg/dL for male patients weighing more than 60 kg)</LI>
<LI>Age: 31-70 years</LI>
</UL>
<P>
<B>Losartan group</B>
</P>
<UL>
<LI>Number: 751</LI>
<LI>Age: 60 (7)</LI>
<LI>Sex (M/F): 462/289</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 762</LI>
<LI>Age: 60 (7)</LI>
<LI>Sex (M/F): 494/268</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>DM type 1 or non-diabetic renal disease</LI>
<LI>MI or CAB grafting within the previous month</LI>
<LI>CVA or percutaneous transluminal coronary angioplasty within the previous 6 months</LI>
<LI>Transient ischemic attack within the previous year</LI>
<LI>History of heart failure</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:24:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Losartan group</B>
<BR/>50-100 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>CCB, diuretics, alpha-blockers, beta-blockers and centrally acting agents</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:24:33 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Doubling of SCr</LI>
<LI>ESKD</LI>
<LI>Death</LI>
<LI>Morbidity and mortality from cardiovascular causes</LI>
<LI>Proteinuria</LI>
<LI>Rate of progression of renal disease</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:37:18 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Rizzoni-2005">
<CHAR_METHODS>
<P>Country: Italy <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding<BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 1 year <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:25:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Mild essential hypertension</LI>
<LI>DM: Type 2 with or without ongoing oral hypoglycaemic therapy</LI>
<LI>Age: 30-70 years</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 7</LI>
<LI>Age: 58 (4)</LI>
<LI>Sex (M/F): 5/2</LI>
</UL>
<P>
<B>Candesartan group</B>
</P>
<UL>
<LI>Number: 8</LI>
<LI>Age: 58 (9)</LI>
<LI>Sex (M/F): 6/2</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Previous treatment with ACEi and AIRA</LI>
<LI>Secondary forms of hypertension or any disease that could have interfered with the study protocol</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:37:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril group</B>
<BR/>10-20 mg/d</P>
<P>
<B>Candesartan group</B>
<BR/>8-16 mg/d</P>
<P>
<B>Co-interventions</B>
<BR/>Diuretics if BP not controlled in 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:37:18 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Indices of subcutaneous small resistance artery structure</LI>
<LI>Endothelium function</LI>
<LI>Death rates</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:38:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Romero-1993">
<CHAR_METHODS>
<P>Country: Spain<BR/>Setting/Design: University-Hospital<BR/>Time frame: NS<BR/>Randomisation method: NS<BR/>Blinding<BR/>- Participants: No<BR/>- Investigators: No<BR/>- Outcome assessors: No<BR/>- Data analysis: No<BR/>Intention-to-treat: No<BR/>Follow-up period: 6 months<BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:38:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Normotensive type 2 diabetic patients</LI>
<LI>AER: 30-300 mg/d in 3, 24h urine collections performing during the previous 6 months</LI>
</UL>
<P>
<B>Captopril group</B>
</P>
<UL>
<LI>Number: 13</LI>
<LI>Age: 53.2 (7.1)</LI>
<LI>Sex (M/F): 9/4</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 13</LI>
<LI>Age: 52.5 (15.1)</LI>
<LI>Sex (M/F): 7/6</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<OL>
<LI>Clinical or laboratory evidence of cardiac disease</LI>
<LI>Liver or renal dysfunction</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:38:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Captopril group</B>
<BR/>Initial dose: 25 mg/d (mean 61 ±19 mg/d)</P>
<P>
<B>Placebo group</B>
</P>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:38:39 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>Microalbuminuria</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:41:31 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sano-1994">
<CHAR_METHODS>
<P>Country: Japan<BR/>Setting/Design: University<BR/>Time frame: NS<BR/>Randomisation method: NS<BR/>Blinding<BR/>- Participants: No<BR/>- Investigators: No<BR/>- Outcome assessors: No<BR/>- Data analysis: No<BR/>Intention-to-treat: No<BR/>Follow-up period: 48 months<BR/>Loss to follow-up: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:40:46 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 50-76 years</LI>
<LI>Persistent microalbuminuria: 20-300 mg/24 h on 3-4 separate occasions over a 3 month period</LI>
<LI>SCr: &lt; 1.2 mg/dL</LI>
<LI>BP: Supine SBP &lt; 150 mm Hg, and DBP &lt; 90 mm Hg over a long term period</LI>
<LI>HbA1c: &lt; 10%</LI>
<LI>No history of non-diabetic renal disease</LI>
<LI>No taking any drugs apart from oral hypoglycaemic agents</LI>
</UL>
<P>
<B>Enalapril group 1</B>
</P>
<UL>
<LI>Normotensive patients</LI>
<LI>Number: 12</LI>
<LI>Age: 62.4 (3.3)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Enalapril group 2</B>
</P>
<UL>
<LI>Well controlled hypertensive patients</LI>
<LI>Number: 11</LI>
<LI>Age: 63.6 (2.2)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Control group 1</B>
</P>
<UL>
<LI>Normotensive patients</LI>
<LI>Number:12</LI>
<LI>Age: 64.4 (2.4)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Control group 2</B>
</P>
<UL>
<LI>Well controlled hypertensive patients</LI>
<LI>Number:13</LI>
<LI>Age: 65.5 (2.6)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:41:24 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril groups</B>
<BR/>Enalapril 5 mg/d</P>
<P>
<B>Control group</B>
</P>
<P>
<B>Co-interventions</B>
<BR/>Nifedipine (30 mg/d) for well controlled hypertensive patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:41:31 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>GFR</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:43:00 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sato-2003">
<CHAR_METHODS>
<P>Country: Japan <BR/>Setting/Design: Teaching hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 11 ± months <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:42:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Diabetic nephropathy: Stage 2 or 3A (defined by the presence of either microalbuminuria with AER of 30-300 mg/g creatinine or overt proteinuria &gt; 300 mg/g creatinine with a GFR &gt; 60mL/min)</LI>
<LI>BP: &lt; 130/85 mm Hg</LI>
</UL>
<P>
<B>ACEi group</B>
</P>
<UL>
<LI>Number: 23</LI>
<LI>Age: 66 (8)</LI>
<LI>Sex (M/F): 13/10</LI>
</UL>
<P>
<B>Candesartan group</B>
</P>
<UL>
<LI>Number: 26</LI>
<LI>Age: 61 (12)</LI>
<LI>Sex (M/F): 13/13</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:42:46 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>ACEi group</B>
<BR/>Enalapril or trandolapril (not specified)</P>
<P>
<B>Candesartan group</B>
<BR/>Not specified</P>
<P>
<B>Co-interventions</B>
<BR/>CCB, alpha 1 blocker and central acting alpha 2 stimulant, nifedipine(30 mg/d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:43:00 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>BP</LI>
<LI>AER</LI>
<LI>Urinary type IV collagen excretion</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:44:30 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Stornello-1992">
<CHAR_METHODS>
<P>Country: Italy <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: Yes <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 6 months x 2 <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:43:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2</LI>
<LI>Persistent albuminuria: &gt; 300 mg/24 h on at least 3 occasions</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 12</LI>
<LI>Age: 46.9 (9.1)</LI>
<LI>Sex (M/F): 6/6</LI>
</UL>
<P>
<B>Atenolol group</B>
</P>
<UL>
<LI>Number: 12</LI>
<LI>Age: 46.9 (9.1)</LI>
<LI>Sex (M/F): 6/6</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Signs of other renal disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:44:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril group</B>
<BR/>5 mg/d</P>
<P>
<B>Atenolol group</B>
<BR/>50 mg/d</P>
<P>
<B>Co-interventions</B>: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:44:30 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>BP</LI>
<LI>GFR</LI>
<LI>AER</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:45:52 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tan-2002">
<CHAR_METHODS>
<P>Country: China <BR/>Setting/Design: Hospital <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: Yes <BR/>Follow-up period: 6 months <BR/>Loss to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:45:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>DM: Type 2</LI>
<LI>HbA1c: &lt; 10%</LI>
<LI>Mean AER: 20-200 µg/min</LI>
<LI>BP: Sitting &#8804; 140/89 mm Hg Controlled hypertension with no changes in antihypertensive therapy in the preceding 3 months</LI>
</UL>
<P>
<B>Losartan group</B>
</P>
<UL>
<LI>Number: 40</LI>
<LI>Age: 54.7 (10.1)</LI>
<LI>Sex (M/F): 22/18</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 40</LI>
<LI>Age: 54.3 (8.8)</LI>
<LI>Sex (M/F): 18/22</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Treatment with ACEi</LI>
<LI>Major CVE</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:45:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Losartan group</B>
<BR/>50 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:45:52 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Endothelium function</LI>
<LI>Mean AER</LI>
<LI>BP</LI>
<LI>CrCl</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:47:17 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Trevisan-1995">
<CHAR_METHODS>
<P>Country: Italy <BR/>Setting/Design: Multicentre <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: Yes <BR/>- Investigators: Yes <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 6 months <BR/>Loss to follow-up: 14</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:47:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age: 18-65 years</LI>
<LI>DM: Type 2 for at least 6 months duration</LI>
<LI>Stable metabolic control with a HbA1c &lt; 10%</LI>
<LI>Persistent microalbuminuria 20-200 µg/min at screening and in at least 2 of 3 consecutive sterile urine samples collected overnight</LI>
<LI>Normotensive or mildly hypertensive without antihypertensive treatment</LI>
</UL>
<P>
<B>Ramipril group</B>
</P>
<UL>
<LI>Number: 60</LI>
<LI>Age: 36 (7)</LI>
<LI>Sex (M/F): 44/16</LI>
</UL>
<P>
<B>Placebo group</B>
</P>
<UL>
<LI>Number: 62</LI>
<LI>Age: 58 (7)</LI>
<LI>Sex (M/F): 50/12</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>BP: &gt; 180/105 mm Hg</LI>
<LI>Unstable angina, heart failure</LI>
<LI>SCr &gt; 1.5 mg/dL</LI>
<LI>History of poor compliance</LI>
<LI>Serum potassium levels &gt; 5.5 mEq/L</LI>
<LI>Liver, gastrointestinal, and connective tissue diseases</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:47:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Ramipril group</B>
<BR/>1.25 mg/d</P>
<P>
<B>Placebo group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:47:17 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
<LI>BP</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-27 14:49:16 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tutuncu-2001">
<CHAR_METHODS>
<P>Country: Turkey <BR/>Setting/Design: University <BR/>Time frame: NS <BR/>Randomisation method: NS <BR/>Blinding <BR/>- Participants: No <BR/>- Investigators: No <BR/>- Outcome assessors: No <BR/>- Data analysis: No <BR/>Intention-to-treat: No <BR/>Follow-up period: 12 months <BR/>Loss to follow-up: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-27 14:48:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Normotensive type 2 diabetic patients</LI>
<LI>Microalbuminuria: AER 30-300 mg/d in at least 3 consecutive 24 hour determinations</LI>
</UL>
<P>
<B>Enalapril group</B>
</P>
<UL>
<LI>Number: 12</LI>
<LI>Age: 51.4 (8.0)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Losartan group</B>
</P>
<UL>
<LI>Number: 12</LI>
<LI>Age: 58.1 (10.8)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>
<B>Enalapril + Losartan group</B>
</P>
<UL>
<LI>Number: 10</LI>
<LI>Age: 57.7 (6.2)</LI>
<LI>Sex (M/F): NA</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>DM type 1</LI>
<LI>Hypertension: &gt; 130/85 mm Hg during ambulatory BP monitoring and a history of taking antihypertensives</LI>
<LI>Secondary diabetes</LI>
<LI>Thyroid disease</LI>
<LI>Alcoholism</LI>
<LI>Renal insufficiency not related to diabetes</LI>
<LI>Chronic liver disease</LI>
<LI>Overt carcinoma</LI>
<LI>Treatment with insulin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-27 14:49:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<B>Enalapril group</B>
<BR/>5 mg/d</P>
<P>
<B>Losartan group</B>
<BR/>50 mg/d</P>
<P>
<B>Enalapril + Losartan group</B>
</P>
<P>
<B>Co-interventions</B>: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-27 14:49:16 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>AER</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin converting enzyme inhibitor; AER - albumin excretion rate; AIIRA - angiotensin II receptor antagonist; BMI - body mass index; CAB - coronary artery bypass; CCB - calcium channel blocker; CrCl - creatinine clearance; CHF - congestive heart failure; CVA - cerebrovascular accident; CVD - cerebrovascular disease; CVE - cardiovascular event; DBP - diastolic blood pressure; DM - diabetes mellitus; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; HD - haemodialysis; MAP - mean arterial pressure; MI - myocardial infarction; NS - not stated; NSAIDs - nonsteroidal anti-inflammatory drugs; PD - peritoneal dialysis; SBP - systolic blood pressure; SCr - serum creatinine; UAE - urinary albumin excretion; UTI - urinary tract infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-REIN-1998">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-ABCD-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AIPRI-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-ATLANTIS-SG-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ahmad-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ahmad-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bakris-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bauer-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bojestig-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-CAPTOPRIL-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Capek-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carella-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chase-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cordonnier-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Crepaldi-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-DETAIL-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-DIABHYCAR-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ESPRIT-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-EUCLID-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garg-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-HOPE-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hansen-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-IDNT-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-IRMA_x002d_2-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-JAPAN_x002d_IDDM-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jerums-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jerums-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ko-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lacourciere-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Laffel-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lebovitz-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Marre-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mathiesen-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Muirhead-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nankervis-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Donnell-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Parving-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Parving-2001a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Phillips-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poulsen-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RENAAL-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ravid-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rizzoni-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Romero-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sano-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sato-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stornello-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tan-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Trevisan-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tutuncu-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-26 16:02:26 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-26 15:59:56 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ACEi versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="11.044561078054093" CI_END="1.1746436512740464" CI_START="0.7088537881400209" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9124969051565235" ESTIMABLE="YES" EVENTS_1="438" EVENTS_2="465" I2="27.5661572835496" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.06990613575025456" LOG_CI_START="-0.14944333541262392" LOG_EFFECT_SIZE="-0.039768599831184664" METHOD="MH" MODIFIED="2008-08-26 15:58:26 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1991871681702726" P_Q="0.0" P_Z="0.4772747491826046" Q="0.0" RANDOM="YES" SCALE="293.4076202711781" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02814843921745141" TOTALS="YES" TOTAL_1="3667" TOTAL_2="3628" WEIGHT="100.0" Z="0.7106926036473494">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.547827059071607" CI_END="3.4437941797660754" CI_START="0.4052187721423493" DF="3.0" EFFECT_SIZE="1.1813086171851022" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="328" I2="34.034430926394556" ID="CMP-001.01.01" LOG_CI_END="0.5370371877110819" LOG_CI_START="-0.39231044374365853" LOG_EFFECT_SIZE="0.07236337198371169" NO="1" P_CHI2="0.20806374417403528" P_Z="0.7601955515401894" STUDIES="11" TAU2="0.4759220189959708" TOTAL_1="2627" TOTAL_2="2634" WEIGHT="52.35394918914242" Z="0.3052240046406291">
<NAME>Half or less maximum tolerable dose</NAME>
<DICH_DATA CI_END="45.39058020945149" CI_START="0.5507750701718138" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.656965734189261" LOG_CI_START="-0.2590257255172236" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="33674" O_E="0.0" SE="1.1254628677422756" STUDY_ID="STD-AIPRI-1996" TOTAL_1="6" TOTAL_2="15" VAR="1.2666666666666666" WEIGHT="1.2821552942272674"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33675" O_E="0.0" SE="0.0" STUDY_ID="STD-Bojestig-2001" TOTAL_1="37" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33676" O_E="0.0" SE="0.0" STUDY_ID="STD-Capek-1994" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33677" O_E="0.0" SE="0.0" STUDY_ID="STD-Chase-1993" TOTAL_1="6" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33678" O_E="0.0" SE="0.0" STUDY_ID="STD-Cordonnier-1999" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2010714688289847" CI_START="0.9037104590531115" EFFECT_SIZE="1.0418353269356135" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="324" LOG_CI_END="0.07956885052911448" LOG_CI_START="-0.04397069140221865" LOG_EFFECT_SIZE="0.017799079563447916" ORDER="33679" O_E="0.0" SE="0.07256773846106028" STUDY_ID="STD-DIABHYCAR-2004" TOTAL_1="2443" TOTAL_2="2469" VAR="0.005266076665352848" WEIGHT="49.68361800833715"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33680" O_E="0.0" SE="0.0" STUDY_ID="STD-Garg-1998" TOTAL_1="7" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.126851770051534" CI_START="0.006663527661151314" EFFECT_SIZE="0.11904761904761904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3277372230047844" LOG_CI_START="-2.1762957951285475" LOG_EFFECT_SIZE="-0.9242792860618817" ORDER="33681" O_E="0.0" SE="1.4708813900148656" STUDY_ID="STD-Nankervis-1998" TOTAL_1="17" TOTAL_2="14" VAR="2.1634920634920634" WEIGHT="0.7574937773792375"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33682" O_E="0.0" SE="0.0" STUDY_ID="STD-Ravid-1993" TOTAL_1="49" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33683" O_E="0.0" SE="0.0" STUDY_ID="STD-Romero-1993" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.91560927775306" CI_START="0.12691141050131804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8507418385268246" LOG_CI_START="-0.8964993290875" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="33684" O_E="0.0" SE="1.613743060919757" STUDY_ID="STD-Sano-1994" TOTAL_1="31" TOTAL_2="31" VAR="2.6041666666666665" WEIGHT="0.6306821091987632"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9490009726276663" CI_END="0.9808329281219238" CI_START="0.6138673247676454" DF="4.0" EFFECT_SIZE="0.7759518578044784" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="137" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.008404962624188973" LOG_CI_START="-0.21192548284510399" LOG_EFFECT_SIZE="-0.11016522273464652" NO="2" P_CHI2="0.7451386875899055" P_Z="0.033850451082634694" STUDIES="10" TAU2="0.0" TOTAL_1="1040" TOTAL_2="994" WEIGHT="47.64605081085758" Z="2.12184863397918">
<NAME>Maximum tolerable dose</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33685" O_E="0.0" SE="0.0" STUDY_ID="STD-Bakris-1994" TOTAL_1="8" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="57.830449822210525" CI_START="0.11036178151415399" EFFECT_SIZE="2.526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7621565703866675" LOG_CI_START="-0.957181297541151" LOG_EFFECT_SIZE="0.4024876364227582" ORDER="33686" O_E="0.0" SE="1.597352524560342" STUDY_ID="STD-Bauer-1992" TOTAL_1="18" TOTAL_2="15" VAR="2.551535087719298" WEIGHT="0.6435494996652225"/>
<DICH_DATA CI_END="1.3004236427558307" CI_START="0.23911184686050624" EFFECT_SIZE="0.5576259489302967" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.11408485672154689" LOG_CI_START="-0.6213989061147238" LOG_EFFECT_SIZE="-0.25365702469658846" ORDER="33687" O_E="0.0" SE="0.43202680299336793" STUDY_ID="STD-CAPTOPRIL-1993" TOTAL_1="207" TOTAL_2="202" VAR="0.18664715850467034" WEIGHT="7.728994731086067"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33688" O_E="0.0" SE="0.0" STUDY_ID="STD-Crepaldi-1998" TOTAL_1="32" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0017890137331389" CI_START="0.6120896455447676" EFFECT_SIZE="0.7830610974416743" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="122" LOG_CI_END="7.762646251696586E-4" LOG_CI_START="-0.21318496721018396" LOG_EFFECT_SIZE="-0.10620435129250716" ORDER="33689" O_E="0.0" SE="0.12568188670526562" STUDY_ID="STD-HOPE-2000" TOTAL_1="553" TOTAL_2="587" VAR="0.015795936645795223" WEIGHT="37.77853275743642"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33690" O_E="0.0" SE="0.0" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="104" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="75.49000455589575" CI_START="0.12950895523487707" EFFECT_SIZE="3.1267605633802815" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8778894515815823" LOG_CI_START="-0.887700200118456" LOG_EFFECT_SIZE="0.4950946257315633" ORDER="33691" O_E="0.0" SE="1.6245210512981663" STUDY_ID="STD-Laffel-1995" TOTAL_1="70" TOTAL_2="73" VAR="2.6390686461108994" WEIGHT="0.6224292923837454"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33692" O_E="0.0" SE="0.0" STUDY_ID="STD-Mathiesen-1999" TOTAL_1="19" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.58673887610161" CI_START="0.07743803372313825" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2197610076438197" LOG_CI_START="-1.1110456829986344" LOG_EFFECT_SIZE="0.054357662322592676" ORDER="33693" O_E="0.0" SE="1.3691273877625736" STUDY_ID="STD-Parving-1989" TOTAL_1="15" TOTAL_2="17" VAR="1.8745098039215686" WEIGHT="0.8725445302861258"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33694" O_E="0.0" SE="0.0" STUDY_ID="STD-Phillips-1993" TOTAL_1="14" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="141" EVENTS_2="133" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-08-26 15:58:35 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.066737783488292" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="2443" TOTAL_2="2469" WEIGHT="0.0" Z="0.0">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.348796601635637" CI_START="0.8511061451949877" EFFECT_SIZE="1.0714331879637695" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="133" LOG_CI_END="0.12994646305413268" LOG_CI_START="-0.07001627376055321" LOG_EFFECT_SIZE="0.029965094646789692" ORDER="33695" O_E="0.0" SE="0.1174591014364575" STUDY_ID="STD-DIABHYCAR-2004" TOTAL_1="2443" TOTAL_2="2469" VAR="0.013796640510260012" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.523622085205666" CI_END="1.002414531791292" CI_START="0.4664949164136003" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.683828401881464" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="145" I2="36.99876006923233" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.001047353906908535" LOG_CI_START="-0.33115308457675485" LOG_EFFECT_SIZE="-0.16505286533492317" METHOD="MH" MODIFIED="2008-08-26 15:58:48 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14620050072380741" P_Q="0.0" P_Z="0.0514622060278674" Q="0.0" RANDOM="YES" SCALE="73.35662719656808" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08326514431253892" TOTALS="YES" TOTAL_1="3399" TOTAL_2="3381" WEIGHT="100.00000000000003" Z="1.9476053257376875">
<NAME>Doubling of serum creatinine</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3153892279338684" CI_START="0.0550883708317081" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.3646240084576048" LOG_CI_START="-1.2589400711420433" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="33696" O_E="0.0" SE="0.9536895771286428" STUDY_ID="STD-AIPRI-1996" TOTAL_1="6" TOTAL_2="15" VAR="0.9095238095238095" WEIGHT="3.8354707082657287"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33697" O_E="0.0" SE="0.0" STUDY_ID="STD-Capek-1994" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8926659224053823" CI_START="0.3605920921228865" EFFECT_SIZE="0.567351982923267" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="43" LOG_CI_END="-0.04931104413706692" LOG_CI_START="-0.4429838016986189" LOG_EFFECT_SIZE="-0.2461474229178429" ORDER="33698" O_E="0.0" SE="0.23124532650323396" STUDY_ID="STD-CAPTOPRIL-1993" TOTAL_1="207" TOTAL_2="202" VAR="0.05347440102958728" WEIGHT="27.847196232822302"/>
<DICH_DATA CI_END="1.1768536874153226" CI_START="0.5554599458142226" EFFECT_SIZE="0.8085141219811707" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="60" LOG_CI_END="0.07072247244583268" LOG_CI_START="-0.2553472525449545" LOG_EFFECT_SIZE="-0.09231239004956088" ORDER="33699" O_E="0.0" SE="0.1915349705307585" STUDY_ID="STD-DIABHYCAR-2004" TOTAL_1="2443" TOTAL_2="2469" VAR="0.03668564493621852" WEIGHT="31.74479280859368"/>
<DICH_DATA CI_END="2.299211840477516" CI_START="0.6670225737818709" EFFECT_SIZE="1.238396624472574" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.3615789873249484" LOG_CI_START="-0.17585946817788956" LOG_EFFECT_SIZE="0.09285975957352945" ORDER="33700" O_E="0.0" SE="0.3156940091256276" STUDY_ID="STD-HOPE-2000" TOTAL_1="553" TOTAL_2="587" VAR="0.09966270739781187" WEIGHT="20.815927789708084"/>
<DICH_DATA CI_END="2.6867519674188247" CI_START="0.1003444288811605" EFFECT_SIZE="0.5192307692307693" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.42922757556851143" LOG_CI_START="-0.998506734520135" LOG_EFFECT_SIZE="-0.2846395794758118" ORDER="33701" O_E="0.0" SE="0.8386582011448874" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="104" TOTAL_2="27" VAR="0.7033475783475784" WEIGHT="4.840772138864051"/>
<DICH_DATA CI_END="3.9301698771521822" CI_START="0.1452517869137287" EFFECT_SIZE="0.7555555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5944113226693997" LOG_CI_START="-0.8378785161355768" LOG_EFFECT_SIZE="-0.12173359673308856" ORDER="33702" O_E="0.0" SE="0.8413341412630905" STUDY_ID="STD-Parving-1989" TOTAL_1="15" TOTAL_2="17" VAR="0.7078431372549019" WEIGHT="4.813263924357592"/>
<DICH_DATA CI_END="0.6468074470052008" CI_START="0.036220576232987196" EFFECT_SIZE="0.15306122448979592" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.18922498849561958" LOG_CI_START="-1.4410446447780076" LOG_EFFECT_SIZE="-0.8151348166368136" ORDER="33703" O_E="0.0" SE="0.735325062707511" STUDY_ID="STD-Ravid-1993" TOTAL_1="49" TOTAL_2="45" VAR="0.540702947845805" WEIGHT="6.102576397388579"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33704" O_E="0.0" SE="0.0" STUDY_ID="STD-Romero-1993" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7082417041873785" CI_END="0.9310036741226078" CI_START="0.38645599210427567" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5998265987231461" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.031048605111003415" LOG_CI_START="-0.41289995446091854" LOG_EFFECT_SIZE="-0.22197427978596093" METHOD="MH" MODIFIED="2008-08-26 15:58:58 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6351031246085691" P_Q="0.0" P_Z="0.022685135624409165" Q="0.0" RANDOM="YES" SCALE="358.57319815393186" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3422" TOTAL_2="3397" WEIGHT="100.0" Z="2.2786961188712507">
<NAME>End-stage kidney disease</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33705" O_E="0.0" SE="0.0" STUDY_ID="STD-Capek-1994" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0671008039421839" CI_START="0.37144387772383713" EFFECT_SIZE="0.6295776842761415" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="0.0282054470983232" LOG_CI_START="-0.4301067954594942" LOG_EFFECT_SIZE="-0.20095067418058546" ORDER="33706" O_E="0.0" SE="0.2692148799606514" STUDY_ID="STD-CAPTOPRIL-1993" TOTAL_1="207" TOTAL_2="202" VAR="0.07247665159222795" WEIGHT="69.41698427831018"/>
<DICH_DATA CI_END="1.287208956514214" CI_START="0.1269597842166205" EFFECT_SIZE="0.40425706099058534" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.10964905296105357" LOG_CI_START="-0.8963338243881377" LOG_EFFECT_SIZE="-0.3933423857135421" ORDER="33707" O_E="0.0" SE="0.5909193218504692" STUDY_ID="STD-DIABHYCAR-2004" TOTAL_1="2443" TOTAL_2="2469" VAR="0.3491856449362185" WEIGHT="14.408125468735188"/>
<DICH_DATA CI_END="2.881944127275317" CI_START="0.27150503692312133" EFFECT_SIZE="0.8845690174804098" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4596855568210537" LOG_CI_START="-0.566222109030471" LOG_EFFECT_SIZE="-0.053268276104708634" ORDER="33708" O_E="0.0" SE="0.6026232412460337" STUDY_ID="STD-HOPE-2000" TOTAL_1="553" TOTAL_2="587" VAR="0.3631547708898754" WEIGHT="13.853901937716541"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33709" O_E="0.0" SE="0.0" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="104" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33710" O_E="0.0" SE="0.0" STUDY_ID="STD-Marre-1987" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33711" O_E="0.0" SE="0.0" STUDY_ID="STD-Mathiesen-1999" TOTAL_1="19" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.879227887230183" CI_START="0.008970836156182358" EFFECT_SIZE="0.16071428571428573" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4592760400950948" LOG_CI_START="-2.047167075228846" LOG_EFFECT_SIZE="-0.7939455175668755" ORDER="33712" O_E="0.0" SE="1.4722970930348027" STUDY_ID="STD-Parving-1989" TOTAL_1="15" TOTAL_2="17" VAR="2.1676587301587302" WEIGHT="2.3209883152380915"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33713" O_E="0.0" SE="0.0" STUDY_ID="STD-Ravid-1993" TOTAL_1="49" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33714" O_E="0.0" SE="0.0" STUDY_ID="STD-Romero-1993" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.4802583121703" CI_END="0.6929560351967818" CI_START="0.28808199124239314" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4467976661341494" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="220" I2="47.13042510780337" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.1592943184576372" LOG_CI_START="-0.5404838897532848" LOG_EFFECT_SIZE="-0.3498891041054609" METHOD="MH" MODIFIED="2008-08-26 15:59:10 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.022474792618734085" P_Q="0.0" P_Z="3.2060892649460993E-4" Q="0.0" RANDOM="YES" SCALE="74.5636650490713" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.27763396753163855" TOTALS="YES" TOTAL_1="1054" TOTAL_2="982" WEIGHT="100.00000000000001" Z="3.598052487631207">
<NAME>Micro- to macroalbuminuria</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9470442030312489" CI_START="0.11285502607244773" EFFECT_SIZE="0.3269230769230769" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.02362974994652874" LOG_CI_START="-0.9474790945665217" LOG_EFFECT_SIZE="-0.48555442225652523" ORDER="33715" O_E="0.0" SE="0.5426736781577942" STUDY_ID="STD-Ahmad-1997" TOTAL_1="52" TOTAL_2="51" VAR="0.2944947209653092" WEIGHT="8.763215663095076"/>
<DICH_DATA CI_END="0.8733762816734137" CI_START="0.0806226926942756" EFFECT_SIZE="0.26535626535626533" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.05879860641310322" LOG_CI_START="-1.0935427010634373" LOG_EFFECT_SIZE="-0.5761706537382704" ORDER="33716" O_E="0.0" SE="0.6078138032634824" STUDY_ID="STD-Ahmad-2003" TOTAL_1="37" TOTAL_2="36" VAR="0.3694376194376194" WEIGHT="7.748272656856271"/>
<DICH_DATA CI_END="1.9456637216644368" CI_START="0.20222974299154156" EFFECT_SIZE="0.6272727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.2890677812326841" LOG_CI_START="-0.6941549700746236" LOG_EFFECT_SIZE="-0.2025435944209697" ORDER="33717" O_E="0.0" SE="0.577549911149026" STUDY_ID="STD-ATLANTIS-SG-2000" TOTAL_1="88" TOTAL_2="46" VAR="0.33356389986824775" WEIGHT="8.203050684177548"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33718" O_E="0.0" SE="0.0" STUDY_ID="STD-Bojestig-2001" TOTAL_1="37" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.926350624260373" CI_START="0.288412447594786" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.360334930007719" LOG_CI_START="-0.5399859998296206" LOG_EFFECT_SIZE="0.4101744650890493" ORDER="33719" O_E="0.0" SE="1.116257920926766" STUDY_ID="STD-Chase-1993" TOTAL_1="7" TOTAL_2="9" VAR="1.246031746031746" WEIGHT="3.2905426956264745"/>
<DICH_DATA CI_END="1.3543857800615084" CI_START="0.06804236547781295" EFFECT_SIZE="0.30357142857142855" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.13174238538939084" LOG_CI_START="-1.1672205966452438" LOG_EFFECT_SIZE="-0.5177391056279266" ORDER="33720" O_E="0.0" SE="0.7630172856176067" STUDY_ID="STD-Crepaldi-1998" TOTAL_1="32" TOTAL_2="34" VAR="0.5821953781512604" WEIGHT="5.831025783797242"/>
<DICH_DATA CI_END="1.5355046094696747" CI_START="0.11196415448840072" EFFECT_SIZE="0.4146341463414634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.18625112450050713" LOG_CI_START="-0.9509209951834303" LOG_EFFECT_SIZE="-0.38233493534146157" ORDER="33721" O_E="0.0" SE="0.6679805321951221" STUDY_ID="STD-EUCLID-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.4461979913916786" WEIGHT="6.92658982866719"/>
<DICH_DATA CI_END="3.884638505683547" CI_START="0.16475149465352495" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.589350610706709" LOG_CI_START="-0.783170636722822" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="33722" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Hansen-1994" TOTAL_1="10" TOTAL_2="12" VAR="0.6499999999999999" WEIGHT="5.404811876050125"/>
<DICH_DATA CI_END="1.097871281663385" CI_START="0.690726087509281" EFFECT_SIZE="0.8708204952641789" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="127" LOG_CI_END="0.04055142486795421" LOG_CI_START="-0.16069414114547612" LOG_EFFECT_SIZE="-0.06007135813876094" ORDER="33723" O_E="0.0" SE="0.118212641657907" STUDY_ID="STD-HOPE-2000" TOTAL_1="552" TOTAL_2="587" VAR="0.013974228647740729" WEIGHT="17.19323102035989"/>
<DICH_DATA CI_END="1.5879132672744254" CI_START="0.13414948780226796" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.20082677732734314" LOG_CI_START="-0.8724109811737293" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="33724" O_E="0.0" SE="0.6304251719561152" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="52" TOTAL_2="12" VAR="0.39743589743589747" WEIGHT="7.426915856455247"/>
<DICH_DATA CI_END="2.1100263956229934" CI_START="0.031158955986880725" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3242878881894985" LOG_CI_START="-1.506417102242497" LOG_EFFECT_SIZE="-0.5910646070264993" ORDER="33725" O_E="0.0" SE="1.0753651735156091" STUDY_ID="STD-Jerums-2001" TOTAL_1="13" TOTAL_2="10" VAR="1.1564102564102563" WEIGHT="3.4961872169889525"/>
<DICH_DATA CI_END="1.526144818711808" CI_START="0.0994638607235768" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.18359574658298852" LOG_CI_START="-1.0023346874886272" LOG_EFFECT_SIZE="-0.4093694704528194" ORDER="33726" O_E="0.0" SE="0.6966214074239933" STUDY_ID="STD-Jerums-2004" TOTAL_1="11" TOTAL_2="15" VAR="0.4852813852813852" WEIGHT="6.571747528550859"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="33727" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Marre-1987" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="3.1779786614171956"/>
<DICH_DATA CI_END="1.0002633024603331" CI_START="0.059221270363476936" EFFECT_SIZE="0.24338624338624337" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="1.1433575381205558E-4" LOG_CI_START="-1.2275222807371522" LOG_EFFECT_SIZE="-0.6137039724916701" ORDER="33728" O_E="0.0" SE="0.721119825426051" STUDY_ID="STD-Mathiesen-1999" TOTAL_1="21" TOTAL_2="23" VAR="0.5200138026224983" WEIGHT="6.285590296796861"/>
<DICH_DATA CI_END="2.8054545628551395" CI_START="0.034330947036081326" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4480032392625791" LOG_CI_START="-1.4643142161818417" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="33729" O_E="0.0" SE="1.123304739452125" STUDY_ID="STD-Muirhead-1999" TOTAL_1="29" TOTAL_2="27" VAR="1.2618135376756066" WEIGHT="3.2568093860839626"/>
<DICH_DATA CI_END="0.3351286623963358" CI_START="0.02079868722934939" EFFECT_SIZE="0.08348794063079777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="22" LOG_CI_END="-0.47478842687007683" LOG_CI_START="-1.6819640759527132" LOG_EFFECT_SIZE="-1.078376251411395" ORDER="33730" O_E="0.0" SE="0.7091009518869771" STUDY_ID="STD-Ravid-1993" TOTAL_1="49" TOTAL_2="45" VAR="0.502824159967017" WEIGHT="6.424030845077121"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33731" O_E="0.0" SE="0.0" STUDY_ID="STD-Romero-1993" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.91085200726295" CI_END="5.345458954789539" CI_START="1.756308795554328" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.064029467640857" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="94" I2="45.63138111493796" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.7279849991566845" LOG_CI_START="0.24460087627115798" LOG_EFFECT_SIZE="0.48629293771392124" METHOD="MH" MODIFIED="2008-08-26 15:59:20 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.03196007744798557" P_Q="0.0" P_Z="8.029544800232414E-5" Q="0.0" RANDOM="YES" SCALE="694.9133296610737" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3487688124784919" TOTALS="YES" TOTAL_1="995" TOTAL_2="915" WEIGHT="100.0" Z="3.943516548147691">
<NAME>Micro- to normoalbuminuria</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<DICH_DATA CI_END="403.63877743783735" CI_START="1.4905346737709855" EFFECT_SIZE="24.528301886792452" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.605992882089905" LOG_CI_START="0.17334208332219045" LOG_EFFECT_SIZE="1.3896674827060478" ORDER="33732" O_E="0.0" SE="1.428951121011817" STUDY_ID="STD-Ahmad-1997" TOTAL_1="52" TOTAL_2="51" VAR="2.041901306240929" WEIGHT="3.372409576708761"/>
<DICH_DATA CI_END="127.44031482769891" CI_START="0.36452347290880666" EFFECT_SIZE="6.815789473684211" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1053068356725753" LOG_CI_START="-0.43827450074369184" LOG_EFFECT_SIZE="0.8335161674644417" ORDER="33733" O_E="0.0" SE="1.4941122679415944" STUDY_ID="STD-Ahmad-2003" TOTAL_1="37" TOTAL_2="36" VAR="2.2323714692135743" WEIGHT="3.1235492546866115"/>
<DICH_DATA CI_END="15.41365517610121" CI_START="0.8686418716406232" EFFECT_SIZE="3.659090909090909" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.1879056390154" LOG_CI_START="-0.06115923992407523" LOG_EFFECT_SIZE="0.5633731995456623" ORDER="33734" O_E="0.0" SE="0.7337068928599161" STUDY_ID="STD-ATLANTIS-SG-2000" TOTAL_1="88" TOTAL_2="46" VAR="0.5383258046301524" WEIGHT="9.088454205030347"/>
<DICH_DATA CI_END="174.40317909429925" CI_START="0.7656446682392823" EFFECT_SIZE="11.555555555555555" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.241554397170676" LOG_CI_START="-0.11597273745176513" LOG_EFFECT_SIZE="1.0627908298594555" ORDER="33735" O_E="0.0" SE="1.384823108824749" STUDY_ID="STD-Bakris-1994" TOTAL_1="8" TOTAL_2="7" VAR="1.9177350427350426" WEIGHT="3.557160860139489"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33736" O_E="0.0" SE="0.0" STUDY_ID="STD-Bojestig-2001" TOTAL_1="37" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="80.1871190643405" CI_START="0.17537105914375778" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.904104610571408" LOG_CI_START="-0.75604207511597" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="33737" O_E="0.0" SE="1.5625833311112296" STUDY_ID="STD-Chase-1993" TOTAL_1="7" TOTAL_2="9" VAR="2.4416666666666664" WEIGHT="2.8892690274962787"/>
<DICH_DATA CI_END="36.03146885523175" CI_START="0.5012979091297115" EFFECT_SIZE="4.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5566819668885714" LOG_CI_START="-0.2999041067879484" LOG_EFFECT_SIZE="0.6283889300503115" ORDER="33738" O_E="0.0" SE="1.0905678499268707" STUDY_ID="STD-Crepaldi-1998" TOTAL_1="32" TOTAL_2="34" VAR="1.1893382352941178" WEIGHT="5.241715012486413"/>
<DICH_DATA CI_END="10.471092623441184" CI_START="1.4817854931587124" EFFECT_SIZE="3.9390243902439024" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" LOG_CI_END="1.019992001217824" LOG_CI_START="0.17078533867694834" LOG_EFFECT_SIZE="0.5953886699473863" ORDER="33739" O_E="0.0" SE="0.49882819721728544" STUDY_ID="STD-EUCLID-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.248829570339047" WEIGHT="13.491199164744835"/>
<DICH_DATA CI_END="29.45197765923085" CI_START="0.44003836176814687" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.46911446237113" LOG_CI_START="-0.3565094608365554" LOG_EFFECT_SIZE="0.5563025007672873" ORDER="33740" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Hansen-1994" TOTAL_1="10" TOTAL_2="12" VAR="1.15" WEIGHT="5.379294482241265"/>
<DICH_DATA CI_END="1.7310293597350765" CI_START="0.9943960106642526" EFFECT_SIZE="1.3119941652550349" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="77" LOG_CI_END="0.23830443394287004" LOG_CI_START="-0.002440626673307125" LOG_EFFECT_SIZE="0.11793190363478148" ORDER="33741" O_E="0.0" SE="0.14141484031321214" STUDY_ID="STD-HOPE-2000" TOTAL_1="552" TOTAL_2="587" VAR="0.01999815706081129" WEIGHT="21.86290928711163"/>
<DICH_DATA CI_END="96.96759283479958" CI_START="0.38778264460646644" EFFECT_SIZE="6.132075471698113" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="1.986626614631094" LOG_CI_START="-0.4114116318749236" LOG_EFFECT_SIZE="0.7876074913780853" ORDER="33742" O_E="0.0" SE="1.4086195364783995" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="52" TOTAL_2="12" VAR="1.984208998548621" WEIGHT="3.4558060368226733"/>
<DICH_DATA CI_END="184.66138308327714" CI_START="0.752204163671017" EFFECT_SIZE="11.785714285714286" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.266376084030765" LOG_CI_START="-0.12366426695942867" LOG_EFFECT_SIZE="1.0713559085356683" ORDER="33743" O_E="0.0" SE="1.4039215330621833" STUDY_ID="STD-Jerums-2001" TOTAL_1="13" TOTAL_2="10" VAR="1.9709956709956709" WEIGHT="3.4754902321146095"/>
<DICH_DATA CI_END="2.7308121996385246" CI_START="0.04068793567196556" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4362918343524308" LOG_CI_START="-1.390534343791756" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="33744" O_E="0.0" SE="1.0730867399773196" STUDY_ID="STD-Jerums-2004" TOTAL_1="11" TOTAL_2="11" VAR="1.1515151515151516" WEIGHT="5.373861879893426"/>
<DICH_DATA CI_END="147.9523539715359" CI_START="0.5474735468932344" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1701218793223758" LOG_CI_START="-0.2616368604437256" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="33745" O_E="0.0" SE="1.4284271211385062" STUDY_ID="STD-Marre-1987" TOTAL_1="10" TOTAL_2="10" VAR="2.0404040404040407" WEIGHT="3.374523025152271"/>
<DICH_DATA CI_END="5.49872541919301" CI_START="1.233319271427278" EFFECT_SIZE="2.6041666666666665" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.7402620335741084" LOG_CI_START="0.09107551769083003" LOG_EFFECT_SIZE="0.4156687756324692" ORDER="33746" O_E="0.0" SE="0.3813353729549183" STUDY_ID="STD-Poulsen-2001" TOTAL_1="32" TOTAL_2="25" VAR="0.14541666666666667" WEIGHT="16.3143579553714"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33747" O_E="0.0" SE="0.0" STUDY_ID="STD-Romero-1993" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.298951100222689" CI_END="4.379486294757312" CI_START="2.2929427602275716" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.16889750435063" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.6414231715917084" LOG_CI_START="0.36039321337468777" LOG_EFFECT_SIZE="0.5009081924831981" METHOD="MH" MODIFIED="2008-08-26 15:59:30 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8906580603411424" P_Q="0.0" P_Z="2.8105618674125707E-12" Q="0.0" RANDOM="YES" SCALE="325.6858429809225" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3538" TOTAL_2="3549" WEIGHT="100.0" Z="6.986885121122755">
<NAME>Cough</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="159.9344641788738" CI_START="0.48752614085645707" EFFECT_SIZE="8.830188679245284" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2039420596806476" LOG_CI_START="-0.3120020927339774" LOG_EFFECT_SIZE="0.945969983473335" ORDER="33748" O_E="0.0" SE="1.4778780492527626" STUDY_ID="STD-Ahmad-1997" TOTAL_1="52" TOTAL_2="51" VAR="2.184123528463151" WEIGHT="1.2476800886114834"/>
<DICH_DATA CI_END="16.1744413768005" CI_START="0.23411662488541038" EFFECT_SIZE="1.945945945945946" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.208829290196227" LOG_CI_START="-0.63056774546768" LOG_EFFECT_SIZE="0.2891307723642735" ORDER="33749" O_E="0.0" SE="1.0804709239111516" STUDY_ID="STD-Bojestig-2001" TOTAL_1="37" TOTAL_2="18" VAR="1.1674174174174174" WEIGHT="2.3342871169078663"/>
<DICH_DATA CI_END="40.598514840553165" CI_START="0.08977244890576629" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6085101466720249" LOG_CI_START="-1.0468569275206365" LOG_EFFECT_SIZE="0.2808266095756942" ORDER="33750" O_E="0.0" SE="1.5597757636597747" STUDY_ID="STD-Capek-1994" TOTAL_1="10" TOTAL_2="6" VAR="2.432900432900433" WEIGHT="1.1200982172059382"/>
<DICH_DATA CI_END="6.205226485911144" CI_START="2.388795613528997" EFFECT_SIZE="3.8500672475293842" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="21" LOG_CI_END="0.7927576375327916" LOG_CI_START="0.37817899290024826" LOG_EFFECT_SIZE="0.5854683152165199" ORDER="33751" O_E="0.0" SE="0.24352554805454424" STUDY_ID="STD-DIABHYCAR-2004" TOTAL_1="2443" TOTAL_2="2469" VAR="0.05930469255526614" WEIGHT="45.9506207707226"/>
<DICH_DATA CI_END="6.937162646027344" CI_START="1.2973603848187074" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.8411818769190388" LOG_CI_START="0.11306063252028602" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="33752" O_E="0.0" SE="0.42770202321811585" STUDY_ID="STD-EUCLID-1997" TOTAL_1="265" TOTAL_2="265" VAR="0.1829290206648697" WEIGHT="14.896966198292587"/>
<DICH_DATA CI_END="8.729381340979193" CI_START="0.01777769122868095" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9409834659599233" LOG_CI_START="-1.7501246411020248" LOG_EFFECT_SIZE="-0.40457058757105074" ORDER="33753" O_E="0.0" SE="1.5807702232881597" STUDY_ID="STD-Hansen-1994" TOTAL_1="10" TOTAL_2="12" VAR="2.4988344988344986" WEIGHT="1.0905433868478924"/>
<DICH_DATA CI_END="5.483288972818503" CI_START="1.5758072807236432" EFFECT_SIZE="2.9394908888579776" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="13" LOG_CI_END="0.7390411340821844" LOG_CI_START="0.1975031027245491" LOG_EFFECT_SIZE="0.46827211840336674" ORDER="33754" O_E="0.0" SE="0.3181021202759633" STUDY_ID="STD-HOPE-2000" TOTAL_1="553" TOTAL_2="587" VAR="0.1011889589240634" WEIGHT="26.930679656229632"/>
<DICH_DATA CI_END="69.09041116722429" CI_START="0.19794412950783802" EFFECT_SIZE="3.69811320754717" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.839417777242083" LOG_CI_START="-0.7034573737307087" LOG_EFFECT_SIZE="0.567980201755687" ORDER="33755" O_E="0.0" SE="1.4936974511164227" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="52" TOTAL_2="27" VAR="2.231132075471698" WEIGHT="1.2213922552994545"/>
<DICH_DATA CI_END="9.717395026105741" CI_START="0.3549284126631742" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.987549857784985" LOG_CI_START="-0.4498592331998251" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="33756" O_E="0.0" SE="0.8443412153342319" STUDY_ID="STD-Ravid-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.7129120879120878" WEIGHT="3.822473322779978"/>
<DICH_DATA CI_END="16.14770111545689" CI_START="0.06612568378267047" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2081107022747464" LOG_CI_START="-1.1796298240455259" LOG_EFFECT_SIZE="0.014240439114610285" ORDER="33757" O_E="0.0" SE="1.4025706046667559" STUDY_ID="STD-Trevisan-1995" TOTAL_1="60" TOTAL_2="62" VAR="1.967204301075269" WEIGHT="1.3852589871025618"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.197962893432713" CI_END="2.5317242143842673" CI_START="0.3345449586321824" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9203127580172293" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="6.190281126752491" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.4034163953838754" LOG_CI_START="-0.47554551026137293" LOG_EFFECT_SIZE="-0.03606455743874874" METHOD="MH" MODIFIED="2008-08-26 15:59:38 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3620986907590279" P_Q="0.0" P_Z="0.8722210020249378" Q="0.0" RANDOM="YES" SCALE="358.57319815393186" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07464421754680498" TOTALS="YES" TOTAL_1="3085" TOTAL_2="3101" WEIGHT="100.0" Z="0.16083799137218227">
<NAME>Headache</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9806405112025807" CI_START="0.005048871788413703" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.29680565768467454" LOG_CI_START="-2.2968056576846743" LOG_EFFECT_SIZE="-1.0" ORDER="33758" O_E="0.0" SE="1.5235001252310245" STUDY_ID="STD-Bojestig-2001" TOTAL_1="37" TOTAL_2="18" VAR="2.3210526315789473" WEIGHT="11.127137340876471"/>
<DICH_DATA CI_END="3.0072813700332546" CI_START="0.21737077612919026" EFFECT_SIZE="0.8085141219811707" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.478174063862427" LOG_CI_START="-0.6627988439615489" LOG_EFFECT_SIZE="-0.09231239004956088" ORDER="33759" O_E="0.0" SE="0.6702131339627854" STUDY_ID="STD-DIABHYCAR-2004" TOTAL_1="2443" TOTAL_2="2469" VAR="0.44918564493621854" WEIGHT="50.889133622448234"/>
<DICH_DATA CI_END="23.346758217488084" CI_START="0.19304535023354344" EFFECT_SIZE="2.122965641952984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.368226585715958" LOG_CI_START="-0.714340654502163" LOG_EFFECT_SIZE="0.32694296560689745" ORDER="33760" O_E="0.0" SE="1.2233103057782226" STUDY_ID="STD-HOPE-2000" TOTAL_1="553" TOTAL_2="587" VAR="1.4964881042232088" WEIGHT="16.966901831219168"/>
<DICH_DATA CI_END="17.6777357203785" CI_START="0.244013686802829" EFFECT_SIZE="2.076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2474266369711573" LOG_CI_START="-0.6125858132668561" LOG_EFFECT_SIZE="0.3174204118521506" ORDER="33761" O_E="0.0" SE="1.0925805204799297" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="52" TOTAL_2="27" VAR="1.1937321937321939" WEIGHT="21.016827205456124"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6086158044507544" CI_END="3.913360782473883" CI_START="0.2642551675268566" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0169197653530326" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.5925498884360044" LOG_CI_START="-0.5779765112808739" LOG_EFFECT_SIZE="0.0072866885775653666" METHOD="MH" MODIFIED="2008-08-26 15:59:47 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4353096406585335" P_Q="0.0" P_Z="0.9805318786503516" Q="0.0" RANDOM="YES" SCALE="27.610822394283637" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="758" TOTAL_2="770" WEIGHT="100.0" Z="0.024402093249740995">
<NAME>Impotence</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placeb/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7513643393140406" CI_START="0.11396248250778593" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5741892456675344" LOG_CI_START="-0.9432380988526224" LOG_EFFECT_SIZE="-0.18452442659254403" ORDER="33762" O_E="0.0" SE="0.8913443335576375" STUDY_ID="STD-Ahmad-1997" TOTAL_1="52" TOTAL_2="51" VAR="0.794494720965309" WEIGHT="59.50406211257558"/>
<DICH_DATA CI_END="16.1744413768005" CI_START="0.23411662488541038" EFFECT_SIZE="1.945945945945946" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.208829290196227" LOG_CI_START="-0.63056774546768" LOG_EFFECT_SIZE="0.2891307723642735" ORDER="33763" O_E="0.0" SE="1.0804709239111516" STUDY_ID="STD-Bojestig-2001" TOTAL_1="37" TOTAL_2="18" VAR="1.1674174174174174" WEIGHT="40.49593788742441"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33764" O_E="0.0" SE="0.0" STUDY_ID="STD-HOPE-2000" TOTAL_1="553" TOTAL_2="587" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33765" O_E="0.0" SE="0.0" STUDY_ID="STD-Ravid-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33766" O_E="0.0" SE="0.0" STUDY_ID="STD-Trevisan-1995" TOTAL_1="60" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05399318084440697" CI_END="2.2059688878585004" CI_START="0.32399171447808783" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8454085651698806" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.3435993830240921" LOG_CI_START="-0.4894660959738094" LOG_EFFECT_SIZE="-0.07293335647485866" METHOD="MH" MODIFIED="2008-08-26 15:59:56 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.8162550546145171" P_Q="0.0" P_Z="0.7314611605457376" Q="0.0" RANDOM="YES" SCALE="13.113003897897594" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="605" TOTAL_2="614" WEIGHT="99.99999999999999" Z="0.34318251221811646">
<NAME>Hyperkalaemia</NAME>
<GROUP_LABEL_1>ACEi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placeb/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.219099832552208" CI_START="0.11869259362281476" EFFECT_SIZE="0.707655213984328" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6252198018013121" LOG_CI_START="-0.9255763800268421" LOG_EFFECT_SIZE="-0.150178289112765" ORDER="33767" O_E="0.0" SE="0.9109453537707638" STUDY_ID="STD-HOPE-2000" TOTAL_1="553" TOTAL_2="587" VAR="0.8298214375565419" WEIGHT="28.85684392240024"/>
<DICH_DATA CI_END="2.832919793838029" CI_START="0.2914490604097152" EFFECT_SIZE="0.9086538461538461" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.4522342788668352" LOG_CI_START="-0.5354373404458699" LOG_EFFECT_SIZE="-0.041601530789517414" ORDER="33768" O_E="0.0" SE="0.5801631982376482" STUDY_ID="STD-JAPAN_x002d_IDDM-2002" TOTAL_1="52" TOTAL_2="27" VAR="0.3365893365893366" WEIGHT="71.14315607759974"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-08-26 16:01:25 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>AIIRA versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.6297669427241825" CI_END="1.1655497420755927" CI_START="0.8487225300361527" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9945995807245156" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="249" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.06653081260389127" LOG_CI_START="-0.07123426896685328" LOG_EFFECT_SIZE="-0.0023517281814810255" METHOD="MH" MODIFIED="2008-08-26 16:00:08 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7298739667897945" P_Q="0.0" P_Z="0.9466490557772804" Q="0.0" RANDOM="YES" SCALE="34.08534206274342" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1813" TOTAL_2="1596" WEIGHT="100.0" Z="0.06691539662412525">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2024415548544884" CI_START="0.7028716667596407" EFFECT_SIZE="0.9193269820045685" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="93" LOG_CI_END="0.08006397650446348" LOG_CI_START="-0.15312396303982667" LOG_EFFECT_SIZE="-0.0365299932676816" ORDER="33769" O_E="0.0" SE="0.13697574998723308" STUDY_ID="STD-IDNT-2001" TOTAL_1="579" TOTAL_2="569" VAR="0.01876235608456498" WEIGHT="34.903271651276775"/>
<DICH_DATA CI_END="14.806942807909655" CI_START="0.162281877175964" EFFECT_SIZE="1.5501285347043703" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1704653989187113" LOG_CI_START="-0.789729977289824" LOG_EFFECT_SIZE="0.19036771081444362" ORDER="33770" O_E="0.0" SE="1.1514284671084958" STUDY_ID="STD-IRMA_x002d_2-2001" TOTAL_1="389" TOTAL_2="201" VAR="1.3257875148678202" WEIGHT="0.49394612929572423"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33771" O_E="0.0" SE="0.0" STUDY_ID="STD-Muirhead-1999" TOTAL_1="54" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2599141714214388" CI_START="0.84906294040728" EFFECT_SIZE="1.0342854688372494" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="155" LOG_CI_END="0.10034096087338834" LOG_CI_START="-0.07106011463426176" LOG_EFFECT_SIZE="0.014640423119563291" ORDER="33772" O_E="0.0" SE="0.10068184020220106" STUDY_ID="STD-RENAAL-2001" TOTAL_1="751" TOTAL_2="762" VAR="0.01013683294650155" WEIGHT="64.60278221942751"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33773" O_E="0.0" SE="0.0" STUDY_ID="STD-Tan-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.22298347359193" CI_END="0.9254126786422622" CI_START="0.6714468092241399" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.788267334278106" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="330" I2="18.232746264103028" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.033664554731677225" LOG_CI_START="-0.17298838563920912" LOG_EFFECT_SIZE="-0.10332647018544316" METHOD="MH" MODIFIED="2008-08-26 16:00:20 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2687760121145696" P_Q="0.0" P_Z="0.003647629814608593" Q="0.0" RANDOM="YES" SCALE="2.1334212926456857" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.00254023384454356" TOTALS="YES" TOTAL_1="1719" TOTAL_2="1532" WEIGHT="100.0" Z="2.9071287933150303">
<NAME>Doubling of serum creatinine</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.900527493870149" CI_START="0.5651386931378755" EFFECT_SIZE="0.7133883451672743" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="135" LOG_CI_END="-0.045503023262200036" LOG_CI_START="-0.24784495700755252" LOG_EFFECT_SIZE="-0.14667399013487628" ORDER="33774" O_E="0.0" SE="0.11885665349074583" STUDY_ID="STD-IDNT-2001" TOTAL_1="579" TOTAL_2="569" VAR="0.014126904079019223" WEIGHT="40.18509410818967"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33775" O_E="0.0" SE="0.0" STUDY_ID="STD-Parving-2001a" TOTAL_1="389" TOTAL_2="201" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0115665805226683" CI_START="0.7024192452034665" EFFECT_SIZE="0.8429376216326949" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="195" LOG_CI_END="0.004994472971357982" LOG_CI_START="-0.1534035979402678" LOG_EFFECT_SIZE="-0.07420456248445494" ORDER="33776" O_E="0.0" SE="0.09304381093658555" STUDY_ID="STD-RENAAL-2001" TOTAL_1="751" TOTAL_2="762" VAR="0.008657150753603076" WEIGHT="59.814905891810334"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.049248392463670465" CI_END="0.9083677616818279" CI_START="0.6670153783671235" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7783927455049292" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="295" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.041738287455532395" LOG_CI_START="-0.17586415309545847" LOG_EFFECT_SIZE="-0.10880122027549545" METHOD="MH" MODIFIED="2008-08-26 16:00:31 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8243763267939899" P_Q="0.0" P_Z="0.001473785549279282" Q="0.0" RANDOM="YES" SCALE="2.110912279729646" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1719" TOTAL_2="1532" WEIGHT="100.0" Z="3.1797964128181073">
<NAME>End-stage kidney disease</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0424387837431963" CI_START="0.6106632738317319" EFFECT_SIZE="0.7978590605174507" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="101" LOG_CI_END="0.01805056085142289" LOG_CI_START="-0.21419819831400472" LOG_EFFECT_SIZE="-0.09807381873129091" ORDER="33777" O_E="0.0" SE="0.13642407078367133" STUDY_ID="STD-IDNT-2001" TOTAL_1="579" TOTAL_2="569" VAR="0.018611527089188163" WEIGHT="33.35172268606336"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33778" O_E="0.0" SE="0.0" STUDY_ID="STD-Parving-2001a" TOTAL_1="389" TOTAL_2="201" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9289170891384831" CI_START="0.6363328234907987" EFFECT_SIZE="0.7688305626861779" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="194" LOG_CI_END="-0.032023047401988886" LOG_CI_START="-0.1963156742912468" LOG_EFFECT_SIZE="-0.11416936084661784" ORDER="33779" O_E="0.0" SE="0.0965063022963693" STUDY_ID="STD-RENAAL-2001" TOTAL_1="751" TOTAL_2="762" VAR="0.009313466382918216" WEIGHT="66.64827731393663"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0988895236934124" CI_END="0.7524413341955064" CI_START="0.3151498066961895" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4869617449265771" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.12352735517382206" LOG_CI_START="-0.5014829549220057" LOG_EFFECT_SIZE="-0.3125051550479139" METHOD="MH" MODIFIED="2008-08-26 16:00:42 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5772703704765834" P_Q="0.0" P_Z="0.0011906299332238995" Q="0.0" RANDOM="YES" SCALE="144.16731028426037" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="491" TOTAL_2="270" WEIGHT="100.0" Z="3.2411153547406086">
<NAME>Micro- to macroalbuminuria</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placbo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.435267719696005" CI_START="0.016937027396652333" EFFECT_SIZE="0.15591397849462366" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.15693291733634138" LOG_CI_START="-1.771162809974262" LOG_EFFECT_SIZE="-0.8071149463189602" ORDER="33780" O_E="0.0" SE="1.132572974450026" STUDY_ID="STD-Muirhead-1999" TOTAL_1="62" TOTAL_2="29" VAR="1.282721542454579" WEIGHT="3.842592970281372"/>
<DICH_DATA CI_END="0.8081523103884304" CI_START="0.3087117642481649" EFFECT_SIZE="0.49948586118251925" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="-0.09250678114681259" LOG_CI_START="-0.5104468203050379" LOG_EFFECT_SIZE="-0.30147680072592525" ORDER="33781" O_E="0.0" SE="0.24550004783810114" STUDY_ID="STD-Parving-2001a" TOTAL_1="389" TOTAL_2="201" VAR="0.06027027348850995" WEIGHT="81.78122474928067"/>
<DICH_DATA CI_END="1.8004229497035906" CI_START="0.18136328038845295" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2553745401840746" LOG_CI_START="-0.7414506375566636" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="33782" O_E="0.0" SE="0.5855400437691198" STUDY_ID="STD-Tan-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.3428571428571428" WEIGHT="14.376182280437963"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5114243208927243" CI_END="1.9271470605988086" CI_START="1.0476049819848339" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.420876089495752" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.28491485693341734" LOG_CI_START="0.020197555086697367" LOG_EFFECT_SIZE="0.15255620601005732" METHOD="MH" MODIFIED="2008-08-26 16:00:53 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4745229882511298" P_Q="0.0" P_Z="0.023880341083114327" Q="0.0" RANDOM="YES" SCALE="28.288435467103348" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="429" TOTAL_2="241" WEIGHT="100.0" Z="2.259048934934513">
<NAME>Micro- to normoalbuminuria</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AIIRA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8965614536383086" CI_START="1.019023732955096" EFFECT_SIZE="1.3901946382666177" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="42" LOG_CI_END="0.277966919563781" LOG_CI_START="0.008184298796819884" LOG_EFFECT_SIZE="0.1430756091803004" ORDER="33783" O_E="0.0" SE="0.15847164688402354" STUDY_ID="STD-Parving-2001a" TOTAL_1="389" TOTAL_2="201" VAR="0.025113262866134647" WEIGHT="96.2801407930399"/>
<DICH_DATA CI_END="12.139495330261088" CI_START="0.5148484207922654" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0842006323868032" LOG_CI_START="-0.2883206150427279" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="33784" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Tan-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.6499999999999999" WEIGHT="3.7198592069601"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4293826735697372" CI_END="24.34612130641388" CI_START="0.9982956506035149" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.929972313234481" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="30.039728444265933" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="1.3864297815918567" LOG_CI_START="-7.408210265448558E-4" LOG_EFFECT_SIZE="0.6928444802826559" METHOD="MH" MODIFIED="2008-08-26 16:01:04 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.2318654679939678" P_Q="0.0" P_Z="0.050245205580623675" Q="0.0" RANDOM="YES" SCALE="788.8687094778178" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5250498290240027" TOTALS="YES" TOTAL_1="80" TOTAL_2="114" WEIGHT="100.0" Z="1.957870539756439">
<NAME>Cough</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="292.55564745891814" CI_START="1.0262056669262136" EFFECT_SIZE="17.326923076923077" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4662084860959315" LOG_CI_START="0.011234408592595863" LOG_EFFECT_SIZE="1.2387214473442638" ORDER="33785" O_E="0.0" SE="1.442063925443133" STUDY_ID="STD-Lacourciere-2000" TOTAL_1="51" TOTAL_2="52" VAR="2.079548365064458" WEIGHT="25.491431353969613"/>
<DICH_DATA CI_END="10.497427905505326" CI_START="0.9796862227619276" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="1.0210829006618487" LOG_CI_START="-0.008912999351890724" LOG_EFFECT_SIZE="0.506084950654979" ORDER="33786" O_E="0.0" SE="0.6050246902300042" STUDY_ID="STD-Muirhead-1999" TOTAL_1="29" TOTAL_2="62" VAR="0.36605487578791246" WEIGHT="74.50856864603038"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-08-26 16:01:13 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="69.28325660434268" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.680926312871346" CI_START="0.029374867486939613" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2222201638915537" LOG_CI_START="-1.5320240838630401" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="33787" O_E="0.0" SE="1.6178567048599568" STUDY_ID="STD-Muirhead-1999" TOTAL_1="29" TOTAL_2="62" VAR="2.6174603174603175" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Impotence</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-08-26 16:01:25 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="67.05768728969393" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="579" TOTAL_2="569" WEIGHT="0.0" Z="0.0">
<NAME>Hyperkalaemia</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.276613280251954" CI_START="1.2033852503818387" EFFECT_SIZE="5.405008635578584" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3851881001837714" LOG_CI_START="0.08040468413998643" LOG_EFFECT_SIZE="0.7327963921618789" ORDER="33788" O_E="0.0" SE="0.7664362373661946" STUDY_ID="STD-IDNT-2001" TOTAL_1="579" TOTAL_2="569" VAR="0.5874245059480497" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-08-26 16:02:26 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>AIIRA versus ACEi</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7843275795111597" CI_START="0.3060239794294451" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.4447203292161362" LOG_CI_START="-0.51424454173456" LOG_EFFECT_SIZE="-0.03476210625921192" METHOD="MH" MODIFIED="2008-08-26 16:01:41 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8870042762960939" Q="0.0" RANDOM="YES" SCALE="6.802910025159775" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="150" WEIGHT="100.0" Z="0.1420958751643629">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7843275795111597" CI_START="0.3060239794294451" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4447203292161362" LOG_CI_START="-0.51424454173456" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="33789" O_E="0.0" SE="0.563300712149108" STUDY_ID="STD-DETAIL-2004" TOTAL_1="130" TOTAL_2="120" VAR="0.31730769230769224" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33790" O_E="0.0" SE="0.0" STUDY_ID="STD-Ko-2005" TOTAL_1="20" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33791" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizzoni-2005" TOTAL_1="7" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6197284983927434" CI_START="0.10462061588879473" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.5586759970326702" LOG_CI_START="-0.9803827276624567" LOG_EFFECT_SIZE="-0.21085336531489315" METHOD="MH" MODIFIED="2008-08-26 16:01:51 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5912427213689604" Q="0.0" RANDOM="YES" SCALE="24.269953307837905" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="150" WEIGHT="100.0" Z="0.5370360408023048">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6197284983927434" CI_START="0.10462061588879473" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5586759970326702" LOG_CI_START="-0.9803827276624567" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="33792" O_E="0.0" SE="0.9040507133494737" STUDY_ID="STD-DETAIL-2004" TOTAL_1="130" TOTAL_2="120" VAR="0.8173076923076923" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33793" O_E="0.0" SE="0.0" STUDY_ID="STD-Ko-2005" TOTAL_1="20" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33794" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizzoni-2005" TOTAL_1="7" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Doubling of serum creatinine</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>End-stage kidney disease</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-08-26 16:02:06 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="191.41035960398136" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Micro- to macroalbuminuria</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.92191868001707" CI_START="0.13545380043757582" EFFECT_SIZE="3.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8628580870424774" LOG_CI_START="-0.8682088054265785" LOG_EFFECT_SIZE="0.49732464080794936" ORDER="33795" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Ko-2005" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7599222761654294" CI_END="1.9405676679704853" CI_START="0.7609242765766224" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.215164618024416" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.287928791272786" LOG_CI_START="-0.11865855991958314" LOG_EFFECT_SIZE="0.08463511567660142" METHOD="MH" MODIFIED="2008-08-26 16:02:14 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3833528831573284" P_Q="0.0" P_Z="0.4145166319658339" Q="0.0" RANDOM="YES" SCALE="170.91491498981878" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="0.8159711711003834">
<NAME>Micro- to normoalbuminuria</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACEi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AIIRA</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.102435408890784" CI_START="0.015050422270841747" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9086155776031525" LOG_CI_START="-1.8224513148659038" LOG_EFFECT_SIZE="-0.4569178686313755" ORDER="33796" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Ko-2005" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="2.2163740285373574"/>
<DICH_DATA CI_END="2.0067566793451146" CI_START="0.7786195586551662" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3024947171691285" LOG_CI_START="-0.10867469115301572" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="33797" O_E="0.0" SE="0.24152294576982397" STUDY_ID="STD-Tutuncu-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.058333333333333334" WEIGHT="97.78362597146264"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.686340881588808" CI_END="48.69742393900994" CI_START="0.006911297618691103" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5801399745803338" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="78.66139008520075" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="1.6875059879361216" LOG_CI_START="-2.160440404763312" LOG_EFFECT_SIZE="-0.23646720841359548" METHOD="MH" MODIFIED="2008-08-26 16:02:26 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0304034037872708" P_Q="0.0" P_Z="0.809639845787728" Q="0.0" RANDOM="YES" SCALE="776.4723166285547" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="8.039091162448484" TOTALS="YES" TOTAL_1="44" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.24089068023124913">
<NAME>Cough</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0460241940099637" CI_START="0.0038714083288411273" EFFECT_SIZE="0.06363636363636363" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.019541729658891057" LOG_CI_START="-2.4121310199468278" LOG_EFFECT_SIZE="-1.1962946451439682" ORDER="33798" O_E="0.0" SE="1.4283766100926396" STUDY_ID="STD-Ko-2005" TOTAL_1="21" TOTAL_2="20" VAR="2.0402597402597404" WEIGHT="50.68747591350426"/>
<DICH_DATA CI_END="111.42849176383541" CI_START="0.2839545299335113" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0469962521816423" LOG_CI_START="-0.5467511986148419" LOG_EFFECT_SIZE="0.7501225267834001" ORDER="33799" O_E="0.0" SE="1.523580091854805" STUDY_ID="STD-Sato-2003" TOTAL_1="23" TOTAL_2="26" VAR="2.321296296296296" WEIGHT="49.312524086495756"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Hyperkalaemia</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Impotence</NAME>
<GROUP_LABEL_1>AIIRA</GROUP_LABEL_1>
<GROUP_LABEL_2>ACEi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AIIRA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACEi</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart showing number of citations retrieved by individual searches, number of trials included in the systematic review and number of trials reporting each outcome.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkYAAAKGCAIAAAAgV8OPAAApW0lEQVR42u3d25LrKJBA0fP/P808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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>